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Chapter I. 
General Introduction and 
Aims of Thesis 
I.I - GENERAL INTRODUCTION 
This thesis provides an overview of the clinical development 
of the somatostatin analogue, octreotide, from my viewpoint 
as the coordinator/ developer of the Clinical Development 
Program at Sandoz*. The thesis describes in detail the ratio-
nales that governed the direction and speed of the various 
branches of the research program, and the unique methods 
by which data were collected and registration was sought are 
outlined. 
The main theme of the thesis is how close cooperation 
between industry and academia for the study and develop-
ment of a new pharmacological agent can be mutually 
beneficial. Academic groups receive economic and structural 
support from the industrial sector, thereby increasing knowl-
edge regarding pathophysiological mechanisms. Industry, 
on the other hand, is rewarded with valuable information 
concerning the utility and hazards of the potential phar-
macotherapy being studied. The clinical development of 
octreotide has not only produced a potent and well toler-
ated medication for the treatment of numerous conditions, 
it has also broadened significantly our understanding of 
many disease mechanisms and has proven singularly successful 
as a commercial drug. 
When dealing with the treatment of relatively rare diseases 
such as acromegaly and gut endocrine tumours, one of the 
most significant obstacles encountered is that of the scattering 
of patients across national and international boundaries. 
Data collection from such patients represents a significant 
hurdle for the individual academic investigator; however, dur-
ing the clinical phase of octreotide's development we showed 
that a multinational pharmaceutical company working 
* The corporate entity Sandoz is now known as Novartis 
together with individual clinical research groups could 
compile successfully data of the highest quality. It attests to 
the effectiveness of this process that octreotide was approved 
rapidly in many countries worldwide based in major part on 
these collections of patient data. 
The successful clinical development of octreotide revolu-
tionised the treatment of gut endocrine tumours, giving back 
dignity, mobility and a significantly improved quality oflife 
to those suffering from this debilitating illness. Had the 
benefits ended there, octreotide would have earned the 
appellation of a "breakthrough medicine". However, with this 
somatostatin analogue, a new chapter has also been opened 
in the treatment of acromegaly, affording hope to those 
patients who were unresponsive or could not avail themselves 
of pre-existing therapies. Moreover, by maintaining close links 
with the premier academic institutions worldwide, other 
potentially valuable avenues of clinical research were pursued. 
Indeed, as noted by Guillemin, "these early observations 
(regarding somatostatin physiology) would become of prac-
tical clinical significance and application only if and when 
taken up by industry"1 • Good evidence regarding octreotide 
continues to accumulate, pointing to its use in the treatment 
of such major problems as variceal bleeding, secretory diar-
rhoea, short bowel syndrome, fistulae, diabetic retinopathy, 
diabetic nephropathy and cancer. 
1.11- AIMS OF THE THESIS 
The thesis begins with an encapsulated history of the dis-
covery of somatostatin and the launching of the somatostatin 
analogue program (Chapter II). This is followed by a brief 
description of the design and preclinical development of 
octreotide and the original conception of the Clinical 
Development Program, including Phase I to Phase IV, 
beginning with the emergence of octreotide in 1982. The 
underlying motives for using octreotide as a clinical agent are 
16 I Chapter I 
highlighted, which involves tracing briefly the physiologi-
cal actions of somatostatin, in addition to explaining the 
pathological basis of the diseases chosen for treatment. 
Furthermore, the rationales involved in the design of the 
Clinical Development Program are discussed, as are the 
decisions underlying the specific clinical goals pursued. This 
provides an insight into the expectations held at the early 
stages of development, and relates these hopes to the final 
results. Where insurmountable problems were enco~tered, 
the effects of these problems on the progression of research 
into specific. therapeutic goals are outlined. Our approach to 
the prioritisation and sequencing of research goals changed 
as the program progressed. This was due to the impact of new 
external research findings and the results gained from the 
trials related to the Clinical Development Program. In 
reality the Clinical Development Program for octreotide 
followed a process of evolution and adaptation, rather than 
sequential steps. 
Separate sections of the thesis are given over to dealing 
with the development of octreotide in the initial primary 
indication, diabetes mellitus (Chapter III), followed by 
acromegaly (Chapter IV), gut endocrine tumours and gas-
troenterological conditions (fistulae,AIDS-related diarrhoea, 
and variceal bleeding) (ChapterV).A separate section details 
a number of fhe miscellaneous Clinical applications of 
octreotide (Chapter VI). The anticipated side effects result-
ing from the known physiological and pharmacological 
effects of native somatostatin and of octreotide have always 
been highlighted and studied in a pro-active way. Indeed, the 
manner in which octreotide was developed facilitated the free 
and frank discussion of the nature of these side effects and 
encouraged research into the mechanisms that underlie 
them. This topic is discussed in the light of clinical data 
derived from the development program (Chapter VII). As 
industry moves further into the realm of"high tech" phar-
maceuticals, the lessons learned during the development 
of octreotide in rare conditions have particular relevance. In 
the Discussion section (Chapter VIII), our experiences dur-
ing the Clinical Development Program for octreotide are put 
into context and recommendations for other pharmaceu-
tical researchers are detailed. This includes how opportuni-
ties for unexpected developments can be leveraged, such as, 
the advent of somatostatin receptor imaging and radio-
therapy developed at Erasmus Medical Centre, Rotterdam. 
Chapter VIII emphasizes how a dynamic approach to data 
gathering and research can be successful if it is backed by 
goodwill and cooperation from key academic leaders. 
Chapter IX relates new advances in clinical research tools -
particularly genornics and proteornics - and somatostatin 
physiology to the possibilities for future research with 
octreotide and the potential for newer analogues. Finally, con-
clusions are presented in Chapter X. 
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Chapter II. 
From Somatostatin to Octreotide 
11.1 - CHARACTERISTICS OF SOMATOSTATIN 
Octreotide is a synthetic analogue of the naturally occur-
ring hormone, somatostatin. Somatostatin was discovered 
by Guillemin and his co-workers following an observation 
by Krulich and Dhariwal in McCann's laboratory in 1968 
that growth hormone (GH) secretion from the pituitary 
gland could be stimulated and inhibited by crude extracts 
of another closely related structure, the hypothalamus 1• 
In the following year, Hellmar and Lernmark noted that 
pancreatic insulin secretion could be inhibited in vitro by 
an unknown agent present in pancreatic extracts 2 • In early 
1973, Brazeau, a post-doctoral member of Guillemin's 
research team, under the supervision of the group's physi-
ologist, Wylie Vale, made the serendipitous discovery of a 
hypothalamic factor that inhibited GH secretion which 
Guillemin termed somatotropin release inhibitory factor 
(SRIF), or somatostatin 3• The primary somatostatin sequence 
was isolated by Roger Burgos, confumed by Nicholas Ling 
using mass spectroscopy, following which Jean Rivier chem-
ically synthesised a replicate sequence identical to somato-
statin. In his historical review of this important period 4, 
Guillemin noted the importance to this work ofBerson and 
Yalow' s development of the radioimmunoassay for GH 
(for which Yalow received the Nobel Prize for Medicine or 
Physiology), and also the development by Wylie Vale of a 
bioassay for hypophysiotropic factors. 
Somatostatin was noted to be a small 14 amino acid pep-
tide (tetradecapeptide).The native molecule was found to 
have a cyclic structure, joined by two intramolecular disul-
phide cysteine bonds, however the linear derivative was 
found to have identical biological activity. A second form 
of somatostatin, termed somatostatin-28 was discovered in 
1980 5• Later, in 1977, Guillemin was awarded the Nobel 
Prize for Medicine based on his work on the hypothalamic-
pituitary axis, including the discovery of somatostatin. 
In the period since its discovery, somatostatin has been 
shown to be present in many other tissues, including the 
D-cells of the pancreas, the lining of the gut and periph-
eral nervous system 6• 7•8• Somatostatin is remarkable also for 
its quite strict conservation throughout different species 9 • 
This so-called phylogenetic conservation gives an inti-
mation of the central importance of somatostatin in the 
regulation of many physiological functions (Figure 1). 
Great developments in the field of somatostatin receptor 
research have been made over the past number of years. 
Five somatostatin receptor subtypes, all of which belong 
to the G-protein family of receptors, with seven membrane-
spanning areas, have been characterised by Reisine, Bell 
and others 10·11 • These receptors are distributed through-
out many tissues, especially on endocrine active cells. 
The binding characteristics of somatostatin to each 
somatostatin receptor subtype are different, indicating a 
variation in functions subserved by each subtype across 
various organ systems. For example, the main receptor 
sub-populations found in pituitary adenomas are types 1, 
2 and 5 12, and the expression of receptor populations 
may vary with cell characteristics 13 • Since these receptors 
are known to be functional, their presence probably plays 
a major role in the regulation activity of these cells in both 
health and disease. 
Given the wide distribution of somatostatin and its recep-
tors throughout the body and somatostatin's varied mech-
anisms of action, it is not surprising that it has numerous 
physiological functions. In general, however, somato-
statin has two important regulatory roles: (a) the inhibi-
tion of brain and gut hormone release and (b) the 
regulation of gastrointestinal absorption and motility. 
Other important functions, such as an involvement in the 
immune system 14, are not yet fully understood and are the 
subject of a great deal of research. 
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Figure 1. Physiological functions of somatostatin in human. 
11.11 - THE ADVENT OF SOMATOSTATIN ANALOGUES 
Somatostatin's role as a GH inhibitor provided an immedi-
ately apparent rationale for its use as a therapeutic agent, 
namely in the treatment of disorders associated with hyper-
secretion of GH or gastrointestinal and/ or pancreatic hor-
mones as well as disorders of gut absorption and motility. 
Although several such diseases exist, somatostatin has not 
become a standard therapy in their treatment for two cru-
cial reasons, 1) its biological half-life, and 2), the non-specific 
nature of somatostatin's inhibitory effects on GH and insulin. 
Somatostatin has a very short plasma half-life (2.5 minutes) 
and is associated with rebound hypersecretion ofhormones 
such as GH and glucagon when treatment is halted 15• 
Somatostatin also suppresses the secretion of insulin and 
GH to approximately the same extent, thereby increasing the 
risk of disturbed glycaemic control. Therefore, somatostatin 
is unsuitable as a treatment to reduce GH secretion over the 
long term, particularly in conditions where glycaemic con-
trol is important, such as diabetes mellitus. For this reason, 
a number oflong-acting somatostatin analogues were devel-
oped, octreotide (SMS 201-995, Sandostatin®) 16, lanreotide 
(BIM-231 04, Somatuline®) 17 , vapreotide (RC-160) 18 and an 
early unsuccessful hexapeptide analogue, MK-678 19 • For 
comparative purposes, the absolute stereochemical structures 
of somatostatin and these peptide analogues are reproduced 
for this thesis in Appendix 1. 
Drug Design 
The development of octreotide by Sandoz began immedi-
ately after the publication of Brazeau and Guillemin's 
discovery of somatostatin in the journal, Science3 (Figure 2). 
In 197 4, Sandoz formed the "SRIF-Project" team, involv-
ing six laboratory units in chemistry and biology, under 
the direction of] Pless, to produce long-acting synthetic ana-
logues of somatostatin. Sandoz had a history of vibrant 
research interest in pituitary hormones, both anterior and 
posterior. During the next five years full size "peptide" ana-
logues were designed but this did not generate any useful 
leads until1978 when Jean Rivier,Wylie Vale and Nicholas 
Ling from the Salk Institute, La Jolla, California, as part of 
their effort to identify the minimal "essential" sequence of 
SRIF, synthesised several analogues of"reduced size" (oligo-
somatostatins).The overall conclusion of this work brought 
about the conclusion that the sequence of phenylalanine at 
position 7 and threonine in 10 was essential for biological 
activity 20• Based on these collected findings, Sandoz directed 
its efforts to the "mini-SRIF" project, which synthesised 
highly potent analogues of reduced size by incorporating 
additional structural elements into the "minimal essential 
sequence". The Phe7-Thr10 sequence was stabilised by 
cyclisisation with a cysteine bridge. Physical and computer-
assisted modelling were used and culminated in the selec-
tion of compound 9, termed "SMS-201-995", for further 
development 16.The introduction of two non-natural amino 
acids,D-Phe at theN-terminal and L-Thr-ol at the C-ter-
minal and substitution ofL-Trp by its D-isomer made this 
octapeptide highly resistant to enzymatic degradation thus 
increasing its half-life dramatically and enhancing its bio-
logical potency. The final synthetic process which was devel-
oped by J. Pless and W Bauer in conjunction with T. Petcher, 
P. Marbach and W Doepfner and their colleagues was 
impressive, involving 25 separate steps, in which neither 
intermediates nor octreotide itself were crystallisable, yet this 
process yielded a 98% pure peptide in industrial amounts 16 • 
The structures of somatostatin and octreotide are depicted 
in Figure 3. The criteria applied by the Sandoz Preclinical 
Research department to putative somatostatin analogues 
were that the analogue should have increased resistance to 
enzymatic attack and greater biological potency than native 
somatostatin. Moreover, it should inhibit GH more selectively 
than insulin and display a longer duration of action than 
somatostatin. Octreotide had a biological half-life of the 
order of 90 minutes and was also relatively more potent in 
the inhibition ofGH and glucagon than insulin, compared 
with somatostatin itself, in animals 16 • The development of a 
specific radioimmunoassay for octreotide helped immensely 
in the modelling of the pharmacological profile of octreotide 
during early stages of preclinical and clinical research. 
The driving force from a therapeutic standpoint was the the-
ory that GH suppression could either prevent or reduce the 
late complications of poorly controlled diabetes mellitus, such 
as diabetic retinopathy. It was felt that the synthesis of 
octreotide could represent an effective means of suppressing 
GH secretion in diabetic patients. Before embarking on 
treatment of patients, pharmacological studies were per-
formed in animals and humans. These studies investigated 
both the pharmacokinetics of subcutaneous and intravenous 
administration and the pharmacodynamic effects of 
octreotide on GH, insulin and glucagons, as these were the 
prototypical endpoints for the investigation of safety and effi-
cacy in somatostatin research. 
FROM SOMATOSTATIN TO 0CTREOTIDE 19 
1 Structure of I I First Regulatory I Somatostatin Approval of Elucidated Octreotide 
Sandoz Registration sought 
Somatostatin for Octreotide in 
- Analog Program 1 Octreotide I GEP Tumors and Began Synthesized Acromegaly 
First Report 
r-
Regarding I Phase II & Ill I Octreotide Clinical Studies Published Commenced 
~ Phasel I Studies 
Completed 
~ Compassionate 
I 
ILAR I Use Of Formulation 
Octreotide Began r nr 1 1. 
~ 
Key Stages in the Clinical Development of Octreotide 
Figure 2. Chronology of the discovery of somatostatin and the clinical development of octreotide. LAR = Long acting repeatable formula-
tion of octreotide. 
Human somatostatin 
0 Amino acids essential for receptor building 
Figure 3. The amino acid structures of somatostatin and octreotide. 
Octreotide 
20 . I Chapter II 
II.III - PRECLINICAL AND CLINICAL DEVELOPMENT 
OF OCTREOTIDE 
Drug development is classically divided into separate phases, 
during which specific types of research are performed to yield 
necessary information about the characteristics, pharma-
cology, safety and efficacy of the potential drug compound 
(Figure 4). The process of drug discovery, development and 
design involves investigative research in vitro and in animal 
models, followed by a process of careful clinical trials for 
appropriate candidate drugs. After the successful development 
of a new pharmaceutical, assessments are made post-launch 
regarding how the new product compares with others, and 
new indications are sought for the drug in the future. During 
the development process many important regulatory require-
ments have to be satisfied, starting with a tight definition of 
the proposed use of the drug in addition to the formulation 
of the drug and the proposed dose. Quality issues are also to 
the forefront, as requirements regarding manufacturing 
including dosage, impurities, stability and additives must be 
strictly adhered to. Early studies must provide information on 
how the body handles the drug metabolically, which involves 
the performance of ADME studies (absorption, distribu-
tion, metabolism, excretion). These studies are accompa-
nied by early safety analyses in animal models to assess safety 
and toxicity in terms of carcinogenesis, damage to gametes 
and potential teratogenicity. Preclinical testing is performed 
in vitro, in vivo and increasingly in computer simulations (so-
called in silico). Phase I trials are the first studies in humans 
and the pharmacological and metabolic properties of the drug 
are tested rigorously in small numbers of healthy adult vol-
unteers to determine tolerability, early safety, pharmacoki-
netics and pharmacodynamics using surrogate biological 
markers of the target disease (e.g. growth hormone and 
acromegaly). Phase II studies represent the first time a poten-
tial drug is used in a patient population, and pharmacolog-
ical, efficacy and safety data are collected regarding the drug 
across a range of possible doses. Based on the results of the 
phase II studies in a limited number of patients demonstra-
bly safe and potentially useful compounds may go forward 
into phase III studies, which are formal therapeutic, ran-
domised controlled trials performed in hundreds or thousands 
of patients to determine the safety and efficacy of the drug. 
Variability in drug response is performed in phases II and III. 
Phase III is a rigorous and intense phase of development that 
is performed according to legal and regulatory requirements 
of agencies such as the Food and Drug Administration 
(FDA) in the United States of America and the European 
Medicinal Evaluation Agency (EMEA) in Europe. Safe, 
effective and useful drugs that meet regulatory study require-
ments may receive a licence to be marketed and commer-
cialised by the pharmaceutical company. In phase IV, 
additional efficacy and safety data are collected and can be 
used to identifY new dosing schedules, discover how it com-
pares with other available treatments, better understand its 
mechanism of action and find new applications. Drug devel-
opment, although heavily regulated, rarely follows a linear 
process from phase I to phase IV, as there is a certain amount 
of overlap between phases in terms of data obtained. 
II.III.I - Preclinical Studies 
Initial toxicological screening of octreotide demonstrated 
a lethal dose 50% (LDso) of 18 mg/kg in rats after acute 
administration 21 • Four-week studies in rats and 
dogs showed that octreotide was safe at a dose of 
4-16 mg/kg/day and 0.2 mg/kg/day, respectively, 
following intraperitoneal administration. Pharmacokinetic 
data from the rhesus monkey showed an IDso for GH 
secretion of 0.038 )lg/kg/h octreotide, which was two 
orders of magnitude lower than the IDso for insulin. 
For glucagon, the IDso was approximately twice that for 
GH (0.075 )lg/kg/h). The t 112 (elimination half-life) of 
subcutaneous octreotide was 40 min in rats and 7 4 min in 
dogs, and approximately one fifth of the dose was recov-
ered unchanged in urine. From these rat data, octreotide 
inhibited GH 45 times more potently than somatostatin, 
and was 33 times more GH/insulin specific. This phar-
macological profile was considered optimal, as it 
provided for much greater GH secretion and minimised 
the risk of hypoglycaemia through the higher IDso for 
insulin suppression. Also, the elimination of octreotide 
was much slower than native somatostatin, thus increasing 
the likelihood of a long duration of action in humans. 
Testing 20-100 100-500 1000-5000 
healthy 
humans 
patients patients 
Aim Safety and Safety and Safety and Long term Review of Refine and 
activity dosage efficacy safety and results and study further 
assessment assessment assessment efficacy regulators the safety and 
assessment ruling efficacy profile 
of 
Figure 4. Diagram of timelines of various phases of drug development. IND = Investigational New Drug; NDA = New Drug Application. 
(For a useful overview of the important steps drug development process in the European Union, the European Medicines Evaluation Agency 
carries up to date information at http:/ jpharmacos.eudra.org/F2/ pharmacosjdocsjbrochurejpharmaeu.pdf, while the Food & Drug 
Administration's Centre for Drug Evaluation Research maintains an informative website at www.fda.gov/cderjhandbookjdev_rev.htm.) 
Gastric acid secretion studies performed in rats showed that 
O.Smg/kg octreotide had similar effects to cimetidine 
1 Omg/kg21 . Octreotide was also tested in rat tumour mod-
els and was shown to reduce oestrogen induced pituitary 
hyperplasia and insulinomas. Mter developing a specific 
radioimmunoassay (RIA) for octreotide, pharmacokinetic 
studies were performed in rats to evaluate its disposition as 
well as its distribution in different organs in rats. These stud-
ies showed the stability of octreotide in biological fluids 
and in tissues and that 50% of the octreotide dose was 
excreted in bile within 8 hours of subcutaneous adminis-
tration 21 . Safety studies showed that octreotide was well 
tolerated in rats, dogs and monkeys. Overall, these charac-
teristics made octreotide an attractive candidate for the 
treatment of diseases associated with hypersecretion of GH 
and gut hormones. 
II.III.II - Phase I Clinical Studies 
II.III.II.I - Clinical Pharmacology Studies 
Based on these animal data, phase I pharmacological stud-
ies were performed in healthy human volunteers across a 
wide dose range via subcutaneous (sc) and intravenous (iv) 
tllla tlll~ tlll~ 
Dose (min) (min) (min) Participants Route (J.Lg) 
Healthy Volunteers IV 25 9 72 
IV 50 11 90 
IV 100 II 99 
IV 200 14 98 
Healthy Volunteers IV 20 
Chronic renal failure IV 20 
Healthy volunteers sc 50 5.3 88 
sc 100 5.6 102 
sc 200 11.7 100 
sc 400 5.6 93 
Healthy Volunteers sc 50 113 
sc 100 113 
AcromeaaJic patients sc 100 110 
sc 100 24.1 11.3 169 
Nasal 500 11.3 12.9 148 
1000 7.9 17.3 155 
2000 7.1 21.3 208 
Healthy Volunteers oral 2000 
Healthy Volunteers Oral (S) 8000 
(per-oral intubation 
studies) 
Oral (P) 8000 
Oral 8000 
(L) 
Oral (J) 8000 
Oral (1) 8000 
Acromegalic patients Oral 4000-
8000 
Vc 
(L) 
5.2 
5.9 
6.2 
10.2 
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routes of administration (Table 1). Single dose pharmacoki-
netic studies revealed that octreotide reached steady state after 
90 min of iv infusion and the tv2 was 41-58 min. Peak 
octreotide concentrations occurred 15-30 min after single 
sc injections (50-100 J.Lg). The t112 was 113 minutes after 
sc injection, which was approximately 2.5 times longer 
than after iv administration. These human data confirmed and 
extended the animal results by showing rapid uptake of 
octreotide after sc injection, in conjunction with a 
prolonged elimination t112. Studies in elderly volunteers 
(median age 76 years) revealed a longer half-life (140 min) 
and slighdy increased area under the curve following single 
dose octreotide 22·23. 
II.III.II.II - Pharmacodynamic Endocrine Studies 
Pharmacodynamic and safety studies were performed to 
examine effects of octreotide on blood glucose concen-
trations and other aspects of glycaemic metabolism (results 
summarised and reviewed in (21.22, 23l. Six healthy volun-
teers were treated with iv octreotide 50-100 J.Lg/hr for 48 
hours and glucose tolerance tests showed no changes in 
peak glucose concentration or area under the curve. The 
time taken to reach maximum glucose concentration was 
delayed23. In healthy volunteers post-prandial glucose con-
Vd CL AUC o.oo AUC 0-4so tmax Cmax 
(L) (mllmin) {llg/L • min) (J.Lg/L • (min) (j.Lg/L) 
min) 
18 177 153 153 3.7 5.7 
21 159 338 342 4.1 9.6 
30 227 648 670 3.4 24.2 
29 198 1244 1271 7.3 27.8 
173 
75 
21.5 320 310 26 2.4 
25.2 695 695 26 4.4 
17.6 1734 1633 35 10.6 
20 3163 3139 28 23.5 
298 1.9 
2.7 
172 27.4 3.4 
896 42 4.5 
957 16.5 8.7 
1923 13.5 20.8 
4597 13.8 43.4 
130 90-120 1.6 
72 60 0.77 
120 53 0.45 
112 45 1.06 
36 23 0.95 
12 0.52 
120- 1.2 
360 
Table 1. Summary of the principal pharmacokinetic data after intravenous, subcutaneous, nasal or oral administration of octreotide.Abbreviations: 
AUC 0-oo =area under the plasma concentration-time curve from time zero to infinity; AUC 0-480 =area under the plasma concentration curve 
from time zero to 480 minutes; CL = today body clearance (to convert to L/h, multiply by 0.06); Cmax = peak plasma concentration; 
t,;,a =absorption half-Life, t'M =distribution half-Life; t,;,, =elimination half-time; tmax =time to reach Cmax; Vd =volume of distribution; 
Vc = volume of central compartment; IV =intravenous; SC = subcutaneous; 5 = stomach; P = proximal duodenum, L = Ligament of Treitz; 
J =jejunum; I= terminal ileum. Adapted from Chanson P, Timsit J, Harris AG 23. 
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centrations rose during treatment with octreotide at a 
dose of 150-1000 !lg sc, although this was only significant 
(>200 mg/dL) at doses of800 !lg and 1000 !lg 23.Median 
post-prandial glucose levels were also found to be ele-
vated in a dose dependent fashion following treatment 
with octreotide (100 - 600 !lg twice daily) 23 • Overall, 
treatment of normal human subjects with octreotide was 
not associated with hypoglycaernia, even at high dose. 
GH secretion was inhibited by octreotide (50 !lg once daily 
- 600 !lg twice daily) in these healthy volunteer studies. 
Normal nocturnal and post-prandial GH surges were sig-
nificantly suppressed by octreotide, while prolactin secre-
tion at night was unaffected by octreotide. This implied that 
octreotide could provide good dynamic GH control in 
patient populations in response to the physiological stim-
uli encountered during sleep and nutrient metabolism. 
II.III.II.III - Gastrointestinal and 
Pancreatic Function Studies 
On a molar basis octreotide was 10 times more potent than 
native somatostatin in reducing gastric acid secretion 24•25 • 
Single sc injection of100 !lg octreotide inhibited gastric 
US Acromegaly 
Reaistration Proaram 
acid secretion for more than 5 hours 26.With respect to pan-
creatic and biliary secretion, octreotide produced an 80% 
decrease in cholecystokinin (CCK) and secretin stimulated 
pancreatic secretion in healthy volunteers 27• 28• 29 • 
This inhibitory effect decreased with time. There was no 
decrease over time with respect to inhibition by 
octreotide of pancreatic enzyme secretion induced by 
Lundh meal 29 • Octreotide reduced amylase and trypsin 
output by three quarters 28 • Gallbladder contraction was 
also decreased in healthy volunteers, and the combina-
tion of this with pancreatic inhibition was suggested to 
raise the risk of reduced nutrient absorption. Lembke et 
al performed a double blind crossover study in nine 
healthy subjects over two seven day periods 29 • Faecal fat 
excretion was higher during octreotide treatment but this 
effect decreased with time. Other individual studies 
demonstrated that octreotide reduced caerulin-stimulated 
pancreatic polypeptide release, but had no effect on basal 
secretion of this gut hormone 30• 31• 32 • Creutzfeldt et al 
found that low dose octreotide (25 !lg) was able to 
reduce meal-stimulated pancreatic polypeptide com-
pletely, while lesser effects were seen on insulin and 
glucagon secretion 33 • 
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II.III.II.IV - Gastrointestinal Motility Studies 
CCK-induced gallbladder contraction was inhibited by 
octreotide but this effect disappeared after treatment for six 
days 29.This may have been due to desensitisation of the gall-
bladder. However, gallbladder contraction in response to a 
Lundh meal remained suppressed completely by 25 !lg 
octreotide after six days of treatment. Octreotide increased 
gastric motility but inhibited intestinal motility (increased 
transit time) 34• Also, octreotide reduced intestinal mucosal 
blood flow to a greater degree than native somatostatin 25•26•35· 
II.III.II.V- Safety Studies 
With regard to safety parameters, octreotide had no clinically 
significant effects on liver enzymes, triglycerides, renal and 
haematological profiles, electrocardiograms or vital signs22•23 • 
Patients reported abdominal discomfort, nausea, loose stools 
and diarrhoea among the most common adverse events 
associated with octreotide. These were accompanied by a rise 
in stool fat, presumably due to reduced exocrine pancreatic 
secretion. Flushing also occurred, and along with abdomi-
nal symptoms appeared to be dose related in that most 
patients at the highest dose (1000 !lg) reported symptoms. 
These adverse events were self-limiting, however, and no seri-
ous sequalae occurred during this phase of development. 
II.III.III - Impact of Phase I Studies 
At the outset our primary indication for octreotide was as 
a treatment for diabetes mellitus and its complications. The 
results from phase I studies demonstrated multiple inhibitory 
effects on hormones (particularly GH with respect to dia-
betes mellitus) and gastrointestinal motility, which suggested 
multiple potential clinical uses. Initially, however, our focus 
remained firmly on using the preclinical and phase I stud-
ies to demonstrate safety and efficacy in terms of diabetes 
mellitus treatment. The disparate nature of the potential 
applications of octreotide provided an excellent opportunity 
for our assessment of the Clinical Development Program 
when the diabetes mellitus indication was proving unsuc-
cessful. Studies with native somatostatin had suggested 
octreotide as a possible treatment in gut endocrine tumours36 
and acromegaly 37, which led to the distribution of octreotide 
on a compassionate use basis in these two indications. 
A unique aspect of octreotide's clinical development was that 
multiple putative indications were eventually pursued in 
parallel (Figure 5).The prevailing model at the time- and cur-
rently - was to develop potential drugs for one tightly 
defined indication, in this case, diabetes mellitus.A:fter com-
pletion of the preclinical phase and phase I, the pharmaco-
logical characteristics of octreotide i.v. and s.c. were all 
published in peer reviewed literature e.g. 38•39 • During this 
period, alternative delivery forms of octreotide were in 
development, including a nasal insuillation powder 40•41 and 
an oral formulation 42•43' 44• 
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Chapter III. 
The Clinical Development of 
Octreotide in Diabetes Mellitus 
III.I - CHARACTERISTICS OF DIABETES MELLITUS 
111.1.1 - Glycaemic Control in Diabetes Mellitus and 
the GH/IGF-1 Axis 
The Clinical Development Program for octreotide in type 
I diabetes mellitus was based on the existing understanding 
of the role of growth hormone (GH) and insulin-like 
growth factor-I (IGF-1) in the regulation of carbohydrate 
metabolism (hormonal and gastrointestinal), and in the aeti-
ology of diabetic retinopathy and nephropathy. It had long 
been recognised that patients with poorly controlled type I 
diabetes mellitus exhibited elevated GH levels 1• It was felt 
that this GH hypersecretion in conjunction with increased 
circulating glucagon levels contributed to poor glycaemic 
control and long-term complications 2•3• It had been demon-
strated that GH administration could elevate plasma glucose, 
while conversely, improved glycaemic control reduced GH 
levels in type I diabetic patients 4• It has since been shown that 
reduced GH secretion enhances insulin sensitivity in type I 
diabetic patients 5• The so-called "dawn phenomenon", an 
early morning (- 4 am) rise in blood glucose is temporally 
associated with a parallel surge in GH, a phenomenon 
which was felt to represent an important target for improved 
diabetic control. When we formulated the Clinical 
Development Program for octreotide in diabetes mellitus, 
octreotide therapy was seen as a method for reducing the 
hyperglycaemic effects of GH, especially during nocturnal 
surges. Consequendy, it was suggested that octreotide admin-
istration in type I diabetes mellitus could reduce insulin 
requirements. 
The aetiology and clinico-pathological findings in type II dia-
betes mellitus differ sigrrificandy from autoimmune type I dis-
ease. Insulin resistance is the primary characteristic of type 
II diabetes mellitus. It is currendy held that metabolic dys-
regulation decreases the sensitivity ofliver, muscle and other 
cells to insulin 6 , which causes elevated blood glucose and 
hyperinsulinaemia.This metabolic syndrome can be accom-· 
panied by elevated low-density lipoprotein (LDL) cholesterol 
and triglycerides and hypertension, which combine to cause 
increased morbidity and mortality (especially vascular) in type 
II diabetes mellitus. Obesity and genetic traits can worsen 
insulin resistance, as can hormones such as GH. Patients 
with acromegaly are now recognised to have significant 
insulin resistance 7 , with 30-40% developing impaired glu-
cose tolerance and 10-20% developing overt diabetes mel-
litus. In the early to mid 1980's research had demonstrated 
that GH affected both hepatic and peripheral insulin sensi-
tivity in normal and acromegalic individuals 8· 9 , while insulin 
secretion itself was possibly unimpaired 10• Subsequent stud-
ies in the 1990's using recombinant GH in patients with 
short-stature or hypopituitarism have confirmed that GH 
decreases insulin sensitivity signi:ficandy 11 •12.At the inception 
of the Clinical Development Program for octreotide we were 
aware of some of these interactions between GH and glu-
cose metabolism in type II diabetes. We also noted that 
blood glucose could potentially be lowered via inhibition by 
octreotide of gastric hormones and motility. We hypothesised 
that by slowing gastric motility, the entry of carbohydrate rich 
material into the duodenum could be slowed, thus reduc-
ing uptake of mono- and disaccharides into portal blood The 
Clinical Development Program in type II diabetes mellitus 
focused primarily on the metabolic effects of octreotide 
on glycaemic control. 
III.I.II ,.. Complications of Diabetes Mellitus 
At the time of the clinical development of octreotide for dia-
betes mellitus in the 1980s, it was recognised that morbid-
ity and mortality was due largely to macro- and 
micro-angiopathic changes. With respect to microangiopathic 
diabetic complications, GH and IGF-1 had been impli-
cated in neovascularisation in diabetic retinopathy and renal 
hypertrophy in diabetic nephropathy 13• 14• 15 • The precise 
mechanisms by which these pathological effects occurred was 
unclear, but our working hypothesis at the time was that 
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octreotide could retard retinal revascularisation and early kid-
ney hypertrophy in type I diabetes mellitus via GH sup-
pression. In the mid 1980's the concept that diabetic 
glycaemic control was a key determinant of disease outcome 
in type I diabetes mellitus was unproven. Prospective evidence 
only became available in the 1990's when the Diabetes 
Control and Complications· Trial (DCCT) showed that 
intensive glycaemic control reduced the risk of retinopathy 
and albuminuria by 4 7% and 54%, respectively 16 • Our aims 
for octreotide in type I diabetes mellitus were pragmatic, 
namely to improve glucose control and (consequently or 
independently) reduce microvascular retinal and renal 
complications. 
111.11 -THE ROLE OF THE GH/IGF-1 AXIS 
IN DIABETES MELLITUS 
III.II.I- GH/IGF-1 and Insulin Regulation 
The mechanisms by which GH affects insulin sensitivity, and 
hence the severity of diabetes, are still not fully understood. 
Animal studies have suggested that GH reduces hepatic 
insulin receptor numbers 17· 18 , causing increased circulating 
plasma insulin. Glucose transport proteins such as GLUT1 
are decreased in response to GH 19, and are increased in 
I TGH I 
l 
I 
I iiGF-1 I 
I I 
I iCirculating IGF-1 I 
I 
GH deficiency 20.Therefore, GH-induced insulin resistance 
may be due to reduced uptake from serum into storage 
tissues such as hepatocytes and adipocytes. 
fu virtually all of the known growth-promoting activities of 
GH are mediated at a tissue level by I GF-1, much research 
has focused on its role in diabetes mellitus. IGF-1 and two 
of its binding proteins (IGFBP's), IGFBP-1 and IGFBP-3, 
are known to influence carbohydrate metabolism. IGFBP-
3 functions as a high afl:inity carrier protein for IGF-1 and 
generally has a stable concentration throughout the day, 
whereas IGFBP-1 is more sensitive to metabolic changes 21 • 
In type I diabetes mellitus, the IGF-1/IGFBP system is 
abnormal; G H secretion is increased 22 but circulating I G F-
1 is low 23.This apparent paradox is currently thought to be 
due to initial hyperglycaemia-induced down-regulation of 
hepatic IGF-1 production and consequently, serum IGF-1. 
Later, these low levels ofiGF-1 feed back to the pituitary and 
stimulate GH production. Therefore, this hormonal distur-
bance is caused by a disconnect between the central and 
peripheral arms of the GH-IGF-1 axis 24·25.Patients with type 
II diabetes mellitus have more heterogeneous disturbances 
ofGH/IGF-1/IGFBP. Low insulin levels in type I diabetes 
mellitus are known to decrease hepatic GH receptors 26·27 , and 
thus decrease the synthesis and release ofiGF-1 in response 
to GH.Furthermore,hepatic IGFBP-1 production is inhib-
ited by insulin 28' 29 and insulinopaenia increases IGFBP-1. 
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III.II.II - GH/IGF-1 and Complications of Diabetes 
Mellitus 
In a recent review of the role of growth factors in the 
pathogenesis of diabetic vascular complications, Blakesley and 
colleagues conclude that one or more growth factors, such 
as, IGF-1, fibroblast growth factor (FGF), epithelial growth 
factor (EGF), vascular endothelial growth factor (VEGF) or 
transforming growth factor beta (TGF-beta), play a signif-
icant role in the initiation and progression of the pathologic 
changes seen in diabetic retinopathy and nephropathy 30. 
Elevated serum (and possibly vitreous) IGF-1levels have been 
associated with proliferative retinopathy and retinal neo-
vascularisation; and rodent studies indicate that IGF-1 and/ or 
GH can lead to mesangial cell proliferation, glomerular 
sclerosis, and glomerular hyper:filtration.Janssen et al, how-
ever, have questioned the pathogenic role of the IGF/IGFBP 
system in the development of diabetic complications at the 
tissue level, as their studies failed to correlate serum levels of 
IGF-1 and IGFBP with their respective tissue levels 31 . In a 
comment on these findings Merimee reviewed the evi-
dence in support ofiGF-1 and IGFBP in the pathogenesis 
of diabetic microvascular complications and noted a num-
ber of potential interfaces between IGF-1 and vascular 
complications, most particularly diabetic retinopathy 32. 
Figure 6 summarises the various strands of evidence regard.,. 
ing the role ofiGF-1 in diabetic complications. 
III.II.II.I - Diabetic Retinopathy 
Diabetic retinopathy is a leading cause of adult blindness 33 
and after 10-15 years of diabetes there is a 90% chance of 
developing retinopathy 34. It is estimated that in the United 
States, 12,000 to 14,000 diabetic patients lose their sight from 
retinopathy each year 33. Diabetic retinopathy results from 
extensive proliferation of new retinal blood vessels and 
visual acuity is lost due to vitreous haemorrhage or fluid loss 
from fragile new vessels. Panretinal argon laser photocoag-
ulation is the only effective intervention for proliferative dia-
betic retinopathy but it can have complications such as 
retinal detachment; it is a destructive procedure and does not 
always provide control of proliferative retinopathy. Figure 7 
summarises in a schematic fashion some of the important 
pathological steps in terrns of retinal vascular changes and 
highlights some important growth factors that are currently 
understood to play an important role in mediating patho-
logical changes in the retinas of diabetic patients. 
At the time of the development of octreotide, there was his-
torical evidence for the role of GH in diabetic retinopathy. 
Pituitary ablation retards the progression of diabetic retinopa-
thy35 and clinical trials have demonstrated the efficacy of elec-
tive hypophysectomy (surgical or Yttrium-90 radioactive 
beads) in preventing blindness 36·37. The severity of hypopi-
tuitarism 38 and GH deficiency 39 and the duration following 
pituitary ablation correlate with the degree of neovascular-
isation 40•41. Retinal capillary hyper-fragility in diabetes mel-
litus also improves after pituitary ablation 42. Merimee's 
original report that diabetic GH-deficient patients exhibited 
a lower rate of retinopathy than other diabetic patients 43 has 
been confirmed by others 44• Preclinical studies have shown 
a direct stimulatory effect for GH on the retinal vascular 
endothelium 45 .A more recent report has shown that exoge-
nous GH treatment in GH-deficient, non-diabetic patients 
can cause retinopathic changes similar to those seen in dia-
betes mellitus 46. 
Little was known about the role of IGF-1 in diabetic 
retinopathy when the Clinical Development Program for 
octreotide in diabetes was designed. In 1983, Merimee and 
colleagues found that total IGF-1 was elevated in patients 
with early neovascular retinal changes 13• In contrast, Flyvbjerg 
and Orskov reported subsequently that circulating IGF-1 was 
normal in type I diabetic patients compared to a matched 
non-diabetic control population 47. Grant and others have 
noted that diabetic patients with proliferative retinopathy have 
three times the vitreous IGF-1 concentrations of age-
matched non-diabetic controls, while IGFBP's also rise 48·49. 
In a porcine model, retinal rnicroangiopathy was induced by 
direct injection ofl GF-1 into the vitreous 50. In recent years, 
the interplay between IGF-1 and its binding proteins has 
become better understood. Janssen et al reported that fast-
ing free IGF-1, total IGF-1 and IGFBP-3 were lower in type 
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Figure 7. Diagrammatic representation of the pathogenesis of dia-
betic retinopathy. 
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I diabetic patients, while IGFBP-1 was higher31 • Interestingly, 
free IGF-1 (age-adjusted) was higher in type I diabetic 
patients with retinopathy than diabetic patients without 
retinopathy, although the authors cautioned that the opthal-
moscopic assessment of retinopathy was subjective and 
could have resulted in mis-classification of some patients. 
Further evidence of the role ofiGF-1 in diabetic retinopa-
thy has come from studies ofhuman recombinant IGF-1. 
The finding that IGF-1 is reduced in diabetes and that 
exogenous IGF-1 can improve hyperglycaemia led to a 
clinical trial, which demonstrated a progression of diabetic 
retinopathy in IGF-1-treated diabetic patients 51•52• 
III.II.II.II - Diabetic Nephropathy 
Approximately 25-50% of diabetic patients develop 
nephropathy and a significant proportion will require cosdy 
dialysis or renal transplantation. Diabetic nephropathy is now 
the commonest cause of renal failure in developed coun-
tries 53 , and the cost of diabetic nephropathy was $2 billion 
in the Unites States in the early 1990's 54. From 1981 to 1990, 
the number of diabetic patients requiring dialysis or trans-
plant for end-stage renal failure rose by 10% year-on-year55 • 
Furthermore, diabetic patients with nephropathy have 
25 - 40 times the all-cause mortality of age-matched non-
nephropathic patients. The morphological changes of early 
diabetic nephropathy have been well characterised. They 
include increased glomerular volume, increased glomeru-
lar capillary lumen area, and expansion of the mesangial cell 
volume 56· 57 • The first measurable manifestation of this is 
increased glomerular filtration rate. Although the progres-
sion of diabetic nephropathy is slow, 30 - 40 % of patients 
with type I diabetes may progress to renal failure. 
In experimental diabetes mellitus in rats, renal mesangial 
cells develop elevated numbers of IGF-1 receptors and 
kidney IGF-1levels rise within the first four days, peak-
ing at 24 to 48 hours after induction of the diabetes 58•59 • 
In the absence of GH, however, renal hypertrophy is 
abolished in experimental diabetes in rats 60 • The primary 
role of IGF-1 in diabetic nephropathy appears to be 
glomerular and mesangial cell expansion, as IGF-1 can 
induces protein synthesis by mesangial cells in culture 61 • 
Mesangial cell expansion contributes to the overall kid-
ney growth and mesangial cell protein synthesis may 
contribute to the basement membrane thickening that is 
characteristic of glomerulosclerosis 62• 63 • IGF-1 has a less 
clear role in causing increased GFR during the devel-
opment of diabetic nephropathy. Because there is a lack 
of correlation between declining GFR and increasing kid-
ney size in patients with diabetic nephropathy and because 
circulating IGF-1 levels do not strictly correlate with 
renal hypertrophy, other factors are likely to be con-
tributing to declining renal function. However, it is 
known that GH administration can normalize the low 
renal plasma flow (RPF) and low GFR seen in GH-
deficient patients; and serum levels ofiGF-1 are seen to 
increase concomitantly 64' 65 • In type I diabetic patients, GH 
hypersecretion has been correlated with glomerular 
hyperfiltration 66 and exogenous GH administration in 
poorly controlled diabetic patients increases glomerular 
filtration 67 • Since transgenic mice expressing increased 
GH develop glomerulosclerosis but mice transgenic for 
IGF-1 hypersecretion do not, it may be that both GH 
and IGF-1 play a combined role at different stages of 
diabetic nephropathy. 
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Circulating and locally generated IGF-1 appear to be 
involved in the development of diabetic nephropathy. 
The IGF-1 synthesised locally in the kidney is regulated 
in part by GH 68•69•70 • IGF-1 receptors are found through-
out the kidney 71 · 72• 73 , including in mesangial cells. There 
is a likely synergism between IGF-1 and other growth fac-
tors such as epithelial growth factor (EGF) and trans-
forming growth factor-B (TGFB) 74• 75 • 76 • IGF-1 and 
IGFBP's may interact with vasoactive factors and kinins 
to link diabetic nephropathy with hypertension. IGF-1 
infusion in rats decreases glomerular afferent and efferent 
arteriolar resistance and this vasodilatory effect may be 
mediated by kinins, which also have the effect of increas-
ing renal plasma flow 77•78 • Kinins appear to cause vasodi-
lation via nitric oxide and interestingly, inhibition of 
nitric oxide synthesis blocks the vasodilator effect of 
IGF-1 79 • IGFBPs may also play a role in modulation of 
IGF-1 related tissue growth in various parts of the kid-
ney, as increased renal cortical and medullary IGFBP 
and IGF-1 receptor numbers have been noted in animal 
studies 80• 59 • 
III.III - OTHER CELLULAR PATHOLOGICAL MECHANISMS 
IN DIABETES MELLITUS 
Hyperglycaemia in diabetes mellitus favours biochemical 
disturbances that can be detrimental to tissue. Glucose 
itself can be toxic to cells, while glycosylation, hypoxia and 
free radical generation can damage proteins, alter membrane 
function and induce inflammatory cell repair mechanisms. 
Glycation of lysine terminal groups in protein leads to 
cross-linking between or within proteins resulting in 
compounds called advanced glycosylation end products 
(AGEs). AGEs may alter cell-cell interactions between 
immune cells like macrophages and vascular endothelial 
cells, producing cytokines and IGF-1 81 • They may also 
induce collagen cross-linking and basement membrane 
thickening and mesangial cell matrix production 82 • 
Cutaneous AGEs in diabetic patients have been shown to 
increase progressively with the severity of retinopathy 83 • 
Aldose reductase (AR) and sorbitol dehydrogenase act 
with NADH to maintain osmotic balance across cell 
membranes.AR is expressed in retinal capillary pericytes, 
retinal pigment epithelium and retinal endothelium.AR 
expression and sorbitol concentrations have been found to 
be elevated in association with retinal dysfunction and 
hyperglycaemia.AR inhibitors can prevent the progression 
of diabetic retinopathy, including reduction or disappear-
ance of micro aneurysms, haemorrhage, and cotton wool 
spots 84• Increased intracellular glucose can initiate bio-
chemical reactions resulting in neovascularisation 85 , pos-
sibly via increased protein kinase C 86 • Mesangial cells 
exposed to elevated glucose concentrations synthesize 
less heparan sulfate, which could alter transcapilliary 
charge and promote proteinuria 54• Intracellular hyper-
glycaemia and auto-oxidation results in the production of 
oxygen free radicals that cause protein damage. Oxidative 
products of glycated proteins are found in elevated con-
centrations in patients with diabetic retinopathy, indicat-
ing an increase in oxidative protein damage by glyco-
oxidation. There is some evidence of decreased natural 
antioxidant system activity in experimental and human dia-
betes 87 • Temporary occlusion of the retinal circulation in 
rats leads to a proliferative response in both retinal capil-
lary endothelial cells and pericytes 88 • IGF-1 is released 
from cultured retinal microvascular endothelial cells, per-
icytes and pigment epithelial cells in response to hypoxia. 
Also the production ofiGFBP's is increased as oxygen ten-
sion decreases 89 • 
While it has been suggested that chronic hyperglyca~mia 
is directly toxic to cells, damage at a tissue level in diabetes 
mellitus is more likely to be caused by the actions of dis-
parate growth factors, cytokines and biochemical pathways. 
Evidence has been put forward for a crucial role for many 
cellular messengers and mechanisms in the development 
of retinopathy and angiopathy in diabetes mellitus (see 
Figures 6 and 7 above). 
III.IV -THE CLINICAL DEVELOPMENT PROGRAM IN 
DIABETES MELLITUS 
III.IV.I - Scientific Rationale 
As noted previously, somatostatin inhibits GH, IGF-1 and 
gut hormones such as insulin, glucagon, gastrin, cholecys-
tokinin, vasoactive intestinal peptide and motilin. In the gut 
somatostatin's effects are manifested as decreased gastroin-
testinal blood flow and motility; decreased gastric acid 
secretion, decreased carbohydrate absorption and increased 
water and electrolyte absorption. In both type I and type 
II diabetes mellitus, basal somatostatin release is increased 
while the somatostatin response to food is impaired. 
Normalisation of glycaemic control using an artificial pan-
creas (Biostator) has the effect of also normalising somato-
statin levels 90• 91 • 92 • Besides the impairment of insulin 
secretion and insulin sensitivity in diabetes mellitus, 
glucagon and somatostatin release are also abnormal and 
contribute to the development of hyperglycaemia. The 
diabetogenic effect of glucagon is mediated mainly by 
increased glycogenolysis and gluconeogenesis. In the case 
of somatostatin, the impaired response to food will con-
tribute to the postprandial glycaemic rise due to enhanced 
transit of nutrients in the gut. Short-term studies with iv 
somatostatin in type I and insulin-treated type II diabetic 
patients improved glycaemic control and had an insulin 
sparing effect 93.With respect to octreotide, we felt that gly-
caemic control could be improved by suppressing GH 
and glucagon secretion and slowing gastric motility and car-
bohydrate absorption (Figure 8). When designing the 
Clinical Development Program we were acutely cautious 
regarding the potential for octreotide to adversely affect 
diabetes mellitus via acute hypoglycaemia or worsening 
hyperglycaernia. In order to address this difficulty, we 
designed and executed a comprehensive program of safety 
studies in both healthy volunteers and in patients with 
type I and type II diabetes. 
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Figure 9. Effect of octreotide (10 11g/kgjmin) or saline on in vivo rat liver glucose in fasted rats." (-labelled glucose was infused with octreotide 
or saline (con) for 60 min and continued alone for the subsequent 60 min. Each time course represents the mean± SD of" C NMR signal inten-
sities derived from four separate experiments with four animals in each treatment group. Maximum signal intensity for liver glycogen was 
arbitrarily set at 100. The figure demonstrates that octreotide treatment had no impact on glucose handling when compared with placebo 
in this model. Adapted from Ezzat S, Pahl-Wostl C, Rudin M, Harris AG 94• 
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Figure 10. Effect of octreotide (10 11g/kgjmin) or saline on in vivo rat liver glycogen in fasted rats." (-labelled glucose was infused with 
octreotide or saline (con) for 60 min and continued alone for the subsequent 60 min. Each time course represents the mean± SD of "C NMR 
signal intensities derived from four separate experiments with four animals in each treatment group. Maximum signal intensity for liver glyco-
gen was arbitrarily set at 100. The figure demonstrates that octreotide treatment was associated with greater glycogen breakdown than placebo 
treatment. Adapted from Ezzat 5, Pahl-Wostl C, Rudin M, Harris AG 94 • 
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III.IV.II - Octreotide: Effect on Metabolic Control in 
Diabetes Mellitus 
III.IV.II.I - Background Studies 
In order to characterise the effect of octreotide on meta-
bolic control and complications in diabetes mellitus, a 
group of 29 individual studies were performed, involving 
141 type I and 61 type II diabetes patients. Particular atten-
tion was paid to potential adverse events, especially hypo-
glycaemia, as the effect of octreotide on glucose suppression 
in diabetes had not been fully investigated at that time. The 
extensive study program involved many trials performed by 
numerous groups worldwide. Studies wich have been pre-
viously reported only in abstract form were summarised 
with S. Efendic and M. Gutniak (see footnote below). 
Type I diabetes patients were insulin deficient (C peptide 
negative) with HbA1 C < 11% and free of major diabetic 
complications with particular reference to autonomic neu-
ropathy.Type II diabetes patients were non-insulin treated 
with fasting or postprandial hyperinsulinaemia (C peptide 
> 200 pmol!rnl) and below 130% ideal body weight. 
Fasting blood glucose levels were > 180 mg/ dl and post 
prandial blood glucose levels were > 60 mg/rnl and < 200 
mg/ dl.Also, gastrointestinal side effects of octreotide were 
studied actively, and in some trials faecal fat excretion was 
measured to better characterise the effect of octreotide on 
dietary fat absorption in diabetes. The efficacy parameters 
chosen were blood glucose (peak, time to peak, AU C), 
insulin requirement in type I diabetic patients, C-peptide 
levels in type II diabetic patients, and hormonal profiles 
( GH, glucagon, cortisol, adrenaline/ noradrenaline). Together 
with Ezzat and colleagues, we used nuclear magnetic res-
onance spectroscopy to study the effect of octreotide on the 
fate of 13C-labeled glucose administered to fasted and 
well-fed rats 94.We found that octreotide did not interfere 
with glycogen synthesis but significantly accelerated the 
onset of glycogenolysis (Figure 9, 1 0). Studies in conscious 
dogs have shown that the suppressant effect of octreotide 
on plasma glucose after an oral glucose tolerance test is 
mainly due to inhibition of glucose absorption as well as 
the suppression ofhepatic glucose output 95 • 
III.IV.II.II - Healthy Volunteer Studies 
A placebo-controlled double-blind study in healthy vol-
unteers showed that 50 !lg bolus and 50 !lg octreotide per 
hour for four hours did not significantly impair glucose 
counter-regulatory hormone responses to experimental 
insulin-induced hypoglycaemia. Following on from this, it 
was demonstrated that octreotide (50 !lg s.c.) delayed meal 
induced hyperglycaemia when administered 30 minutes 
before eating. Multiple dose studies using 25 !lg octreotide 
twice daily before meals for one week reduced gastroin-
A number ofthese studies were published in abstract form, which can be found 
summarized in : Harris AG, Gutniak M, Efendic S. Somatostatin analogue therapy 
of diabetes mellitus. In: New antidiabetic drugs. (ed.) CJ Baily, PR Flatt. Smith 
Gordon, Nishimura 1990: 279-288. 
testinal absorption and pancreatic hormonal function. 
These results demonstrated safety and efficacy for octreotide, 
and particularly highlighted no counter-regulatory hormone 
inhibition and no hypoglycaemia with octreotide 96 • 
In a study of nine healthy volunteers, Kahn and colleagues 
noted that octreotide (50 !lg bid) suppressed fasting and 
glucose-stimulated insulin secretion, leading to mild fasting 
hyperglycaemia 97 • They concluded that these changes 
in insulin secretion were due to lower pancreatic B-cell 
sensitivity to glucose, rather than diminished B-cell secre-
tory capacity.Also the effect of octreotide to decrease B-cell 
sensitivity did not lead to insulin resistance, rather, octreotide 
was associated with relative glucose resistance as assessed 
by reduced B-cell glucose responses at basal and zero 
levels of insulin. 
SubsequentlyVogt and Petrides studied six healthy volun-
teers to examine the effects of chronic changes in plasma 
insulin concentration on insulin sensitivity 98 • Glucose 
turnover and other glucose parameters were measured 
before and after administration of octreotide (200 f.lg/ day 
for 4 days sc infusion). This treatment decreased post-
absorptive and meal-stimulated plasma insulin levels by 
approximately 30-40%, but did not significantly alter over-
all glucose tolerance, free fatty acid, growth hormone, or 
glucagon levels. Furthermore, octreotide was associated 
with significantly increased insulin-mediated whole body 
glucose disposal, non-oxidative glucose disposal, and frac-
tional glycogen synthase activity. Placebo did not alter 
metabolic parameters. The authors concluded that lower-
ing plasma insulin concentration over a prolonged period 
increases insulin sensitivity. 
III.IV.II.III - Metabolic Effects of Octreotide in Type I 
Diabetes Mellitus 
We performed studies in Type I diabetic patients, beginning 
with glucose and gut hormone profiles. Octreotide was no 
different from placebo in terms of glucose dynamics dur-
ing insulin-induced hypoglycaemia and subsequent recov-
ery. This occurred despite significant reduction in GH 
and glucagon secretion, however counter-regulation via 
cortisol, epinephrine and pancreatic polypeptide were 
unaffected. The overwhelming majority of studies were ran-
domized double blind placebo controlled and cross over 
design. Patients were well versed with the control of their 
own diabetes and adjusted their insulin dosage accordingly 
in order to prevent hypoglycaemia possibly due to improved 
tissue sensitivity of insulin. Patients continued their normal 
diet, exercise and insulin regimen throughout the study. The 
criteria for efficacy were based on reduction of insulin dose 
and/ or improvement in blood glucose control. As insulin 
doses were freely modified according to the patient's needs, 
this was considered to be a confounding factor in terms of 
linking possible improved blood glucose control exclusively 
to the addition of octreotide.To this end, insulin doses and 
the number of study days during which blood glucose con-
trol was improved during octreotide as compared to placebo 
were taken into consideration. 
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Overnight Metabolic Profile Studies: 
Effect of Bedtime Octreotide in Type I Diabetes Mellitus 
In a euglycemic clamp study seven patients with Type I dia-
betes received 50 !lg octreotide sc or placebo at 11 pm after 
having been stabilized with a constant intravenous glucose 
infusion. During the next 24 hours, glucose levels were kept 
constant so that the effect of octreotide was assessed by the 
patients' insulin requirements. No insulin was required 
between 11 pm and lam in the octreotide treated patients. 
However insulin requirements were not altered by 
octreotide between 3am and 9am. Mean GH and peak GH 
levels were signifi.candy reduced between midnight and 2am 
compared to placebo. In another euglycaemic clamp study 
five patients with type I diabetes received 50 !lg octreotide 
or placebo at 11 pm. Insulin requirements were signi:fi-
candy reduced at dawn between 3.30am and 7.30am. GH 
levels were signi:ficandy reduced between 11.30pm and 
3am. Glucagon and cortisol levels remained unaffected . 
.In puberty, a temporary rise in insulin resistance occurs. As 
other putative causes of pubescent insulin resistance, such as, 
a rise in body mass index, increased fat deposition, and sex 
hormone secretion have been shown not to cause insulin 
resistance in puberty, it is likely that GH and IGF-I increases 
are of central importance 99• 100' 101' 102, particularly at night due 
to nocturnal GH spurts. Thus, together with Aarsen and 
Bruining et al we studied overnight hormonal profiles and 
the effects of octreotide in 10 type I diabetic patients aged 
12-16 years old 103 • Patients were studied on two different 
nights one week apart and were randomised to receive either 
a single dose of 50 !lg of octreotide sc or placebo at 10pm in 
a double blind, cross-over design. No changes were made to 
insulin therapy or diet during the study period. Bedtime 
octreotide was associated with suppression of GH levels over 
the following 4 hours, and blood glucose concentrations 
fell concomitandy. Early morning glucose rises were not 
inhibited by octreotide administration, and glucagon levels 
were suppressed only at one time point 120 minutes after 
octreotide administration. Interestingly, however, 3-hydroxy-
butyrate levels were lower following octreotide therapy com-
pared with placebo (Figure 11, 12). From the results of this 
study we concluded that it was likely that the duration of 
action of octreotide was too short to have a marked impact 
on the early morning rise glucose concentration. The fact that 
triglyceride and free fatty acid mobilisation and gluconeo-
genesis were not impacted by octreotide compared with 
placebo leads to the possibility that hepatic ketogenesis was 
reduced by octreotide. As glucagon was unaffected by 
octreotide administration in this study, it may be that hepatic 
ketogenesis was altered indirecdy by octreotide via a sup-
pressive effect on GH or IGF-LThere was no difference in 
the diabetogenic effect (gluconeogenesis) of GH surges at 
night between patients receiving a continuous insulin infu-
sion compared with those on intermittent injected insulin. 
It appears, therefore, that the diabetic state is the determinant 
of the diabetogenic effect of GH, rather than variations in 
insulin concentration at night. We noted that the reduction 
in both ketogenesis and blood glucose following octreotide 
18 19 20 21 22 23 2q 1 2 3 q s 6 7 8 9 
hour 
18 19 20 21 22 23 2q 1 2 3 ~ s 6 1 8 9 
hour 
Figure 11 (a) Individual courses of GH after placebo (PLA) admin-
istration in teenage (n=lO) type I diabetic patients. On the horizontal 
axis the hours and on the vertical axis GH expressed as the square 
root of the concentration in !Jg/l. {b) Individual courses of GH after 
SO!lg sc octreotide (SAN) administration in the same group of 
teenage type I diabetic patients. The horizontal axis represents time 
(hours), while the vertical axis expresses GH as the square root 
of the concentration in !Jg/L. Bold Line indicates mean blood 
glucose Levels. Adapted from Aarsen RSR, Bruining GJ, Grose WFA, 
Van-Strik R, Lamberts SWJ, Harris AG 103• 
administration in teenage patients with diabetes possibly 
argued against repeated bedtime administration of octreotide, 
as both are important sources of energy for the brain. 
Serrano-Rios' et al demonstrated that after stabilising 
blood glucose by means of an artificial pancreas, octreotide 
and insulin were more effective than insulin alone 
in preventing nocturnal increases in blood glucose in nine 
often type I patients. Octreotide (100 !lg scat midnight) 
was administered with a continuous overnight insulin 
(0.15 mg/kg/min) and glucagon infusion (0.6 ng/kg/min) 104• 
Glucagon, cortisol and C-peptide levels were sinlll.ar in both 
regimens. Although bedtime (1 Opm - 11 pm) administra-
tion of octreotide in other studies was associated with a 
a 
b 
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Figure 12. 
Upper figure: Median courses of free insulin after either 50 llg sc 
octreotide (SAN) or placebo (PLA) administered at 10pm in 10 
teenage type I diabetic patients. The horizontal axis represents 
time (hours) while the vertical axis represents the free insulin con-
centration in mU/L. 
Middle figure: Median courses of blood glucose after either octreotide 
50 !lg sc (SAN) or placebo (PLA) administered at 10pm in 10 teenage 
type I diabetic patients. The horizontal axis represents time (hours) 
and the vertical axis the blood glucose concentrations in mmoljl. 
Lower figure: Median courses of 3-0H-butyrate after either octreotide 
50 llg sc (SAN)" or placebo (PLA) administered at 10pm in 10 teenage 
type I diabetic patients. Hours are on the horizontal axis and the 
vertical axis represents the 3-0H-butyrate concentration in mmoljl. 
The dotted Line represents the upper limit of normal values (±2SD). 
Ins=insulin. Adapted from Aarsen RSR, Bruining GJ, Grose WFA, 
Van-Strik R, lamberts SWJ, Harris AG 103 • · 
significant reduction of blood glucose and GH levels for 
4 to 6 hours 105· 106· 107 , octreotide failed to prevent early 
morning hyperglycaemia ("dawn phenomenon") and 
octreotide significantly reduced ketogenesis resulting from 
insulin d~privation 108 • 
With Scheen et al we studied the ability of octreotide to pre-
vent the metabolic changes induced by a 6-h nocturnal 
arrest of an insulin pump 109 • Nine C-peptide negative 
Type 1 diabetic patients were submitted to two interrup-
tions of a continuous s.c. insulin infusion, once after a 
single s.c.injection at 11.00 pm of SO Jlg of octreotide and 
once a control (saline) injection. Plasma octreotide levels 
peaked at midnight and then declined with an elimination 
half-life averaging 144 ± 15 min. Plasma glucagon and 
growth hormone levels were significantly reduced after 
octreotide whereas the progressive fall in plasma-free insulin 
levels from 11 pm to Sam was unaffected. In the control test, 
blood glucose levels tended to decrease slightly from 11 pm 
to 2am and then increased markedly from 2am to Sam, 
while after octreotide they decreased significantly from 
11 pm to 2am. This resulted in blood glucose values below 
3 mmol/L in seven subjects, but a secondary increase in 
glucose occurred up to Sam. Rises in plasma non-esterified 
fatty acid and glycerol levels were not reduced by octreotide, 
plasma 3-hydroxbutyrate levels were reduced late in the 
study (from 2am to. Sam). We concluded that octreotide 
50 Jlg sc significantly reduced the variations in plasma 
glucose usually seen during insulin interruption, although 
there was a higher risk of early hypoglycaemia. 
Overnight Metabolic Profile Studies : 
Effect of Octreotide on the Dawn Phenomenon 
., 
As mentioned above, normal early morning GH surges 
were thought to be strongly associated with increased blood 
glucose and worsened control in diabetic patients. A group 
of studies were performed specifically to examine the effect 
of octreotide on glycaemic control during this so-called 
"dawn phenomenon". Type I diabetic patients underwent 
euglycaemic clamping to maintain blood glucose overnight, 
and also received a night-time dose of octreotide 50 !lg s.c. 
Mean and peak GH levels were reduced during the early 
part of the night and morning insulin requirements were 
reduced in two studies. These euglycaemic studies then 
progressed to double blind placebo-controlled trials of 
50 Jlg octreotide at bedtime, examining effects on overnight 
hormonal and metabolic profiles. Octreotide reduced GH 
and blood glucose for 5 hours post-administration, after 
which octreotide was fully metabolised. The low octreotide 
dose may have contributed to the fact that morning blood 
glucose readings were reduced in only 50% of patients. 
In addition to effects on glucose metabolism, octreotide also 
reduced overnight lipolysis and ketogenesis, without reduc-
ing circulating insulin. We proposed that chronic suppres-
sion of free fatty acid levels in adolescents could prove 
beneficial with regard to the development of atherosclerosis. 
These metabolic results clearly indicated to us that octreotide 
was well tolerated in type I diabetic patients and that 
pre-bedtime administration of octreotide could reduce 
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ketogenesis, lipolysis, GH and glucagon overnight. In con-
firmation of our findings, in a recent study of eight patients 
with type I diabetes Lunetta et al investigated the effective-
ness of octreotide in controlling the "dawn phenomenon". 
All patients consistently experienced morning hypergly-
caernia, and octreotide was administered as a subcutaneous 
injection at various times in the evening (50 J-Lg at 8pm, 10pm 
or 12am), or as a continuous s.c. infusion from 12am to Sam 
with an increased rate between 3am and Sam. However, the 
authors found that infused octreotide provided greater 
control of overnight glucose (and GH) secretion than 
intermittent injections of octreotide 110 • 
Effects of Pre-meal Octreotide 
on Metabolic Control in Type I Diabetes 
In a short-term administration study, Spinas et al reported 
in 1985 that octreotide 50-100 ).lg s.c reduced significantly 
post-prandial glucose concentration from 8.9 ± 0.7 to 
7.8 ± 0.6 mrnol/L (p<0.001) in patients with type I diabetes, 
while glucagon and triglyceride levels were also signifi-
cantly reduced during a 180 minute period immediately afi:er 
injection 111 • The acute effects of octreotide on insulin 
requirements in six patients with type I diabetes, who were 
connected to a feedback glucose-controlled insulin infusion 
system, have been studied by Hadjidakis et al 112 • 
Administration of octreotide 50 ).lg three times daily by s.c. 
injection resulted in a significant reduction in mean insulin 
requirements, GH and postprandial glucagon secretion dur-
ing the 24 hours of observation. In a long-term study with 
Kirkegaard et al, we investigated the influence of octreotide 
treatment on glycaernic control in a controlled trial of 14 type 
I diabetes patients 113 • Seven patients received s.c. octreotide 
(initially 50 J-Lg increasing in 50 ).lg increments every two days 
to a maximum of 400 J-Lglday for 12 months) and seven acted 
as controls. Overall, octreotide had no effect on metabolic 
control in Type I patients. Insulin requirements were reduced 
by approximately 25% and these returned to pre-treatment 
levels at the end of the trial. The frequency of daytime, but 
not noctt.irnal,low blood glucose values (<3.6 mrnol/1) was 
significantly lower during octreotide therapy than after 
withdrawal (p<0.02). In a further study, which used a clamp 
technique, a 24-hour metabolic and hormone profile was 
performed before and after subcutaneously infused 
octreotide (200 ).lg/ day for eight days) in six type I diabetes 
patients. Compared with baseline, octreotide suppressed 
24-hour GH and glucagon levels, reduced insulin 
requirements, increased glucose storage and reduced energy 
expenditure 114 • Di Mauro et al compared subcutaneous 
intermittent octreotide with subcutaneous infusion 
(50 ).lg tid sc or 150 ).lg/24 hours) and reported significantly 
reduced daily glucose levels in seven type I diabetic patients 
with poor metabolic control 115• GH levels were also reduced 
during octreotide treatment, but in contrast to other 
studies above no change in glucagon levels were seen. 
In a subsequent follow up study the same group reported 
that glucagon, GH and glucose were all reduced by 
subcutaneous injected and infused octreotide, with greater 
effects on glucagon being noticed at higher infused doses 
of octreotide 116 • Octreotide may reduce glucose levels by 
increasing the rate of oxidative but not non-oxidative glucose 
disposal 117 • Glucose storage as assessed by total glycogen 
synthase activity was not changed by octreotide. 
III.IV.II.IV - Metabolic Effects of Octreotide in Type II 
Diabetes MeLLitus 
Given the complex pathophysiology of type II diabetes 
mellitus and the relative heterogeneity of patient character-
istics, responses and disease severity, the results obtained 
from studies with octreotide in type II diabetes mellitus 
are diverse (Table 2). 
Author Octreotide dose (n) Blood Glucose C-peptide Other Results 
Haupt et al"4 25)lg tid ( n=5) Overall unchanged j, post breakfast j, 
Verschoor et al"5 12.5 )lg tid (n=6) j, j, 
Rodier et al'26 25 !l9 scjiv (n=6~ 8 mg po ~ j, 
30 mm post mea 
Anton et al 127 50 !19 iv (n=5) j, 
30 mm post meal 
Davies et al 119 50 !lg 30 min pre meals ~ j, 
Williams et al 118 50 !lg tid (n=7) Delarced pp rise j, j, gg 
in b ood glucose 
Candrina et al'20 100 !lg insulin treated j, meal 
Giustina et al 121 25, 50, 100 !ld sc (n=11) j (ns) j, j, gg 
insulin treate obese 
Table 2. Summary of studies detailing the metabolic effects of octreotide in patients with type II diabetes mellitus. ~ = unchanged, 
tid= three times daily, sc =subcutaneous, iv =intravenous, po =per os, ns =non-significant, pp =post prandial, gg= glucagon. 
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The effects of octreotide in doses ofS, 25, and 100 f.lg s.c. 
injected 30 minutes before a 530 kcal breakfast were stud-
ied by Williams et al from Prof. Bloom's group in 6 type 
II diabetic patients treated with diet and/ or oral hypogly-
caemic agents 118 • Octreotide decreased pre- as well as post-
prandial plasma levels of insulin by 50% with 5 f.lg; with 100 
f.lg of octreotide, basal levels were suppressed by 75% with 
no postprandial rise at all. Basal glucagon was suppressed 
by 40% with 5 f.lg of octreotide.With 100 f.lg of octreotide 
basal levels of glucagon were reduced by 80% to a level that 
was maintained throughout the whole study period. 
Pancreatic polypeptide, gastrin, secretin and motilin were 
also suppressed by octreotide to a greater extent by 100 f.lg 
than by 5 f.lg. Glucose tolerance was not significantly 
changed by octreotide. Metabolic and hormonal effects of 
octreotide or placebo were also studied by Davies et al in 
5 non-insulin-dependent diabetic patients on diet alone or 
diet with oral hypoglycaemic agents 119.The 24-hour mean 
blood-glucose levels did not differ between the placebo and 
octreotide periods. In contrast to the Williams et al find-
ings, the 24-hour mean insulin and glucagon levels were 
not significantly reduced, however at many individual 
time points significant reductions in both were seen. Blood 
lactate, pyruvate concentration, as well as 24 hour·mean 
levels of glycerol and 3-hydroxybutyrate were not changed 
by octreotide. 
In five patients with Type II diabetes with secondary 
failure of oral agents, octreotide 100 f.lg s.c. twice daily plus 
insulin produced a lowering of plasma glucose, plasma 
glucagon and serum C-peptide levels 120 • The same group 
studied the effects of single doses of octreotide on the 
glycaemic response to a mixed meal in 8 insulin-treated 
type II diabetic patients 121 • All patients underwent simul-
taneous treatment with insulin (0.1 U/kg s.c.) and 
octreotide (25 f.lg, 50 f.lg or 100 f.lg s.c.), followed by a stan-
dardized pre-constituted mixed meal. Following insulin 
alone, a significant increase in blood glucose levels after the 
meal was observed. Blunted blood glucose responses to the 
meal after each of the three doses of octreotide as compared 
to insulin alone were observed. It should be noted, how-
ever, that the confounding effect of concomitant insulin 
makes the precise interpretation of the activity of octreotide 
in these patients very difficult. More recently, Spanti et al. 
reported that octreotide at a dose of 150 f.lg per day as con-
tinuous infusion reduced insulin requirements but did not 
significantly reduce blood glucose in six type II diabetic 
patients with chronic renal failure who required insulin 
treatment 122 • This effect may have been mediated by a 
reduction in circulating glucagon. The same group also 
noted divergent metabolic effects in type I and type II 
diabetic patients treated with octreotide 100 f.lg per day for 
5 days in a euglycaemic clamp study 123• The type II diabetic 
patients ,ex:perienced no change in glycaemic control or 
hepatic glucose production (in contrast to type I patients), 
despite low:~red GH profiles. The authors suggested that a 
temporary ·-reduction in insulin secretion (assessed via 
decreased C-peptide secretion) mediated by octreotide 
may have blunted glycaemic effects of octreotide in this 
euglycaemic clamp model. 
Conclusion : Metabolic Effects 
The relative heterogeneity of results with respect to GH 
suppression and glycaemic control across type I and type 
II diabetic patients made it difficult for us to interpret 
data during the Clinical Development Program. Before 
attempting to draw any definitive conclusions from the data 
generated from these diabetes studies, we emphasized that 
several confounding factors hampered the interpretation of 
these results in both type I and type II diabetes patients. 
The pathophysiology of type II diabetes is more compli-
cated than that of type I diabetes because the entity is 
heterogeneous and characterized by both an impairment 
of beta cell function and diminished tissue sensitivity to 
insulin. Speculation persists about which of these two 
effects initiates the process. In both Type I and Type II the 
effects of octreotide on digestion, absorption and disposal 
of nutrients are also complex. Octreotide inhibits most of 
the peptide hormone secretions from the gut and pancreas. 
Suppressing several of these hormones simultaneously 
obviously interferes with the interpretation of glycaemic 
control data. In particular, the balance between suppression 
of insulin on one hand and of the anti-insulin counter-reg-
ulatory hormones GH and glucagon on the other depends 
upon the physiological importance of each of these hor-
mones postprandially. 
Other important issues include patient compliance in 
terms of ascertaining drug administration during the 
ambulatory phase of the study and the validity of capillary 
blood values reported by patients. Also the order in which 
drug or placebo are given in cross over designed studies is 
crucial because of the beneficial effect hospitalization itself 
has on blood glucose control. 
From the data available, although fairly well tolerated, 
octreotide showed limited beneficial effects on glucose 
homeostasis.Yet it is interesting that octreotide did not cause 
significant deterioration in glucose tolerance in type II dia-
betes patients contrary to normal subjects who experienced 
impaired glucose tolerance suggesting that relative insulin 
suppression caused by octreotide is overridden by inhibi-
tion of counter-regulatory hormones which may play an 
important role in type II diabetes. Unfortunately, the bal-
ance between these opposing actions of octreotide in type 
II diabetes remains to be clarified. 
We fostered an active discussion between study leaders to 
ascertain the direction of future studies with octreotide in 
diabetes at an investigators conference under the aegis of 
Sandoz. From their advice we concluded that octreotide did 
not cause hypoglycaemia in diabetes mellitus and the 
gastrointestinal hormone effects were tolerable and safe. Also, 
octreotide had a beneficial effect on hormonal profiles and 
glucose metabolism over acute and 24-hour administration, 
but the magnitude of this effect was moderate and hetero-
geneous across different studies. We believed that larger 
clinical trials would be needed to assess the clinical relevance 
of octreotide on glycaemic control in diabetes. 
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III.IV.III - Octreotide: Effect on Complications of 
Diabetes Mellitus 
Diabetic Nephropathy 
During the clinical development of octreotide in diabetes 
mellitus we performed and fostered numerous studies into 
its effect on diabetic nephropathy in animal and human 
studies. 
Animal Studies 
Rodent models of experimental (streptozotocin-induced) 
diabetes showed that octreotide (100 !lg bid) reduced initial 
renal hypertrophy possibly via inhibition of renal IGF-1 
accumulation 128.We showed that lower dose octreotide only 
partially reduced kidney IGF-1 and renal growth, indicating 
a dose-response effect. With Allan Flyvbjerg and colleagues 
we studied the effect oflonger-term octreotide treatment 
(100 !lg bid for 6 months) in streptozotocin-induced diabetic 
rats in comparison with untreated rats (Figures 13, 14) 129• 
Untreated diabetic and non-diabetic animals were used as ref-
erence groups. No differences were seen between the two 
diabetic groups in respect to body weight, food intake, blood 
glucose levels, urinary glucose output, haemoglobin A1C, 
:fructosamine, serum growth hormone or creatinine clearance, 
but kidney weight, urinary albumin excretion, kidney and 
serum IGF-I were all reduced in the octreotide-treated 
diabetic animals when compared to the untreated diabetic 
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group. In non-diabetic rats octreotide reduced body weight, 
kidney weight, urinary albumin excretion, kidney and serum 
IGF-1 and serum GH compared to untreated controls. When 
kidney weights were expressed in relation to body weight no 
difference was found between octreotide-treated and 
untreated non-diabetic controls, while the difference between 
octreotide-treated and untreated diabetic animals was still 
significant. In conclusion, chronic administration of octreotide 
reduced diabetic renal hypertrophy and urinary albumin 
excretion. These results are interesting in light of the findings 
(see below) in the section on human studies, where a signifi-
cant effect on renal size in type I diabetic patients was seen 
with three months of octreotide therapy, but not with nine 
months' treatment with another somatostatin analogue, lan-
reotide. It could be that tolerance to the effects of somato-
statin analogues develops and early renal hypertrophy may 
therefore be IGF-1 dependent and amenable to octreotide 
therapy, while established diabetic nephropathy may be gov-
erned by other mechanisms. 
The choice of animal model may also influence significandy 
the applicability of data to the effect of octreotide on diabetes 
in hurnans.As noted above, Flyvbjerg and colleagues have per-
formed a series of experiments in diabetic rats. It may be, how-
ever, that their work in mice is a more accurate model of 
human endocrine dysregulation in diabetes 130, as the main rat 
model, namely the streptozotocin-induced diabetic rat, 
displays GH suppression in contrast to the GH hypersecre-
tion seen in humans and in mice 131 • In a practical sense 
murine models may be more useful to study diabetes given 
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Figure 13. Individual kidney weights in each of four groups of rats (control and streptozotocin-induced diabetic; treated or untreated with 
octreotide (100 !lg bid)) at the end of 180 days treatment with octreotide. Mean values for each group are indicated by a horizontal bar. 
Octreotide treatment was associated with significantly Lower kidney weight than non-octreotide treated control animals and diabetic 
animals. Statistical significance between groups are as indicated in the figure. SMS = octreotide. (Adapted from Flyvbjerg A, Marshall SM, 
Frystyk J, Hansen KW, Harris AG, Orskov H "'). 
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that they have a 10-ti.mes lower body weight than rats and 
their relatively short growth and development cycle means 
that practical data may be generated using models of only one 
months' duration, such as that o±Van Neck et al 132 • 
Human Studies 
Human studies of diabetic nephropathy during the clinical 
development program were limited in scope as retinopathy 
and metabolic control were the primary targets of research. 
An important factor in the development of diabetic 
nephropathy is glomerular hyperfiltration. The importance 
of regulatory pep tides in renal failure has been described 133 • 
The effect of octreotide on kidney function has been eval-
uated in type I diabetes patients; a significant decrease in 
glomerular filtration rate (GFR) was noted in some 
studies 134 but not in others 135 • We investigated the renal 
response to increasing doses of octreotide (50, 100 and 
200 J..Lgl day over 3 days), in seven insulin-dependent diabetic 
patients without microalbuminuria, with Poirier et al 136 • 
Reduction of GFR was marked in four of the patients, of 
whom three fell into the normal range. Two patients also had 
a simultaneous reduction of renal plasma flow (RPF), but 
there were no significant changes in GFR, renal plasma flow 
or filtration fraction in three patients, including two who 
had high GFR initially. Similarly, Christensen et al. also 
found that constant i.v. infusion of octreotide 8 J..Lglhour 
acutely reduced renal hyperperfusion and hyperfiltration in 
10 patients with insulin-dependent diabetes 137• 
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Stegeman et al reported that the acute renal effects of 
octreotide (20 J..Lg bolus, then 10 J..Lglhour i.v.) were antag-
onised by glucagon (2-3 ng/kg weight/minute) in 
13 insulin-dependent diabetic patients 138 • Administration 
of octreotide alone led to. significant decreases in both 
glomerular filtration rate and effective renal plasma flow (by 
6.3 rnl/min/1.73 m 2 and 43.9 rnl/min/1.73 m 2, respec-
tively, compared with baseline (p<0.001). Urinaryflow,free 
water clearance and sodium excretion were also reduced 
during octreotide infusion. Administration of glucagon in 
addition to octreotide completely abolished these reduc-
tions. The authors suggested that octreotide and glucagon 
might functionally antagonise one another's acute effects 
on renal dynamics in diabetic patients. 
Octreotide infusion in type I diabetic patients reduced 
renal plasma flow and glomerular filtration rate, which are 
elevated in early diabetic renal disease 139• Plasma GH and 
glucagon fell in these patients and the fall in glucagon was 
statistically correlated with the decrease in renal plasma 
flow and glomerular filtration rate. With Serri et al, we 
performed a 12-week study with octreotide in human 
diabetic nephropathy; octreotide was administered by con-
tinuous s.c. infusion (300 )lg/ day) for 12 weeks 140 • 
Octreotide was safe and well tolerated and caused no hypo-
glycaemia. A number of metabolic and renal benefits were 
noted. Insulin requirements fell during the study without 
any worsening of glycaemic control, possibly via an increase 
in insulin sensitivity. GH secretion was not significantly 
affected by octreotide, but IGF-1 fell significantly through-
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Figure 14. Changes in urinary albumin excretion over six months in non-diabetic rats with (e) or without (0) octreotide (100 )lg bid) and 
in steptozotocin-induced diabetic rats with (A.) or without (6) octreotide. Data are expressed as means ( SEM. *Octreotide treatment was 
associated with significantly lower urinary albumin excretion than non-octreotide treated groups. P<O.OS octreotide treated animals versus 
all other groups. (Adapted from Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris AG, Orskov H 129). 
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out the study (Table 3).The reason for this disconnect is not 
known, although serum IGF-1levels could have been affected 
by an octreotide-induced increase in IGFBP's. Renal 
hyperfiltration was reduced in the octreotide group 
(136 mL/min/1.73m2) compared with placebo 
(157 mL/min/1.73m2) (Table 4). Kidney hypertrophy was 
also lower with octreotide compared with placebo 
(379 mL/1.73m2 versus 389 mL/1.73m2) (Figures 15, 16). 
Despite the clear-cut benefits of octreotide in experimen-
tal and human diabetic nephropathy, large-scale clinical 
trials were not performed. It is noteworthy that a subsequent 
longer study oflanreotide failed to show a substained reduc-
tion in glomerular filtration and IGF-1 after 9 months of 
treatment 141 • The advent of angiotensin converting enzyme 
(ACE) inhibitors coincided with the Clinical Development 
Program for octreotide. The proven benefit of ACE inhibitors 
in reducing renal albumin excretion, progression of nephropa-
thy to dialysis and progression to transplantation effectively 
ended further interest in octreotide in this regard for prag-
matic_ reasons.A safe effective oral therapy such as captopril 
thus had enormous benefits over octreotide in terms of 
compliance, and costs were significantly lower. 
Diabetic Retinopathy 
In vitro studies indicated that octreotide inhibited new ves-
sel growth and endothelial cell replication 142 • The initial 
human study performed by Kohner's group in London in 
proliferative and pre-proliferative diabetic retinopathy treated 
nine type I patients with octreotide at doses up to 1500 flg 
per day remained unaffected 143 • No worsening of glycaemic 
control was seen, but GH suppression was incomplete with 
three times per day intermittent injections and a subcuta-
neous pump study (500 flg/ day) was instituted in six of the 
nine patients.Although GH was not fully suppressed in this 
trial, IGF-1 levels fell into the hypopituitary range and 
insulin requirements were cut by 50%. Clear improvements 
in diabetic retinopathy were seen in individual patients, but 
these changes were heterogeneous. Furthermore, the small 
patient numbers did not provide evidence of dose-responses. 
In another study we performed with Shumak and Zinman 
et al in type I diabetes patients with background retinopa-
thy, the picture was also unclear, as octreotide provided no 
reduction in disease severity (microaneurysm formation, 
capillary leakage) compared with placebo 144• However visual 
activity improved significantly in right (p<0.05) and left eyes 
(p<0.03) in six type I diabetes patients treated with octreotide 
for eight weeks and retinopathy improved in two of these 
subjects. GH levels and insulin requirements fell 
significantly during octreotide treatment. Similar results 
were obtained in another pilot study of six type I diabetes 
patients, three who underwent hypophysectomy and three 
who received octreotide (400 f.lg/day by CSI for 9-18 
months). In the former group, GH levels were undetectable 
and the ocular condition improved rapidly.After octreotide, 
GH levels fell by 50%, the patients' retinopathy was stabilised 
and there was improvement in visual acuity 145 • Important 
studies of octreotide in diabetic retinopathy are outlined in 
Table 5. 
• 
Treatment Group Placebo Octreotide (n=6) (n=S) Pt 
Glucose level, (mmoljl) 
Baseline 11.7 ± 0.7 8.7 ± 0.8 .030 
Week 3 11.2 + 1.7 10.9 ± 1.7 .895 
Week 12 10.7 ± 0.3 10.1 ± 0.8 .533 
Glucagon level, ( ng/L) 
Baseline 145 ± 16 113 ± 9 .095 
Week 3 153 ± 4 102 ± 20 .699 
Week 12 135 ± 10 106 ± 16 .735 
Growth hormone level, (J.Lg/L) 
Baseline 3.05 ± 0.64 2.5 + 0.4 .622 
Week 3 3.24 ± 0.65 1.84 ± 0.25 .095 
Week 12 3.13 ± 0.64 2.58 ± 0.45 .735 
Insulin-like growth 
factor-!, (U/ml) 
Baseline 0.91 + 0.14 0.96 + 9,17 .792 
Week 3 0.99 ± 0.19 0.50 ± 0.12 .000 
Week 12 0.91 + 0.14 0.57 ± 0.10 .001 
Glycosylated haemoglobin level, (%) 
Baseline 0.11 ± 0.01 0.12 ± 0.005 .247 
Week 12 0.11 ± 0.01 0.11 ± 0.01 .420 
Daily Insulin dose, (U) 
Baseline 55± 10.9 63 ± 7.2 .329 
Week 12 55.3 ± 8.9 41.6 ± 4.2 .002 
Table 3. Metabolic and hormonal parameters before and after treat-
ment with octreotide or placebo in patients with insulin-dependent 
diabetes mellitus. Values are mean ± SE. t Baseline comparison of 
placebo and octreotide groups was made using the Mann-Whitney U 
test. Week 3 and 12 comparison of placebo and octreotide groups, 
controlling for baseline values, were made using nonparametric 
analysis of covariance (Adapted from Serri 0, Beauregard H, Brazeau 
P, Abribat T, Lambert J, Harris A, Vachon L 140). 
Treatment Group Placebo Octreotide (n=6) (n=S) Pt 
Glomerular filtration rate, 
(ml/min per 1.73m2) 
Baseline 159 ± 5 173 ± 15 .662 
Week 12 157 ± 7 136 ± 12 .037 
Kidney volume, 
(R+L, ml1/1.73 m2) 
Baseline 384 ± 18 426 ± 42 .429 
Week 12 389 ± 18 379 ± 30 .047 
Table 4. Glomerular filtration rate and kidney volume before and 12 
weeks after treatment with octreotide or placebo in patients with 
insulin-dependent diabetes mellitus. Values are mean ±SE. tBaseline 
comparison of placebo and octreotide groups was made using the 
Mann-Whitney U test. Week 12 comparison of placebo and octreotide 
groups was made controlling for baseline values using non paramet-
ric analysis of covariance. (Serri 0, Beauregard H, Brazeau P, Abribat 
T, Lambert J, Harris A, Vachon L 140). 
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Figure 15. Individual values for glomerular filtration rate in placebo 
(n = 6) (open circles) and octreotide (n = 5; 300 llg/24hours) (closed 
circles) treatment groups at the start and end of 12 weeks' treatment 
and after cessation of octreotide therapy (Off) in type I diabetic 
patients. Mean glomerular filtration rate was significantly Lower 
(P = 0.037) in the octreotide-treated group compared with placebo-
treated patients. The horizontal bars indicate mean values. (Serri 0, 
Beauregard H, Brazeau P, Abribat T, Lambert J, Harris A, Vachon L '") 
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Figure 16. Individual values for kidney volume in placebo (n = 6) 
(open circles) and octreotide (n = 5; 300 llg/24hours) (closed cir-
cles) treatment groups at the start and end of 12 weeks' treatment 
and after cessation of octreotide therapy (Off) in type I diabetic 
patients. Mean kidney volume was significantly Lower (P = 0.047) in 
the octreotide-treated group compared with placebo-treated patients. 
The horizontal bars indicate mean values. (Adapted from Serri 0, 
Beauregard H, Brazeau P, Abribat T, Lambert J, Harris A, Vachon L '"). 
RESULTS 
No effect 
Shumak et al 144 6 NPR 50-150 !lg /d CSI, SC 2 patients improved (angiograms) 
8 weeks 
Kirkegaard et al 113 7 early PR 400 !lg/d CSI for 12 months No effect 
Mallet et al 145 4 PR 400 !lg /d CSI 2 patients stabilized 2 patients had 
6-20 months regression of neovascularisation 
Luettke et al 146 5 PR type 1 diabetes 300 !lg /d sc Significant reduction hemorrhage vitreous 
4 PR type 2 diabetes 12-36 months Regression neovascularization 
Grant et al 168 8 severe NRP 200-5000 11g /day CSI 1/22 eyes vs. 9/24 eyes control reached 
high risk ocular disease progression 
for 15 months 27% OCT vs. 42% Control decreased IGF-1 
Table 5. Summary of clinical studies on the effect of octreotide on diabetic retinopathy. PR =proliferative, PPR = preproliferative, NPR =non 
proliferative; ON= ocular neovascularization, CSI =continuous subcutaneous infusion, GH =growth hormone, IGF-1 =insulin-like growth fac-
tor-1, OCT= octreotide, sc =subcutaneous, HbAlc =haemoglobin Ale. 
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The results of clinical trials with octreotide in diabetic 
retinopathy were discussed in 1988 with a group of experts. 
With octreotide treatment GH and IGF-1 levels were 
not fully suppressed at the doses used. This prevented the 
conference from making a clear-cut finding regarding the 
importance ofGH/IGF-1 in diabetic retinopathy and by 
extension the possible therapeutic role of octreotide. 
It was concluded that since GH and IGF-1 play a partial 
role in the pathogenesis of diabetic retinopathy, octreotide 
might reduce disease severity by inhibiting neovasculari-
sation. It was recommended that prospective dose-response 
trials be performed to ascertain whether complete GH sup-
pression could be achieved with acceptable patient toler-
ability and safety. These trials would then have to be 
followed by large prospective clinical trials of octreotide in 
diabetic retinopathy. Despite the apparent lack of success 
of the clinical development program in diabetes, the results 
we obtained have to be re-evaluated in the light of subse-
quent studies with octreotide the availability of a once a 
month slow release preparation of three dosage strengths 
of octreotide LAR (10, 20, 30 mg) and the advances 
in understanding of the pathophysiology of diabetic 
complications. 
III.V- REVIEW OF THE IMPACT OF OCTREOTIDE 
RESEARCH IN DIABETES MELLITUS 
Many of the clinical trials that we instigated during the 
clinical development program were continued and pub-
lished by our collaborating investigators. In particular, stud-
ies regarding the effects of octreotide on diabetic retinopathy 
have continued and important evidence has accumulated. 
III. V.I - Metabolic Effects of Octreotide 
There have been conflicting reports about the efficacy 
of octreotide in the reduction of postprandial hypergly-
caemia 147•148• Divergence in reported results may be due to 
inter-subject variability in the severity of diabetes, or, as 
suggested by the work of Osei et al, minor variability in the 
in vivo metabolism of octreotide during 24-hour continu-
ous subcutaneous infusion (as assessed by inter-individual vari-
ations in trough, mean and peak plasma octreotide 
concentrations at steady state) 149 • Octreotide 50 !lg s.c. tid for 
eight weeks decreased mean insulin requirements in six 
patients with type I diabetes, although there was no change 
in the 24-hour glucose profiles 150 • Nosari et al, showed sig-
nificant reductions, compared to placebo, in postprandial 
glycemic peaks (p<0.05), insulin requirements (p<0.01), 
glucagon (p<0.05) and GH levels (p<0.05) in 8 type I 
patients receiving octreotide 50 !lg sc at 1 pm plus a 
standardised meal 151 • However, chronic administration of 
octreotide 10 or 50 !lg twice daily for four weeks to 
26 patients with type I diabetes did not appear to improve 
overall metabolic control 111• The authors speculated that 
administration of higher doses of octreotide by continuous 
s.c. infusion would avoid dose-limiting gastrointestinal side 
effects and produce GH and glucagon suppression. 
Patients with type II diabetes comprise almost '90% of all 
diabetic patients, and only 10% of these achieve adequate 
glycemic control through dietary measures alone. It is 
estimated that 11% to 36% of type II patients no longer 
respond to diet and sulfonylurea therapy after one year of 
treatment 152 : Patients who develop failure to sulfonylureas 
usually require exogenous insulin to overcome their meta-
bolic insulin resistance. Often treatment with insulin alone 
or combined insulin-sulfonylurea provides sub-optimal 
long-lasting satisfactory metabolic control 153 and may con-
tribute to worsening obesity. 
Orskov et al have studied the effect of continuous subcu-
taneous octreotide, in type II diabetic patients.Mter only 
four days of continuous octreotide therapy (1!-lg/kg/ day), 
decreased insulin requirements, increased insulin sensitiv-
ity (in the form of increased peripheral glucose disposal and 
increased suppression of hepatic glucose output) and 
increased oxidative glucose disposal could be demon-
strated 154• Subcutaneous pre-meal octreotide (50 !lg s.c.) 
reduced 155 or delayed 156 post-prandial glycaemic peaks in 
type II diabetic patients. Octreotide (50 !lg s.c.) has also 
been reported to inhibit insulin secretion without a dete-
rioration of glycaemic control 157• 158• 159 • In five type II 
patients with secondary failure of oral therapy, octreotide 
100 !lg sc twice daily plus insulin produced a lowering of 
plasma glucose, plasma glucagon and serum C-peptide 
levels, suggesting that octreotide may lead to a reduction 
of daily insulin requirements and have a role as an adjunct 
to insulin in type II diabetes after failure of oral hypogly-
caemics 115 • 
Overall, the results with octreotide in metabolic control of 
type I and type II diabetes during and after the Clinical 
Development Program have been mixed. Treatment with 
octreotide was not associated with a major increase in 
hypoglycaemia in type I or type II patients. Indeed, in 
patients with suphonylurea overdose, octreotide has been 
recommended as a valid emergency room treatment for 
hypoglycaemia 160 • Interest in octreotide in diabetes melli-
tus waned in the late 1980's as the dawn phenomenon fell 
out of favour as a major mechanism for poor glycaemic 
control. Also, the publication of the DCCT trial shifted the 
focus of diabetologists to maximizing insulin therapy to 
achieve near-normal HbA1c when appropriate in type I 
patients. The subsequent publication of the UKPDS trial 
in type II diabetes in the late 1990's provided firm evidence 
for tight blood glucose and blood pressure control as effec-
tive interventions 161 • The practicality of adding octreotide 
to the treatment regime for patients with diabetes already 
on multiple medications raises major compliance issues. It 
remains to be seen how well current therapy with insulin, 
oral hypoglycaemics and insulin sensitising drugs reduce 
complications over the longer term. Indeed, some poorly 
responsive sub-groups may benefit from octreotide as an 
add-on therapy, especially as the clinical development pro-
gram conducted intensive safety studies. This may pave the 
way for the eventual study of once monthly depot 
octreotide long acting repeatable (LAR) or newer more 
potent and more subtype receptor specific somatostatin ana-
logues in the metabolic control of diabetes mellitus. 
THE CLINICAL DEVELOPMENT OF 0CTREOTIDE IN DIABETES MEuxrus 41 
III.V.II- Effect of Octreotide on Diabetic Complications 
While interest in the role of octreotide as a treatment for 
metabolic and nephropathic disturbances decreased with the 
advent of new guidelines recommending intensified insulin 
therapy and ACE inhibitor therapy, pre-clinical and clinical 
research continues in diabetic retinopathy. In 1997, Smith et 
al reported that GH is essential for retinal neovascularisation 
in mice in response to ischaemia 162• This study used transgenic 
mice that expressed dwarf(GH-antagonist) and giant (GH-
agonist) phenotypes and retinal neovascularisation was 
induced by hypoxia/reperfusion similar to retinopathy of pre-
maturity. GH antagonist expressing mice had reduced lev-
els of revascularisation compared with normal controls, 
although GH agonist mice had no increased degree of 
retinopathy compared with controls. Non-transgenic mice 
were treated with a somatostatin analogue,MK 678, and this 
reduced retinal revascularisation by 44 % compared with con-
trols. Interestingly this anti-angiogenic effect was dose-
related and linear regression analysis demonstrated that 
neovascularisation was correlated strongly with IGF-1 con-
centration. The importance of GH in neovascularisation 
was shown subsequently by co-administering GH and 
MK678 in normal mice. Compared with controls, GH sup-
pressed/replaced (MK 678 plus GH) mice had increased reti-
nal neovascularisation. Furthermore, replacement ofl GF-1 
in somatostatin analogue treated mice restored retinal 
neovascularisation to control levels, although exogenous 
I GF-1 alone did not increase retinopathy. These results sug-
gest that GH is a vital facilitator ofhypoxia-induced retinal 
neovascularisation, and that its actions are mediated in part 
by IGF-1.Blockade of the GH-IGF-1 axis by transgenic GH 
antagonist expression or somatostatin analogue administra-
tion did not abolish neovascularisation fully, however.Vascular 
endothelial growth factor (VEGF) is another important 
growth factor in retinal neovascularisation, and GH/IGF-1 
axis modulation did not alterVEGF dynamics in this model. 
Despite the fact that this was an animal model of hypoxia-
induced retinopathy (not diabetic retinopathy), some impor-
tance ofGH/IGF-1 in retinal neovascularisation in diabetic 
humans can be inferred, especially in combination with 
the other data outlined above. 
The precise role of GH, IGF-1 and IGFBP's in diabetic 
angiopathy, however, remains to be resolved. Evidence exists 
in the literature both in favour and against a stimulatory role 
for IGF-1 in diabetic retinopathy.While Merimee reported 
elevated IGF-1levels in a small number of patients with pro-
gressive retinopathy 13 , a recent review has pointed out that 
the statistical analysis used in the Merimee series may not be 
valid 25 • Other studies have not confirmed Merimee et al's 
observations, with a large study finding that IGF-1levels were 
not predictive of developing retinopathy over a six-year 
follow-up 163 • Much of the continuing uncertainty regarding 
the role of the GH/IGF-1 axis in diabetes may be appor-
tioned to the unknown relative effects of tissue and circu-
lating changes in I GF-1 and its binding proteins in response 
to hyperglycaemia. 
Smith et al have recently reported that an IGF-1 receptor 
antagonist suppresses retinal neovascularisation in a mouse 
model of ischaemia induced proliferative retinopathy 164 • 
They also proposed that interactions between IGF-1 and 
IGF-1 receptor may be necessary for maximal induction of 
neovascularisation by VEGF and that increased IGF-1 
levels are likely to promote retinal neovascularisation by 
supporting VEGF-induced endothelial cell proliferation. 
Hellstrom recently demonstrated that low IGF-1levels sup-
press VEGF surviving signalling, with retinal endothelial 
cells acting as a permissive factor for maximum VEGF 
stimulation of angiogenesis 165 • These data from patients 
with Laron-type dwarfism (GH receptor and IGF-1 allelic 
mutations) provide the first genetic evidence for a role of the 
GH-IGF axis in normal retinal vascularisation in humans and 
adds significantly to the body of data supporting a role for 
IGF-1 in diabetic retinal neovascularisation. 
Grant et al have previously shown that human retinal 
endothelial cells (HRECs) have somatostatin receptors and 
that octreotide decreases the proliferation of HRECs in 
response to IGF-1 and fibroblast growth factor 166• Grant pro-
poses the theory (personal communication) that somatostatin 
analogues acting as anti-angiogenic agents for the treat-
ment of proliferative diabetic retinopathy may mediate their 
growth inhibitory effects on HRECs in part by increasing 
IGFBP-3 expression. In a rat study, octreotide was found to 
acutely stimulate hepatic IGFBP-1 and IGFBP-3 mRNA 
in vivo, which may represent a relevant form ofiGF-1 reg-
ulation, although similar studies have yet to be performed in 
retinal tissue 167 • Until these complex interactions between 
IGF-1 and IGFBP's are defined more precisely the relative 
merits of research findings will be obscured. 
Despite the pathophysiological uncertainty, clinical trials 
with somatostatin analogues in retinopathy have continued. 
In 2000, Grant and colleagues published a study with high-
dose octreotide 168. From the safety studies during and 
after the clinical development program in acromegaly and 
gut endocrine tumours, it had been demonstrated that 
high-doses of octreotide are safe and relatively well tolerated. 
Grant et al studied the effects of maximally tolerated doses 
of200 - 5000 ).lg/ day of octreotide via continuous sc infu-
sion for 15 months in 11 patients with severe non-prolifer-
ative diabetic retinopathy compared 12 with control patients. 
Octreotide treatment was well tolerated and no patient 
dropped out of the study early. The endpoint was develop-
ment ofhigh-risk proliferative diabetic retinopathy in an eye. 
Only one of 22 eyes in the octreotide group developed 
proliferative retinopathy, requiring photocoagulation com-
pared to 9 of 24 eyes in the control group. Considered 
independently, tllls was statistically significant (p = 0.006), 
although the overall treatment effect was not (p = 0.0605). 
The incidence of patients with disease progression to severe 
proliferative diabetic retinopathy was 9% in the octreotide 
treated patients compared with 42% in the conventionally 
managed control group during the 15-month study period. 
HbA1c improved with octreotide therapy from 8.3 ± 0.8% 
to 7.1 ± 0.6 % while no change was seen in the control 
group. IGF-1 secretion fell by SO% in the octreotide group 
(p<O.OS), but was essentially unchanged in controls. As this 
was a pilot study, the authors were cautious about extrapo-
lation of their results. 
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Boehm et al administered 100 )..lg octreotide sc tid for a max-
imum of 36 months to nine patients with type I (n=S) 
or type II (n = 24) diabetes and high-risk proliferative 
diabetic retinopathy 169 • Nine patients served as controls. 
Neovascularization decreased in 12 of 14 eyes (86%) and 
remained stable in 2 of14 eyes (14%). In the control group, 
neovascularization worsened in 5 of 12 eyes and remained 
stable in 7 of12 eyes (58%) .Vitreous haemorrhage occurred 
in 10/14 eyes (7%) in the octreotide treated patients and in 
5 of 12 eyes (42%) in the control groups. None of the 
patients needed vitrectomy in the octreotide population 
compared to 3 (25%) in the control group. HbA1 C remained 
unchanged in the octreotide treated patients and insulin 
requirements were reduced by up to 50%. 
Somatostatin subtype receptors SST2A and SST3 have been 
described in the human retina establishing that these recep-
tors are synthesized in the human retina. In vitro SST 
expression in ischemic retinas from diabetic retinopathy 
patients was investigated by van Hagen et al and others 170•171 • 
They found sporadic expression in non-proliferative and vari-
able expression in early proliferative and end stage prolifer-
ative ischaemic retinal disease. Intraretinal neovascularisations 
stained generally negative and pre-retinal neovascularisations 
stained variably positive. In end stage pre-retinal vascular-
izations, variable but marked positive staining was detected 
in the pre-retinal membranes. The authors suggest, based on 
this data, that the anti-angiogenic effects of somatostatin ana-
logues may be limited. This was confirmed by pilot studies 
showing a limited effect of octreotide in non-proliferative 
diabetic retinopathy and a more beneficial effect of the 
analogue in advanced proliferative diabetic retinopathy fol-
lowing extensive laser therapy. The development of somato-
statin analogues with greater selectivity for somatostatin 
receptor subtypes 2 and 3 may thus provide greater control 
of retinal neovascularisation. 
With reference to the original recommendations of the 
NIH regarding retinopathy and octreotide in 1988, it appears 
that large-scale trials may be both feasible and warranted. 
Indeed, the recognized safety ofhigh-dose octreotide would 
facilitate this process by obviating the need for a preliminary 
dose-ranging study. 
Conclusion 
In the time that has passed since the completion of the dia-
betes mellitus phase of the Clinical Development Program 
for octreotide, the complex pathophysiology of the disease 
and its complications has become even more apparent. 
Despite the advances in genetics and molecular biology 
that have revolutionized diabetology in the last decade, we 
are far from a full understanding of the cellular mecha-
nisms behind tissue damage in diabetes. Evidence has accrued 
from epidemiological population studies regarding the heavy 
impact of diabetes mellitus on morbidity and mortality, and 
it remains an important risk factor for cardiovascular disease 
and stroke 172• Of great concern is the rising incidence of type 
II diabetes mellitus in developed and developing countries, 
which appears to be mirrored by near-epidemic rates of 
obesity. The direct and indirect impacts of chronic hyper-
glycaemia and insulin resistance on the endothelium in large 
and narrow calibre vessels are significant 173 • The metabolic or 
insulin resistance syndrome comprises a complex of metabolic 
risk factors, including obesity (body mass index >25), hyper-
triglyceridaemia (> 1.69 mmol/L), low high-density lipopro-
tein levels (<1.04 mmol/L in men; <1.29 mmol!L in 
women), hypertension, impaired glucose tolerance and 
family histories of type II diabetes mellitus, cardiovascular 
disease and polycystic ovary syndrome. These factors com-
bined with complex issues such as a sedentary lifestyle and 
ethnicity combine to account for an increased risk of type II 
diabetes mellitus, cardiovascular disease and stroke in up to a 
third of people in the United States 174· 175· 176 • The meta-
bolic/insulin resistance syndrome has risen in incidence by 
over 60% in the time since the Clinical Development 
Program for octreotide in diabetes mellitus was concluded 177 • 
Given the increasing impact of particularly type II diabetes 
mellitus, it is unfortunate that, apart from the glitazones, no 
new class of medications has become available to clinicians 
for the treatment of metabolic disturbances and complications. 
It is instructive, therefore, to reflect on the Clinical 
Development Program for octreotide as a roadmap for how 
testing of :future anti-diabetic therapies might proceed. 
Our overriding concern during the clinical development of 
octreotide was to maintain a "safety first" approach. In doing 
so we began by characterizing the effects of octreotide on 
counter-regulatory hormones to ensure that the broad 
inhibitory effects of octreotide on brain and gut hormones 
was not associated with blunting of the body's natural 
responses to the dangers of hypoglycaemia. We demon-
strated the safety of octreotide in these terms in healthy 
volunteers and subsequendy in diabetic patients 96·111•120•148• Our 
work on glucose profiling targeted the effects of octreotide 
following pre-meal administration and particularly the effects 
of bedtime administration on overnight glucose and hor-
monallevels 105· 109•150•151 • Adolescents with type I diabetes are 
known to experience a decrease in insulin sensitivity, which 
is thought to be linked in part to elevated circulating GH or 
IGF-1, particularly at night 178•179•180.The GH inhibiting effects 
of octreotide enabled us to investigate this phenomenon 
more fully, while further characterizing the impact of 
octreotide on glucose profiles and counter-regulatory 
hormones. With Aarsen and Bruining et al we found that 
overnight 3-hydroxybutyrate levels were lower following 
octreotide therapy (SO !lg single dose sc), indicating that 
hepatic ketogenesis was suppressed 103 • This finding and other 
supportive evidence by Scheen and colleagues 109 intrigued us 
as it indicated to us that octreotide might play a protective 
effect against the build-up of ketone bodies during periods 
of metabolic stress, e.g. during incipient ketosis. Since then 
some groups have studied octreotide in the setting of the 
treatment of overt diabetic ketoacidosis, and while octreotide 
is not an alternative to standard therapy; the addition of 
octreotide to regular therapy resulted in an improved profile 
of metabolic recovery from ketosis and hyperglycaemia 181•182 • 
Our work in teenagers with type I diabetes mellitus per-
form~d with Aarsen and Bruining et al bridged the gap 
betwe\;n the anti-diabetic effects of octreotide (decreased glu-
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cose levels, decreased GH levels) and its safety in terms of a 
relative lack of effect on glucagon, while decreasing hepatic 
ketogenesis 103 • 
Compared with our work on type I diabetes, the number 
of studies performed in type II diabetes was relatively small. 
Given the importance now ascribed to insulin resistance in 
overt type II diabetes mellitus and the much larger prob-
lem of metabolic syndrome, the effect of long-tern 
octreotide treatment on GH in insulin resistant states would 
be of significant interest today. The morbidity and mortal-
ity of diabetes is accounted for to a great extent by macro-
and microvascular complications, and indeed diabetes mel-
litus is now recognized as being a primarily cardiovascular 
disease 172-175 • Uniting large and small vessels at a structural 
level is the endothelium, which, in contrast to the mid 
1980's, is known to be sensitive to a vast number of pro- and 
anti-inflammatory signals. The aetiology of diabetic retinopa-
thy, for instance, focuses on the interplay between various 
inflammatory and angiogenic mediators, such as, vascular 
endothelial growth factor (VEGF) and IGF-l 183.The find-
ings of an early study in type I diabetic patients may be 
instructive for the future. In the study we performed with 
Kirkegaard's group we found that long term octreotide 
treatment ( 400 !lg daily by continuous s.c. infusion for 1 year) 
was associated with a significant decrease in plasma LDL-
cholesterol and serum apolipoprotein A-I, while von 
Willebrand factor and fibrinogen levels were reduced, but 
not significantly 184• In a more recent study, Clemens et al also 
noted a decrease in endothelial dysfunction (assessed using 
serum thrombomodulin) in diabetic patients treated with 
200 !lg/ day of octreotide for 6 months 185 • 
The utility of somatostatin analogues like octreotide in dia-
betic retinopathy is still an open question, with much pre-
clinical evidence pointing to a role for somatostatin receptors 
in mediating new vessel growth. This anti-angiogenic effect 
may be mediated direcdy or indirecdy via inhibition of 
IGF-1. In terms of the potential macrovascular effects of 
somatostatin analogues, work since the Clinical Development 
Program for octreotide has shown that large calibre vessels 
express somatostatin receptors (type 1 primarily) 186 • 
Modulation of angiogenesis by somatostatin analogues has 
been recognized since the work of E. Woltering and 
T. O'Dorisio 187 • The effect oflong-term octreotide therapy 
on macrovascular complications in future studies of 
acromegaly may provide an indication as to whether effects 
of somatostatin analogues on the endothelium of diabetic 
patients could modulate accelerated atherosclerosis, and 
large-vessel pathology often seen in diabetes. 
In conclusion, while the overall aim of the Clinical 
Development Program in diabetes mellitus did not conclude 
with an approved therapy for diabetes, the growing problem 
of type II diabetes indicates that long-term studies of the 
effect of octreotide on insulin resistance may be of interest. 
It is increasingly likely that the treatment of type II diabetes 
mellitus requires a multi-pronged approach in many patients 
to address metabolic abnormalities, such as, disordered 
insulin sensitivity, hepatic glucose output and hypergly-
caemia. Given that these key components are all influenced 
by octreotide as oudined in this chapter, perhaps the utility 
of octreotide in this condition may have to be revisited in 
the future as an adjuvant or co-therapy. Microvascular dia-
betic retinal disease remains an area of active preclinical 
and clinical research with octreotide and other somato-
statin analogues, and octreotide still may represent a viable 
pharmacotherapy for diabetic retinopathy and possibly a 
treatment for diabetic nephropathy that is refractory to 
ACE inhibitor therapy. 
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Chapter IV. 
The Clinical Development 
of Octreotide in Acromegaly 
IV.I- CHARACTERISTICS OF ACROMEGALY 
The physiological importance of hypothalamic somato-
,statin in the regulation of GH secretion by the anterior 
pituitary was demonstrated first in the early 1970's and was 
well characterised by the beginning of the 1980's. The clin-
ical development team had gained an understanding of the 
effect of octreotide on GH and IGF-1 during the diabetes 
mellitus program (see Chapter III).Also, the pharmacologi-
cal profile in animals and normal humans had shown us that 
octreotide could inhibit GH secretion potently without 
concomitant hypoglycaemia. Regarding acromegaly itself, 
it was understood that the disease was caused by excessive 
GH secretion from an anterior pituitary adenoma in the 
majority of cases 1.Acromegaly due to ectopic GH releasing 
hormone (GHRH) or ectopic GH secretion was known to 
be rare 2•3· 4• GH hypersecretion was thought to be due to 
either an intrinsic loss of regulatory control by a population 
of anterior pituitary cells or due to excessive stimulation by 
the hypothalamus 5• Subsequently; specific mutations in stim-
ulatory G proteins (Gsa) have been identified that lead to 
unregulated expansion of a population of adenomatous 
cells secreting GH and other hormones 6· 7•8• This aetiology 
is similar to adenoma formation by many other glandular 
tissues. 
From work by Alexander et al, it was acknowledged that 
acromegaly was a rare condition with a prevalence ofS0-70 
patients per million population9, and this rate has not changed 
subsequently 10• 11•12• Acromegaly has an insidious onset and 
may be present for up to a decade before diagnosis13 • During 
this time of unrecognised disease activity, organ damage 
can occur due to the effects of unopposed GH and IGF-1 
hypersecretion (Figure 17). Therefore, the prognosis of 
acromegaly appears to depend on early detection and treat-
ment, although prospective outcome data remains lacking 
even today. Mortality in acromegaly was known to be 
double that of the general population 14 and subsequent 
Figure 17. The stimulatory effect of growth hormone releasing hor-
mone (GHRH) on pituitary growth hormone (GH) secretion is mod-
ulated by insulin-like growth factor I (IGF-1), a peptide formed in the 
liver and peripheral tissues under the influence of GH. IGF-1 is thus 
involved in the negative feedback loop governing GH secretion. GH 
secretion is stimulated by ghrelin, stress, exercise and protein and 
inhibited by glucose. Dark lines, peripheral to central regulation; open 
lines, central regulation; light lines, putative regulation. (Adapted 
from Harris AG, Acromegaly, Lippincott Raven, New York, 1996). 
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evidence has shown that this rate can be as high as four times 
normal 15.Wright et al reported that 26% of deaths occurred 
before the age of 50 years and 64% by the age of 60. 
Cardiovascular and respiratory disease and cancer cause the 
majority of deaths. Rajasoorya et al noted that patient sur-
vival in acromegaly was a function of GH level, with a 
higher mortality being noted in patients with higher post-
treatment GH concentrations 16. Impact on mortality appears 
only to be gained when GH levels post-treatment are below 
2 flg/L. Bates et al noted similar findings; patients with GH 
levels of <5 flg/L had twice the normal mortality rate, 
while in patients with a nadir GH of <2.5 flg/L, mortality 
was only 1.4 times normal 17 • Taken together these data 
point to the necessity for tight GH control in the long-term 
management of patients suffering from acromegaly. 
IV.II- TREATMENT OF ACROMEGALY IN THE 
PRE-OCTREOTIDE ERA 
The standard therapy for acromegaly before and since the 
development of octreotide is transsphenoidal surgical resec-
tion 18. This surgical approach introduced by H. Cushing, has 
been used for nearly a century, but success rates vary accord-
ing to the ease of resection, tumour size/bulk and surgical 
expertise. Data available at the time of the clinical develop-
ment program suggested that 60-80% of patients with GH-
secreting microadenomas (<10mm diameter) achieved a 
cure following surgery. However, this dropped to 20% for 
macroadenomas 19.A further complication was the variable 
definition of'cure'. Historically, many surgical series chose 
a GH level of::; 10 !lg/L or::; 5 !lg/L after an oral glucose 
tolerance test (OGTT) as normal. In the 1980's it was 
realised that the definition of'normal' GH had to be revised 
downwards to< 2 !lg/L or less after OGTT, as active dis-
ease could be detected via IGF-1 at higher GH concentra-
tions. We incorporated this advance into the clinical 
development program for octreotide in acromegaly by per-
forming12 and 24 hour GH profiles in which 75% ofGH 
values had to be < 2 !lg/L before we considered disease to 
be quiescent. Patients in whom pituitary surgery was unsuc-
cessful (or too dangerous) had two options before the advent 
of octreotide, radiotherapy and dopamine agonists. Pituitary 
radiotherapy has the disadvantages ofhaving a slow onset of 
action and variable efficacy. Only 50% of patients were 
known to have 'normal' GH (::;5 !lg/L) a decade post radio-
therapy. Also radiotherapy damages surrounding normal 
pituitary tissue, causing hypopituitarism and concerns still 
exist regarding the incidence of second brain tumours 20·21 
Before the development of octreotide the only medical 
therapy for acromegaly was treatment with dopamine ago-
nists like bromocriptine. In normal individuals, L..:dopa 
increases GH secretion, but in acromegaly a paradoxical 
decrease had been reported. Also, some pituitary adenomas 
derive from GH and prolactin co-secreting cells and sup-
pression ofboth hormones with dopamine agonists can be 
achieved. However, the biochemical efficacy of these agents 
is variable, with only 10-20% of patients achieving normal 
GH and IGF-1 concentrations 22. 
IV.III -THE CLINICAL DEVELOPMENT PROGRAM 
IV.III.I - Introduction 
When developing a drug for the treatment of a specific 
condition, one must be able to demonstrate an unmet need 
· for the new therapy to address. In the case of octreotide in 
acromegaly, surgical, radiotherapeutic and medical treat-
ments were all available at the time of the clinical develop-
ment of octreotide. We identified that patients were 
not achieving adequate biochemical control in terms of 
GH and IGF-1 normalisation with any of the available 
treatments 23 24·25 .Also, significant treatment failure occurred 
with both surgery and dopamine agonists, while radiother-
apy often required many years for GH control to manifest 
itself Furthermore, risks of general anaesthetic and pituitary 
surgery meant that elderly or debilitated patients were often 
unsuitable for first-line therapy. The research program in 
acromegaly was designed to address each of these unmet 
needs and define a specific role for octreotide. 
The phase I and II trials with octreotide had demonstrated 
potent selective inhibition of GH and a good safety profile 
in terms of glucose metabolism 26.As acromegaly is a relatively 
pure model of the effects of GH and IGF-1 excess, our 
pharmacological data regarding GH suppression in healthy 
volunteers provided us with a clear rationale for using 
octreotide to improve hormonal and clinical disease meas-
ures in acromegaly. We designed and pursued studies to 
document rapidly the efficacy and safety in acromegalic 
patients. Octreotide was distributed to clinicians initially 
on a compassionate use basis in acromegaly and gut 
endocrine tumours. The benefits reported by acromegalic 
patients and their physicians stimulated us to collect data ret-
rospectively in the form of a case collection. These data 
were collected in a standardised fashion (outlined below) to 
allow us to compare and judge treatment effects across a 
widely scattered population. Standardisation of data collec-
tion was a key factor due to the specific challenges of treat-
ing a rare condition like acromegaly. By definition, the 
clinical development program had to be multinational and 
cooperative in order to recruit sufficient patient numbers to 
perform pharmacological and comparative clinical studies. 
Cohesion amongst clinical research groups in various coun-
tries was crucial to the eventual success of the clinical devel-
opment program for octreotide in acromegaly, and this 
represented one of our primary research functions. As the ret-
rospective case collection was being performed and analysed, 
we instituted a series of prospective studies that examined 
safety, signs and symptoms of disease and compared octreotide 
with available therapy. These studies were performed to sat-
isfy some of the requirements of drug regulatory authorities 
that sought placebo-controlled efficacy and safety data. 
IV.III.II - Pituitary Pharmacodynamics of Octreotide 
Pharmacological data from normal volunteers demon-
strated that octreotide had profound effects on static and 
dynamic pituitary function tests 24. Exercise-induced GH 
secretion was significantly reduced by iv octreotide. 
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Subcutaneous octreotide (50 and 100 f.lg) reduced 
thyrotropin releasing hormone (TRH) induced rises in 
thyroid stimulating hormone (TSH) and prolactin. 
Combined pituitary. function testing with TRH, 
gonadotropin releasing hormone (GnRH) and insulin was 
also performed in healthy subjects. TRH-stimulated 
prolactin and TSH concentrations fell during octreotide 
infusion. Intravenous octreotide blunted the rise in GH due 
to insulin-induced hypoglycaemia, although no effect on 
ACTH or cortisol response was seen. Lutenising hormone 
(LH) dropped slighdy with octreotide but FSH and poste-
rior pituitary hormones were unaffected. 
We investigated the pharmacology of octreotide in 
acromegaly 24• Pharmacokinetic studies in 12 acromegalic 
patients following single 100 !-lg iv or sc. doses of octreotide 
showed that the disposition and elimination half-lives and the 
absolute bioavailability were comparable to healthy volun-
teers. The meant- following sc octreotide was 44 ± 16 min-
utes in acromegalies and 23 ± 7 minutes in healthy volunteers 
(p<0.01), while the meanAUC was 490 ± 185 ng/mL/min 
in acromegalies and 676 ± 159 ng/mL/min in volunteers 
(p<O.OS). 
IV.III.III - Clinical Research with Octreotide in Acromegaly 
Data on the clinical effects of octreotide in acromegaly 
were retrieved in two ways, retrospectively and prospectively. 
The retrospective data was collected from 155 individual 
patients treated with octreotide on a compassionate need basis 
between 1983 and 1987. Sandoz provided octreotide at an 
early stage to experienced endocrinologists for the treatment 
of new patients or others that had failed or were unsuitable 
or unwilling to undergo existing standard therapies. The fol-
lowing recommendations were provided to facilitate data col-
lection and standardisation: 
1. Dose titration should begin with 50 f.lg sc octreotide 
twice or three times daily. Based on early clinical findings 
from Lamberts and colleagues, the eventual optimal s.c. 
dose was found to be 100 !-lg eight hourly, as GH sup-
pressive effects only lasted for four to six hours after 50 f.lg 
octreotide. 
2. Maximum daily dose was 300 f.lg per day sc, but this 
could be exceeded if a clinical response was reasonably 
expected, and tolerability was satisfactory. The highest 
daily dose achieved was 1500 f.lg 27 • 
3.Adverse event profiles were to be monitored extremely 
rigorously. We modelled our adverse event monitoring on 
the possible side effects that could be expected from 
somatostatin and octreotide's biological effects (gut hor-
mone inhibition, malabsorption, gallstones, glucose intol-
erance). In the case ofbiliary stones, ultrasonography pre-
and post treatment was recommended where feasible. 
Efficacy data was measured, collected and reviewed under the 
following headings: 
1. Improvement in signs and symptoms 
2. Magnitude of reduction in GH and IGF-1 concentrations 
3.Reduction in GH and IGF-1 compared with bromocriptine 
4. Effect on pituitary tumour size 
5. ~linical response in terrns of associated safety I tolerability 
1ssues 
Sandoz personnel performed collection of data and inter-
actions with clinician investigators, with multiple on-site vis-
its and discussions. Case report forms were designed to 
capture standardised demographic information, disease char-
acteristics and history, radiology data, disease response and 
adverse events (Table 6). Octreotide was provided to the 
investigators on the understanding that case report forms 
would be completed at the onset on treatment and on a 
monthly basis thereafter. Data were collated and analysed cen-
trally by the clinical development team. 
The patient population was heterogeneous in order to 
maximise the number of patients receiving octreotide, 
but also to determine effects in treatment-naive patients 
(who were unwilling or unable to undergo standard 
therapy) and in those who had undergone failed surgical, 
medical or radiological therapy. The inclusion criteria 
were simple, with demonstration of acromegaly by elevated 
basal GH (>5 f.lg/L), or a failure to suppress GH secretion 
to <2 f.lg/L following a 75-100 g OGTT, or an elevated 
IGF-1level. 
Data from the compassionate use program were assessed 
retrospectively. A total of 155 patients from 20 centres in 
Europe, Canada, Australia and New Zealand were included. 
The retrospective analysis was accompanied by two small 
prospective trials performed from September 1986 to 
February 1987 involving 23 patients. Data collection in the 
prospective trials was similar to that for the retrospective 
analysis. The decision to pursue prospective trials was taken 
because of the evolution of good clinical practice (GCP) 
guidelines and regulatory oversight by the EU (then the 
EEC) to match the FDA guidelines in force in the United 
States. Regulatory approval for the use of octreotide in 
acromegaly in several European and a number of other 
countries was based on the combined results of the retro-
spective case collection and the two small prospective tri-
als. The final number of patients analysed was 178, who 
were treated with doses of octreotide that ranged from 
50-1500 f.lg/ day administered mainly by subcutaneous 
injection or by continuous subcutaneous infusion in a 
limited number of patients. Of particular note was the 
fact that 135 patients had previously failed to respond to 
(or were unsuitable or unwilling for) surgery, radiotherapy, 
bromocriptine or combinations of these treatments. This 
large subgroup was representative of the unmet needs of 
acromegalic patients up to the advent of octreotide. 
Due to the heterogeneity pf the patient population and 
the multicentre design, octreotide treatment was not entirely 
standardised and not all patients were assessed for all clini-
cal parameters. The safety population was 178 patients and 
of these 149 were evaluable for efficacy in reducing GH and 
17 5 were evaluated for other efficacy parameters. The mean 
duration of therapy was 226 days, with some patients receiv-
ing octreotide for up to 35.4 months at the time of analy-
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Table 6: Case report form used for data collection in acromegaly during the Clinical Development Program. 
Case Report Form Heading Data Collected 
Background Information Demographic data, age, weight, height, sex, race and background medical history. History and treatment of acromegaly. 
Coexistent Diseases and Significant medical conditions present at baseline. 
Conditions 
Prior Medication Drugs taken in the three months prior to baseline. 
Concomitant Medications Any other medications taken during treatment with octreotide. 
Physical Examination Findings of complete physical examination were entered at baseline and every subsequent visit. 
Vital Signs Standing and supine heart rate and blood pressure in addition to temperature. 
Clinical Evaluation Patients disease sign and symptom severity was rated by the investigator at baseline and on each subsequent visit as: 0 =absent, 
1 = mild, 2 = moderate, 3 =severe. Signs and symptoms evaluated were: distortion of facial features, acral growth, soft tissue 
swelling, peripheral neuropathy, carpal tunnel syndrome, paresthesiae, osteoarthritis, myopathy, headache, impariment of vitality, 
somnolence, depression, hyperhydrosis/sweating, hypertrichosis, decreased libido, erectile dysfunction, dyspnoea, sleep 
apnoea, galactorrhoea, other endocrine disturbances and visual impairment. Endocrine and neurological examinations were performed 
specifically, and finger circumference was measured by graded rings on the 4th finger of each hand. 
Electrocardiographic A 12-lead electrocardiogram was recorded at baseline and during study visits. 
Evaluation 
Opthalmological Testing Visual fields and perimetry were measured by the Goldman and Friedman methods before and during treatment visits. 
Computerised Tomography Pituitary tumour dimensions, radiological characteristics and extension were recorded prior to treatment and copies of scans 
were to be held by Sandoz. A grading scheme was used for enclosed tumours (I= microadenoma {<10 mm), II= adenoma {>10 
mm)) and invasive tumours (III= localised, IV= diffused). Suprasellar expansion was also graded according to severity as 
A, B or C. Pituitary tumour size changes were assessed as mm reductions in vertical, horizontal or anterior-posterior diameters. 
Gallbladder Echography A gallbladder and biliaJY tree ultrasound was performed prior to starting octreotide therapy and during treatment if so requested by investigator. 
Chest X-ray A chest radiograph performed within the previous six months was to be available before starting octreotide, and a follow up X-ray was 
performed during treatment. 
Laboratory Evaluation The foUowing parameters were measured at baseline, during treatment and if eari.y discontinuation of octreotide occurred: haemoglobin, haematocrit, 
el)lthrocyte, leukocyte and platelet counts (plus differential), ESR, prothrombin time, AST, ALT, alkaline phosphatase, g-GT, total bilirubin, 
urea, creatinine, uric acid, calcium, albumin, sodium, chloride, potassium, cholestero~ triglycerides. A urine dipstick for albumin, glucose, 
acetone, pH, el)lthrocytes and casts was recorded. 
Plasma GH Day curves for GH were to be determined before octreotide and at discretional)~ timepoints during treatment On!¥ similar day-curve timepoints 
were compared in subsequent statistical analyses. 
IGF-1 IGF-1 was recorded before and during treatment 
Diabetes evaluation Insulin requirements and glycaemic control were measured in diabetic patients. 
Oral Glucose Tolerance Test A standard 75 g OGTI was performed following an overnight fast, and glucose, insulin and GH levels were measured. This was performed 
(OGTI) before octreotide commenced and during octreotide therapy. 
Endocrine Assessment Prolactin, TSH, T3 and T4 were measured at baseline and during treatment. 
Dynamic Pituitary Function TRH, GnRH, GHRH and insulin tolerance tests were optional. 
Testing 
Drug Administration Record Drug dose, timing of injections and dose escalations were all recorded. The actual time of administration of octreotide during GH day 
curves/profiles was to be recorded to assess the onset and degree of GH suppression. 
Adverse Events Patients were questioned specifically regarding any adverse events that occurred during octreotide treatment. The nature, severity, duration 
and relationship of the adverse event to octreotide were recorded by the investigator. 
Interim Evaluation All interim response and adverse event data were recorded on separate forms. 
Final Evaluation This form detailed the whether the patient completed the scheduled course of octreotide and any reasons for early termination. 
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sis. Overall results showed that octreotide administration 
significantly reduced GH in most patients and similarly 
most individuals experienced a rapid improvement in clin-
ical symptoms (Table 7). Pituitary tumour shrinkage by 
more than 20% occurred in 19 out of 31 evaluable patients 
after octreotide therapy. Octreotide was well tolerated up to 
a high daily dose (1500 !lg/day) and adverse events were 
experienced in 62/178 (34.4%) patients. Over 90% of these 
adverse events were rated as being only mild to moderate in 
severity and most consisted of transitory gastrointestinal 
upset (abdominal discomfort, nausea, flatulence and loose 
stools). Only one patient discontinued octreotide therapy due 
to an adverse event (diarrhoea). Octreotide had only a mar-
ginal effect on glucose tolerance. Laboratory data including 
thyroid function did not vary in a clinically relevant man-
ner with octreotide therapy. One finding of note was the dis-
covery of non-symptomatic gallstones in three patients.As 
native somatostatin inhibited gallbladder contraction, con-
cerns were expressed that prolonged octreotide therapy 
could lead to the development of gallstones. For this reason 
we became highly vigilant regarding gallbladder function in 
all of our subsequent prospective trials. Moreover, the deci-
sion was made to actively foster study of this phenomenon 
(see Chapter VII). 
The results of the retrospective and prospective studies were 
combined with data.:from a further 11 patients in the U.S. and 
published later in 1991 28 • Analysis of this final collection 
showed a clinical response rate of88%, with lowered GH lev-
els in 172/182 evaluable patients (Table 8). Of these respon-
Results (% improved; total improved/total assessed) 
Distorted fadal features: 45.2 % (76/168) 
Headache: 84% (79/94) 
Ring Size: 55% (22/50) 
Impaired vitality: 78.6% (77 /98) 
Paresthesia: 87.3% (83/95) 
Carpal Tunnel Syndrome: 70.9 % (56/79) 
Osteoarthritis: 58.2% (46/79) 
Somnolence: 64.9 % (37 /57) 
Myopathy: 71.9% (41/57) 
Peripheral Neuropathy: 71.9% (41/57) 
Decreased Libido: 48.0 % (24/50) 
Depression: 68.0 % (32/47) 
Hypertrichosis 23.0% (11/47) 
Erectile Dysfunction: 51.7 % (15/29) 
Dyspnoea: 47.0% (8/17) 
Galactorrhoea: 66.6 % {10/15) 
Sleep Apnoea: 33.3% (1/3) 
Table 7: Improvement in signs and symptoms with octreotide ther-
apy in 178 patients with acromegaly case collection group 
Total Before After 
Dosage, # Octreotide Octreotide p 
IJQ/d Patients Therapy Therapy 
GH, IJQ/L 
100 30 38.2 ± 5.8 21.1 ± 4.7 .0001 
(27. 7) (9.2) 
150 16 30.7 ± 6.8 12.1 ± 4.6 .0001 
(18. 7) (3.9) 
200 23 41.9±11.6 16.1 ± 5.4 .0001 
(19.1) (6.4) 
300 69 38.2 ± 8.8 9.3 ± 2.1 .0001 
(16.2) (4.4) 
400 11 41.2 ± 16.6 5.1 ± 1.1 .0001 
(24.8) (4.4) 
500 4 49.9 ± 19.7 12.4 ± 3.4 .. 0001 
(45.4) (11.4) 
600 13 47.2±17.0 9.8 ± 3.8 .0002 
(24.6) (4.8) 
750 3 7.6 ± 1.3 3.8 ± 0.7 .002 
(7.2) (3.4) 
1500 8 65.9 ± 30.0 13.4 ± 8.4 .0003 
(16.3) (6.7) 
ALL doses 182 39.4 ± 4.4 12.2 ± 1.5 .0001 
IGF-1, U/ml 
100 24 4.00 ±0.61 2.38 ± 0.37 .0001 
(2.96) (1.86) 
150 10 7.69 ± 2.41 3.90 ± 1.25 .02 
(5.52) (2.30) 
200 11 4.67 ± 0.79 2.01 ± 0.29 .003 
(3.90) (2.10) 
300 38 5.63 ± 0.46 2.74 ± 0.27 .0001 
(5.15) (2.40) 
400 2 11.50 ± 5.90 2.14 ± 0.67 .0001 
(11.50) (2.14) 
500 3 7.89 ± 2.36 3.07 ± 0.23 .0001 
(7.80) (3.60) 
600 3 7.88 ± 2.36 3.60 ± 0.23 .002 
(7 .80) (3.60) 
750 2 3.35 ± 0.05 1.21 ± 0.30 .002 
(3.35) (1.21) 
1500 5 4.72 ± 0.84 1.94 ± 0.37 .02 
(4.30) (1.91) 
All doses 99 5.62 ± 0.41 2.64 ± 0.19 .0001 
Table 8. Mean (±SE) serum GH and IGF-1 concentrations before and 
at final evaluation of octreotide therapy in 189 acromegalic patients. 
P values refer to comparison with pretreatment values. The number 
of patients for all doses for GH includes five patients who received 
a total dosage other than those listed; The number of patients 
under the heading IGF-1 includes one patient who received a total 
dosage other than those listed. (Adapted from Vance ML and Harris 
AGzs) 
54 I Chapter IV 
100 150 200 
250 
200 
~ 150 
x 
"' 
100 
50 
300 
""' 
250 
200 
~ 
:L 150 
x 
"' ~~rn.m-100 50 
""" E"l 600 I ~~I 1500 
250 
200 
~ 150 
:L 
x 
"' 
100 
50 
Figure 18. Serum growth hormone (GH) before and at final evalu-
ation of octreotide therapy in a subset of 99 evaluable acromegalic 
patients. Each vertical line represents one patient; the horizontal 
line indicates the pretreatment value. Patients are grouped accord-
ing to total octreotide dosage (in micrograms per day) at final 
evaluation, shown at the top of the figure. (Adapted from Vance ML 
and Harris AG 28). 
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Figure 19. Individual mean plasma GH levels in samples taken hourly 
from 0700-1800 h as . a percentage of pre-treatment levels 
(day 0) during treatment (days 4, 6, 8, and 14) and 6 days after treat-
ment (day 20) with octreotide (up to 200 !lg daily) or placebo for 14-
days in 20 patients with acromegaly. Patient numbers are indicated in 
the figure. 
A: Treated with placebo; the dashed lines indicate approximations of the 
spontaneous variation of plasma GH. 
B: Treated with octreotide; the dashed line indicates reduction of GH lev-
els by 50%. (Adapted from Fredstorp L, Harris A, Haas G, Werner 530). 
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Figure 20. Individual serum IGF-I levels in fasting samples of 0700 h as a percentage of pre-treatment levels (day 0) during treatment (days 2, 
4, 6, 8 and 14) and 6 days after treatment (day 20) with octreotide (up to 200 !lg daily) or placebo for 14-days in 20 patients with acromegaly. 
Patient numbers are indicated. 
A: treated with placebo; the dashed lines indicate approximations of the spontaneous variation of serum IGF-1. 
B: treated with octreotide; the dashed line indicates reduction of IGF-I levels by 20%. (Adapted from Fredstorp L, Harris A, Haas G, Werner S "). 
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ders, 82/182 had GH <5 flg/L (Figure 18). Mean IGF-1 
levels pre- and post- treatment were 5.62 ± 0.41 IU/mL and 
2.64 ± 0.19 IU/mL, respectively (normal <2.2 IU/mL). 
Fifteen of34 radiologically evaluable patients experienced 
a >20 % decrease in pituitary tumour size during treatment. 
The side effect profile was similar to the 178 patient col-
lection. 
While the collection of data was ongoing at Sandoz, other 
groups had already published prominendy in the medical lit-
erature regarding short-term octreotide therapy in 
acromegaly. My colleague from Sandoz E. del Pozo with S. 
Lamberts reported that 50 - 1 OO!lg of octreotide decreased 
GH levels by up to 86% over a period of 2 - 6 hours fol-
lowing subcutaneous (sc) administration 29 • The 50 !lg dose 
suppressed GH by 62% of pre-treatment levels, while the 
100 !lg dose suppressed GH by 81% and for a longer dura-
tion. These short-term effects were studied and confirmed 
prospectively by us in the first double-blind placebo-
controlled trial of octreotide in acromegaly at the Karolinska 
Institute in Sweden (Figure 19, 20) 30 • We performed a 
prospective multicentre dose-ranging study of octreotide in 
France over six months with G. Sassolas et al. 31 • Fifty-eight 
acromegalic patients were included and received increasing 
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Figure 21. Individual mean plasma GH concentrations in 29 patients 
with acromegaly treated with high-dose octreotide (1500-!Jg/day). 
Each line represents an indicidual patient and their respective GH 
concentrations (vertical axis) during incremental rises in octreotide 
dose (horizontal axis). The numbers on the horizontal axis refer to 
daily dose of octreotide. (Adapted from Sassolas G, Harris AG, 
James-Deidier A"). 
doses (300-1500 !lg) of octreotide. Of these, 34 were 
maintained on octreotide for 12-26 months on a minimal 
efficacious dose. GH normalised in 22% of the patients, 
improved in 56%, and remained unchanged in 22% regard-
less of the dose. This study confirmed that the optimal dose 
was 100 !lg eight hourly in 50% of the patients, but 20% 
required a total daily dose of 1500 !lg. Pituitary tumour size 
reduction occurred in 4 7% of the patients harbouring large 
tumours (Figures 21, 22). 
Chronic oct):eotide treatment of acromegaly was reported 
in the rnid-1980s and demonstrated maintenance of short-
term benefits 32, with further decreases in GH being reported 
over time 33 • Accompanying the inhibition of GH secre-
tion, circulating IGF-1 levels also decreased in long-term 
studies and normalised in up to 50% of patients. This high 
response rate was quite uniform across these long-term 
studies and the Sandoz data collections, quite in contrast to 
the variable responses seen with dopamine agonists and 
surgery. In order to classifY patients better, we performed a 
study to assess the long-term responsiveness of acromegaly. 
In this study, with K. Schmidt et al, we found that patients' 
responses to acute administration of octreotide doses in 
acromegaly predicted whether or not they would respond 
adequately to long-term treatment 34 • 
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Figure 22. Individual mean plasma GH concentrations in 27 acrome-
galic patients who did not reach the maximum 1500 !Jg daily 
octreotide dose during dose escalation. When responders (nor-
malised and improved) were considered, the lowest dose was opti-
mal in 50%, whereas the maximal dose was the most efficient in 20% 
however, the difference in plasma GH reduction was often minimal 
(2 !Jg/L in mean GH levels. The numbers on the horizontal axis refer 
to the daily dose of octreotide. (Adapted from Sasso las G, Harris AG, 
James-Deidier A"). 
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At the time of the Clinical Development Program 
bromocriptine occupied the leading position for medical 
treatment in acromegaly, and as such, represented a major 
obstacle to the acceptance of octreotide. Clarification of the 
relative benefits of octreotide and bromocriptine in 
acromegaly was important for the success of our clinical 
development program. We performed a number of studies 
with octreotide and bromocriptine to investigate the rela-
tive efficacies of the two treatments. In conjunction with the 
Department oflnternal Medicine, Erasmus Medical Centre, 
Rotterdam, we studied the acute effects of octreotide and 
bromocriptine alone and in combination in acromegaly 35 
(Figure 23). These findings were confirmed by a similar 
study we conducted in Norway with]. Halse et al 36.These 
studies followed on from early direct comparisons that 
demonstrated better GH suppression with octreotide than 
bromocriptine 37• 38 • We found that octreotide suppressed 
GH secretion more markedly than bromocriptine and had 
a faster onset of action (Table 9). Most interestingly, we 
reported that the two drugs, given in combination, provided 
better control of GH than either one alone, although this 
effect was not seen by another group 39 • Others have also 
reported the increased GH suppressive effect of combina-
tion therapy 40.The benefit of co-administration is partially 
explained by the fact that octreotide increases the bioavail-
ability ofbromocriptine by approximately 40%, while the 
pharmacology of octreotide is unaffected 40 • 
Leading on from this comparative work, we performed an 
analysis with van der Lely at the Department of Internal 
Medicine, Erasmus Medical Centre, Rotterdam, of the 
effects of age and sex on the sensitivity of GH secretion to 
octreotide and bromocriptine 41 • This study of 100 acrome-
galic patients found that tumour size correlated well with 
basal and 24-hour mean GH secretion. Also baseline and 
mean 24 hour GH were closely correlated. Interesting there 
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was only a correlation between GH and IGF-1levels only 
up to a certain GH concentration (not above 40 flg/L).This 
indicated the presence of an upper threshold for GH stim-
ulation of maximal IGF-1 production, above which no fur-
ther enhancement ofiGF-1 secretion occurs. There was a 
negative relationship between age and circulating GH or 
· IGF-1 in male patients, but none between tumour volume 
and age (Figures 24, 25). Higher circulating prolactin pre-
dicted better subsequent GH suppression with bromocrip-
Mean GH day profile 
(!Jg/L) 
Baseline 
Day 14 
Day 28 
Day 56 
Follow-up 
Mean IGF-1 
(U/ml) 
Baseline 
Day 14 
Day 28 
Day 56 
Follow-up 
Octreotide 
13.8 ± 5.2 
4.0 ± 1.4' 
3.3 ± 1.0' 
2.9 ± 0.7a 
12.5 ± 4.4 
3.0 ± 0.36 
1.60 ± 0.43a 
1.43 ± 0.36' 
1.43 ± 0.36a 
2.90 ± 9.38 
Bromocriptine 
18.8 ± 7.5 
7.3±1.9a 
5.3 ± 1.2 a·b 
5.4 ± 1.2 a,b 
13.8 ± 4.4 
2.93 ± 0.40 
2.30 ± 0.31 a 
2.04 ± 0.31 a 
2.13 ± 0.27"' 
3.09 ± 0.33 
Table 9. Effects of treatment with either octreotide 50 ~g s.c. or 
bromocriptine 2.5 mg on serum GH and IGF-1 concentrations in 25 
patients with acromegaly. Results obtained on days 14, 28, 55, and 
56 represent treatment effects. Data are presented as the mean ±SEM. 
a Significantly different from baseline (P < 0.01). 
b Significantly different from day 14 of treatment (P < 0.01). 
cOne patient taking 15 mg bromocriptine daily since day 37 was 
included in the analysis. 
(Adapted from Wagenaar AH, Harris AG, van der Lely AJ, Lamberts SWJ35). 
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Figure 23. Absolute mean changes of circulating GH levels throughout the day in 25 acromegalic patients treated with placebo (n = 51}, 
octreotide (50 ~g sc) (n =51}, bromocriptine (2.5mg po) (n = 40) or combination therapy (n = 25). 0 =placebo;.._= bromocriptine; •= octreotide; 
e = octreotide and bromocriptine. (Adapted from Wagenaar AH, Harris AG, van der Lely AJ, Lamberts SWJ "). 
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Figure 24. Correlation between age and the decrease in GH levels after 50 ~Jg octreotide subcutaneously in 42 male acromegalies. The decrease 
in GH level reflects the area under the curve of the first 12 hours after octreotide administration as percentage of the curve on the control 
day. r =0.32; P = 0.014. (Adapted from van der Lely, Harris AG, Lamberts SWJ 41). 
100 
~ 0 
Q) 60 -o 0 0 0 
_. 
0 
Q) 
,_ 
_. 60 (.) 
0 
C) 
:::i. 40 
0 
I.() 
0 ~ •oe 0 
0 0 • 
• 0 • 0 • 0 0 0~ 0 cP 0 
• • • ,_ 
Q) 20 _. .,__ 
ro 
en 
• • • • 
., 
Q) 0 > 
Q) 
I 
(.') 
-20 0 20 40 60 80 100 
GH levels after 2-5 mg bromocriptine (%) 
Figure 25. Correlation between decrease of GH levels after octreotide and bromocriptine. The decrease in GH level reflects the area under the curve 
of the first 12 hours after the administration of each of the drugs as percentage of the area under the curve on a control day. Both decreases 
correlate well: r = 0.60. P<O.Ol. Note that men (0, n = 23) show a greater decrease in. GH levels after octreotide, while women (e; n = 18) tend to 
show a greater decrease after bromocriptine. r = 0.60; P < 0.01. (Adapted from van der Lely, Harris AG, Lamberts SWJ41). 
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tine. Elderly and male patients responded most profoundly 
to octreotide, and acromegaly tended to be less active in older 
patients. Consequently it was felt that these elderly patients 
could benefit from octreotide as first-line medical therapy, 
rather than resorting to pituitary surgery with all of its 
attendant risks. Recently in 2002, Colao et al confirmed 
that elderly patients with acromegaly had lower GH and 
IGF-1levels, and that a negative correlation existed between 
patients' age and GH and IGF-llevels 42• However unlike in 
our study this group did find a negative correlation between 
patients' age and tumour size. Taken together these results 
suggest that elderly patients with acromegaly have less active 
disease and possibly smaller pituitary adenomas. 
IV.III.IV - Formulations of Octreotide 
Despite the marked benefits of octreotide on disease sever-
ity, we recognised the compliance problems associated with 
administering octreotide by two or three daily injections. 
We also sought to reduce disease activity further with alter-
nate administration forms that exhibited greater 24-hour 
GH suppression. Continuous subcutaneous insulin infusion 
pumps had been developed for use in patients with type I 
diabetes mellitus. We adapted this technology for use with 
octreotide in acromegaly. It had been noted in previous 
injection studies that GH escape could occur approxi-
mately four to six hours after octreotide administration. The 
aim of sc. infusion administration of octreotide was to pro-
vide consistent GH suppression via sustained plasma 
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octreotide levels. In 1987 we reported with Christensen 
from Orskov's group and Timsit et al that sc. pump-admin-
istered octreotide provided superior and stable GH sup-
pression in short-term studies 43• 44 (Figures 26, 27). We 
confirmed these results with Tauber et al., the following year 
with long-term sc. pump octreotide therapy 45 • We subse-
quently demonstrated with RoelfSema and colleagues that 
continuous sc. octreotide at a dose of 300 - 400 )lg/24 hr 
reduced IGF-1 to a significantly greater degree than inter-
mittent injections 46 • However,James et al found no differ-
ence between intermittent injections and continuous sc. 
infusion of octreotide in terms of IGF-1 control, but 
reported better subjective symptom improvement and less 
glucose intolerance with pump delivery of octreotide 47 • 
Continuous pump infusion of octreotide heralded the devel-
opment of repeatable depot octreotide in the 1990's, which 
confirmed the importance of consistent 24-hour GH and 
IGF-1 control. A major concern with both delivery for-
mulations was the possibility of increased adverse events. 
When trials of continuous sc. pump octreotide were 
reviewed, no rises in glycaemic or biliary side effects were 
seen 48 • With respect to gallstone formation specifically, we 
found that no increased risk exists with continuous sc. infu-
sion of octreotide 49 • Although the long-acting repeatable 
(LAR) and intermittent sc formulations of octreotide are the 
predominant routes of delivery and patients found the pump 
form convenient and effective. Moreover, the experienced 
gained with pump delivery facilitated the development of 
the depot long acting repeatable (LAR) form of octreotide. 
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Figure 26. Serum growth hormone (GH) and octreotide profiles in two patients treated with a continuous subcutaneous infusion of octreotide. 
GH concentrations are shown on the vertical axis (left), while octreotide concentrations are on the vertical axis on the right. The horizontal 
axis displays time in hours and days. GH control with octreotide was achieved across the full 24-hour period during sc infusion, while three 
times daily sc injections of octreotide (day 7, right) showed octreotide and GH levels fluctuating reciprocally. (-) Serum GH values; ( ---) serum 
octreotide values. (Adapted from Christensen SE, Weeke J, Orskov H, Moller N, Flyvbjerg A, Harris AG, Lund E, Jorgensen J '"'). 
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& peptides such as octreotide are rapidly degraded in the gut, 
an orally administered form was not felt to be feasible. 
However, clinically relevant effects (50 % reduction in GH) . 
were achieved with 4-8 mg oral octreotide three times a day 
in acromegalic patients 50 • Although acceptable plasma 
octreotide levels have been achieved following oral adminis-
tration 5\ 24-hour octreotide concentrations were variable 
and not dose-dependent. A nasal insuillation formulation of 
octreotide was also developed, which demonstrated approx-
imately 25% bioavailability via the nasal mucosa 52.We showed 
that a 500 J.J.g dose of nasally administered octreotide had the 
bioavailability of 100 J.J.g of sc. injected octreotide, but was not 
as potent as the injectable form (Figures 28, 29, Table 10). 
Neither oral nor nasal octreotide were developed commercially 
due to the relatively poor pharmacological profile compared 
with the sc injectable and infusion pump formulations. 
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Figure 27. Serum GH profiles in 5 acromegalic patients examined 
hourly before (day 1); during continuous sc pump infusion of 
100 iJg/24 h octreotide (day 2, 3 and 4); and during sc injections 
of 33 j.lg octreotide at 0800, 1600 and 2400 h (day 5, 6 and 7). 
Samples were obtained from 0800 to 1200 h at day 2, 3, 5, 6 and 
8; and from 0800 to 0800 h at day 1, 4 and 7. (Adapted from 
Christensen SE, Weeke J, Orskov H, Moller N, Flyvbjerg A, Harris AG, 
Lund E, Jorgensen J 44). 
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Figure 28. Average serum octreotide Levels (y-axis) (±SEM) in 13 
patients with acromegaly after different applications of octreotide. 
Note the faster resorption phase after nasal insufflations and the 
similar AUC after sc injection of 100 j.lg octreotide (solid Line) and 
after nasal application of 500 !Jg octreotide (thick dashed Line). Other 
dashed Lines indicate 1000 j.lg (- - -) and 2000 !lg ( ..... ) intranasal 
octreotide doses (Adapted from Weeke J, Christensen SE, Orskov H, 
Kaal A, Pedersen MM, Illum P, Harris AG "). 
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Figure 29. Average serum GH patterns (±SEM) in 15 patients with 
acromegaly after different applications of actreotide via subcutaneous 
injection and nasal insufflation. Note the similar suppressive effects 
of octreotide after sc injection of 100 j.lg (solid Line) and after nasal 
insufflation of 500 !lg ( -- -- --) and 1000 !Jg (- - -) of octreotide. The 
dotted Line ( ..... ) refers to the effects of the 2000 j.lg dose of 
octreotide (Adapted from Weeke J, Christensen SE, Orskov H, Kaal A, 
Pedersen MM, Illum P, Harris AG "). 
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Parameters 100 1!9 sc 500 1!9 1000 1!9 2000 1!9 p 
intranasal intranasal intranasal intranasal 
t 112 Kamin 24.1 ± 2.5 11.3 ± 1.9b 7.9 ± 1.6b 7.1 ± 1.6b < 0.0001 
t 112 a min 11.3 ± 1.9 12.9 ± 1.9 17.3±2.5 21.3 ± 3,8 b,c < 0.02 
t 1/2 rs min 169 ± 20 148 ± 17 155 ±57 208 ± 26 ns 
tmax min 42.3 ± 5.4 16.5 ± 1.6 b 13.5 ± 1.8b 13.8 ± 1.8b < 0.0001 
Max ~g/L 4.5 ± 0.4 8.7 ± 1.9 20.8 ± 4.2 b, d 43.4 ± 2.8b,c,e < 0.0001 
F 0.22 ± 0.03 0.22 ± 0.05 0.27 ± 0.03 ns 
AUC (0-690 min) 896 ± 81 957 ± 168 1923 ± 439 b,d 4597 ± 536 b,c,e < 0.0001 
~g L/min 
Table 10. Pharmacokinetics of nasal and injectable octreotide. Results are presented as mean ± SEM, n =13 patients. Ns = non significant 
' Analysis of variance, multiple range tests by Least significant difference procedure. 
b P < 0.05, 100 f!g sc vs. intranasal 500 ~g or 1000 ~g or 2000 ~g. 
' P < 0.05, 500 flg intranasal vs. 2000 ~g intranasal. 
d P < 0.05, 500 f!g intranasal vs 1000 ll g intranasal. 
' P < 0.05, 1000 flg intranasal vs. 2000 ~g intranasal. 
(Adapted from Weeke J, Christensen SE, Orskov H, Kaal A, Pedersen MM, Illum P, Harris AG ") 
Given the lack of a feasible oral formulation and in an effort 
to improve the convenience of administration, the LAR 
depot form of octreotide was produced. As mentioned 
above, the approach taken was to emulate the excellent 
24-hour GH control achieved with continuous sc. infusion. 
This process began while we were running the clinical 
development program but the clinical studies were per-
formed, analysed and reported later on. In summary, LAR 
octreotide consists of the drug incorporated into biodegrad-
able DL-lactide-co-glycolide polymer rnicrospheres that 
are injected intramuscularly and slowly release effective 
doses of octreotide over a period of weeks. Octreotide LAR 
reduces GH/IGF-1 secretion effectively when adminis-
tered once every 28 days at a dose of3-30 mg 53· 54• GH was 
persistently suppressed during the plateau octreotide con-
centration phase on days 14-42, with consistent stable inhi-
bition of GH secretion beginning with the third monthly 
dose of octreotide. In patients who had a good response to 
intermittently injected octreotide, 79.5 % experienced a 
drop in GH levels to <2 flg/L, with 67.9% demonstrating 
normalisation ofiGF-I levels. All patients experienced an 
improvement in their clinical signs and symptoms (headache, 
sweating, fatigue, joint pain, carpal tunnel syndrome and 
paraesthesia). Recently; LAR octreotide has been compared 
in head-to-head trials with another long acting depot 
somatostatin analogue, lanreotide slow release (SR) 55 • The 
authors found that octreotide LAR was more effective in 
terms ofGH and IGF-1 control when administered once 
monthly than lanreotide SR given twice to three times per 
month. The better efficacy of octreotide LAR was due to its 
more favourable pharmacokinetic profile, which facilitated 
sustained release of octreotide over a period of 30 days, 
compared with lanreotide that required administration every 
10- 15 days.The LAR and SR formulations of somatostatin 
analogues have become very popular, however intermittent 
injections are still widely used. Razzore et al, highlighted in 
a recent retrospective study that improved GH and IGF-1 
control occurred with intermittent sc. octreotide (150 -
600 !lg/ day) compared with lanreotide SR (30-60 mg 
intramuscularly every 10-14 days) during six months of 
treatment 56• They suggested that patients undergoing pre-sur-
gical somatostatin analogue treatment use intermittent 
octreotide therapy. 
IV.IV - REGULATORY APPROVAL OF OCTREOTIDE 
The data concerning the 178 acromegalic patients was 
compiled and a dossier submitted in 1987 to various 
European regulatory authorities. Regulatory approval for the 
use of octreotide in the treatment of acromegaly followed 
in 1989. The approval process in the U.S. was not as straight-
forward as that we experienced in Europe. In late 1987, 
approval was sought for GEP tumours (including glucagono-
mas, gastrinomas and insulinomas) and acromegaly together, 
however, as described elsewhere, the FDA restricted approval 
to symptomatic carcinoids andVIPomas.A multicentre ran-
domised double blind placebo-controlled trial was imple-
mented in the US, in contrast to the more direct approach 
allowed by the European regulatory authorities. Data was 
eventually presented to the FDA from a prospective North 
American placebo-controlled, multicentre trial of octreotide 
(100 or 250)-lg sc every 8 hours) in 115 acromegalic patients 57• 
Integrated mean GH levels were reduced to <5!-lg/1 in 
49 - 53 % of patients and IGF-1 levels were normal in 
55-68% of patients. They also found that the higher dose of 
octreotide (250 ).lg sc every 8 hours) did not improve 
biochemical control significantly. In summary, octreotide 
(100!-lg every 8 hours) decreased GH to <5!-lg/L in approx-
imately 50% of patients, while 85 - 90 % of patients expe-
rienced a significant drop in GH secretion. IGF-1levels were 
also well controlled by octreotide, with normal levels noted 
in 40 - 70% of patients treated. Together with Ezzat and col-
leagues, we examined the effects of different octreotide 
doses in 99 patients with acromegaly and determined that 
for 50% of patients a dose of 300 !lg/ day of octreotide was 
sufficient, although some patients required a small dose 
escalation (Figures 30, 31) 58 • It is interesting to note that the 
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Figure 30. Growth hormone Levels in response to escalating doses of 
octreotide. Mean GH concentrations are shown in response to increas-
ing amounts of octreotide administered subcutaneously in 3 divided 
daily doses of 100, 200, 200 and 500 !lg. Blood was sampled imme-
diately before and after an injection every hour for 12-24 h to 
obtain mean GH determinations. *p<0.001 indicates that comparisons 
between baseline and each dose of octreotide were statistically sig-
nificant. (Adapted from Ezzat S, Harris AG, Gnehm M, Ferber G, 
Boerlin V "). 
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Figure 31. IGF-llevels in response to escalating doses of octreotide. 
Shown are IGF-1 levels expressed as percentage of their respective 
baseline values. Octreotide was given subcutaneously in 3 divided 
doses of 100, 200, 300 and 500 llg. *p<O.OOl indicates that com-
parisons between baseline and each dose of octreotide were statis-
tically significant. (Adapted from from Ezzat S, Harris AG, Gnehm M, 
Ferber G, Boerlin V '"). 
eventual findings of the North American randornised trial 
and the dose-ranging study match well with the results of 
not only our European-based prospective trials, but indeed 
with the original retrospective case collection. The FDA 
finally approved octreotide for use in acromegaly in 1994. 
Long term U.S. experience with octreotide in acromegaly 
has been published since its approval in 1994. Newman et 
al reported safety and efficacy data from 103 acromegalic 
patients treated with octreotide (300 - 1500 flg s.c.) for a 
mean duration of24 months 59• GH levels fell from 30.9~/1 
to 5. 7 f.lg/1 after three months and remained suppressed, 
while plasma IGF-1 concentrations were normal at 
< 50% of the assessment periods in 64% of patients treated 
for 12-30 months. No evidence of patients developing 
gradual resistance to octreotide was noted. 
Following on from the valuable data derived from the 
original 178 patient retrospective analysis 60 , many subse-
quent trials have assessed the marked effect on patients 
symptoms and signs in acromegaly. Large studies have 
shown that octreotide treatment improves signs and symp-
toms of acromegaly dramatically, in many cases before the 
improvement in biochemical parameters is significant. 
Headache, soft-tissue swelling, arthralgia, fatigue and hyper-
hidrosis improve in up to 95% of acromegalic patients 
treated with octreotide, and improvement is often seen 
within the first few days of administration. 
As part of MJ Forster's doctoral thesis, I was co-supervis-
ing we developed the data collection undertaken for the 
Clinical Development Program in acromegaly into the 
largest descriptive collection of acromegalic patients 61 • 
We defined the clinical and biochemical features of 
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Figure 32. Age distribution by decade of 500 patients with 
acromegaly. (Adapted from Ezzat S Forster MJ, Berchtold P, Boerlin 
V, Redelmeier, Harris AG 61 ). 
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Figure 33. Prevalence of various signs and symptoms in 500 patients with acromegaly. Severe features are represented by solid histograms, 
moderate b~ diagonally hatched and mild/slight features by open histograms. (Adapted from Ezzat S, Forster MJ, Berchtold P, Boerlin V, Redelmeier, 
Harris AG 6 ). 
Figure 34. Magnetic resonance images (MRI) of a pituitary macroadenoma one month before (above) and four months after (below) initia-
tion of octreotide therapy. (Adapted from Stevenaert A, Harris AG, Kovacs K, Beckers A 64). 
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Figure 35. GH cell adenoma of a patient treated with octreotide. The 
cells are somewhat smaller than normal, the nucleus contains more 
heterochromatin, and the size and number of secretory granules 
are increased. Morphological changes in the pituitary tumours of 
octreotide-treated acromegalic patients are heterogeneous and the 
above figure is not illustrative of either "typical" changes nor does 
it catalogue all changes that are seen pathologically. Magnification 
x 4900. (Adapted from Ezzat S, Horvath E, Harris AG, Kovacs K ") 
Figure 36. Crinophagy (uptake of secretory granules by a large com-
plex lysosomal body) is depicted in a GH cell adenoma from an 
octreotide-treated patient. As noted in the previous figure, octreotide-
associated morphological effects in GH-secreting pituitary tumours 
are heterogeneous and this figure is merely illustrative of one notable 
feature. Magnification x 12,400. {Adapted from Ezzat S, Horvath E, 
Harris AG, Kovacs K ") 
acromegaly in 500 individual patients, thus providing in the 
context of an industry setting a unique higher educa-
tional opportunity that led to the awarding of Dr. Forster's 
M.D degree. (Publications with Annie Wagenaar 35 and 
Brenda Koop (see Chapter VII)) were also the result of col-
laborative research that was performed during their intern-
ship at Sandoz on the clinical effects of octreotide in 
acromegaly. The mean age at diagnosis was approximately 
40 years in both men and women and acromegaly occurred 
equally in both sexes (Figure 32). Obesity and hyperten-
sion were present in 75 % and 50% of patients, respectively. 
Impaired glucose tolerance was diagnosed in 36%, while 
nearly a third of patients were diabetic. Hyperprolactinaemia 
was noted in 18% of patients. Symptoms and signs like acral 
growth, soft tissue swelling, and hyperhidrosis were pres-
ent in the majority (98%) of patients (Figure 33). Such 
large-scale data collections are rare in acromegaly, and our 
study remains the largest case collection to date. Recently 
Katznelson and colleagues reported an acromegaly registry 
pilot study of hypogonadism in acromegalic patients 62 • 
This internet-based registry of data collected informa-
tion retrospectively on 363 patients between 1976 and 
1996, compared with our collection of 500 patients. The 
dynamic relationship fostered between the clinical devel-
opment group at Sandoz and the various academic research 
groups thus allowed us to collect, analyse and disseminate 
data on acromegaly that has helped to deepen our under-
standing of the characteristics of the disease. 
Early during the process of collecting data on the compas-
sionate use of octreotide in acromegaly, we noted significant 
effects on pituitary tumour size 63 in our series of 189 
acromegaly patients, pituitary tumour size decreased by 
greater than 20% in 15 (44%) of24 patients 28 • Subsequent 
studies have used tumour size as an outcome measure, but 
the effects of octreotide are heterogeneous. Up to 50% of 
patients have smaller tumours after octreotide therapy 64 
(Figure 3 4), but the magnitude of shrinkage is very variable 
(10-80%) 65•66•67•68•69•70•71 .The morphology of the tumour may 
also change during octreotide treatment making it softer and 
easier to remove surgically. With Ezzat et al we reported that 
the GH inhibitory effects of octreotide were sigrllficantly bet-
ter in patients harbouring adenomas with densely granulated 
somatotroph cells, compared with those harbouring sparsely 
populated sornatotrophs 72.This was confirmed by Stefaneanu 
et al, who reported that GH and somatostatin receptor sub-
type 2 (SSTR2) messenger RNA signals were mildly 
decreased in densely granulated somatotroph cells from 
patients treated with octreotide, compared with soma-
totroph cells from untreated patients 73 • However, the effects 
of octreotide on tumour morphology appears to be variable, 
as in another study with Ezzat et al, we found that no con-
sistent morphological change typified the effect of 
octreotide74• Changes we noted included variations in secre-
tory granule number and size, cell size, nuclear characteris-
tics among others (see Figure 3 5, 3 6 for illustrative examples). 
This variability may explain the poor correlation between 
GH suppression, immunohistological characteristics and 
pituitary tumour shrinkage in patients with acromegaly 
treated with octreotide, as noted by Plockinger et al. 75 • 
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Major cardiorespiratory morbidities associated with 
acromegaly have improved with octreotide therapy. Most sig-
nificant among these is cardiomyopathy76•77•78.With Chanson 
and colleagues, we demonstrated that the improvement in 
cardiac status can occur as soon as within a few weeks of start-
ing octreotide 79 • Others have shown left ventricular hyper-
trophy in particular has decreased with octreotide 80 and 
this decrease has been associated with improved cardiovas-
cular filling parameters and enhanced exercise tolerance81•82• 
Colao et al recently reported similar improvements in left 
ventricular wall thickness within three months of starting 
octreotide LAR therapy83 • Interestingly, only the patients that 
achieved normalisation ofGH/IGF-1 exhibited significant 
improvement in left ventricular function. Hypertension 
and glucose intolerance, common in acromegaly, correlate 
independently with the severity of acromegalic cardiomy-
opathy 84• Even in normotensive acromegalic patients, base-
line and dynamic noradrenalin responses are abnormal 85 .In 
response to octreotide infusion, basal noradrenalin secretion 
and catecholamine response to posture normalised.Abnormal 
catecholamine responses may play a role in hypertension and 
cardiovascular disease in acromegaly and may represent one 
mechanism of action of octreotide in this regard. Sleep 
apnoea has also been shown to improve on octreotide ther-
apy through a reduction in pharyngeal/palatal soft tissue 
swelling and hence decreased upper airway resistance 86• 
Mortality in acromegaly is mainly due to cardiovascular 
disease.We have studied two of the main determinants of car-
diovascular mortality, namely lipids and regional haemody-
narnics.With Cohen and colleagues, we treated 17 patients 
with active acromegaly with octreotide 100-500 j.tg three 
times a day sc for three months 87 • At the end of treatment, 
GH and IGF-1 had fallen by 61% and 36% respectively, 
while insulin levels fell by 42%. Total cholesterol fell over 
the treatment period, but not significantly. In contrast, 
mean triglycerides fell from 2.2 ± 0.4 mmol/L to 
1.6 ± 0.3 mmol/L (p<O.OS) during octreotide treatment.An 
interesting phenomenon was noted in this study: patients 
with diabetes mellitus had higher triglycerides and GH 
levels before treatment, and the effect of octreotide on these 
parameters was significantly (p<O.OS) less than in non-
diabetic patients. Acromegalic patients commonly suffer 
from diabetes mellitus, and it appears that the complex 
metabolic/ counter-regulatory hormonal disturbance asso-
ciated with diabetes mellitus leaves these acromegalic patients 
less responsive to octreotide, although this issue requires 
further investigation. With respect to regional blood flow, we 
again collaborated with Chanson and colleagues in France 
to describe cardiovascular disturbances associated with 
acromegaly 88 • This collaboration had begun during the 
Clinical Development Program for octreotide in acromegaly, 
and the academic relationship has lasted for many years 
since our first work together. In 12 active acromegalies 
patients, we found cardiac index and stroke volume to be 
higher than normal values. Importantly, mean arterial blood 
pressure was higher in acromegalies patients, while brachial 
mean arterial velocity and blood flow were significantly 
higher and lower than normal, respectively. We found a 
negative relationship between IGF-1 and brachial arterial 
blood velocity and a positive linear relationship between 
IGF-1 and mean blood flow. The results of this study, 
published in 1998, suggest that cardiovascular disturbances 
in acromegaly are not simply limited to the heart, but also 
effect regional blood flow in a heterogeneous fashion. 
IV.V- Advances in Current Research 
Acromegaly remains an area of active research for octreotide 
and other somatostatin analogues. Long-term studies with 
sc injectable and LAR octreotide have demonstrated safety 
and continued efficacy over years of treatment. Many of the 
criteria that were studied as part of the Clinical Development 
Program for octreotide have been expanded upon by other 
research groups. A recent development that will be useful 
in assessing the long-term efficacy of various treatments, 
including octreotide, is the publication of a partially 
validated acromegaly quality of life questionnaire, called 
ACROQOL89 • Most other diseases have been studied with 
this type of tool, which can measure more complex -often 
termed "soft"- endpoints that assess the impact of the 
disease on the patients daily life. Full validation of the 
ACROQOL will require pre- and post-treatment applica-
tion of the questionnaire to large numbers of patients with 
acromegaly across many countries. It will be particularly 
interesting to compare the impact of surgical and medical 
therapies on the ACROQOL and its correlation with 
GH and IGF-1levels before and during therapy. 
Comparative studies between octreotide LAR and lanreotide 
slow release (SR) have become more common as the use of 
both drugs has increased in the clinical setting. Ronchi et al 
compared the effects of octreotide LAR and lanreotide SR 
in 10 patients with acromegaly, two of who had diabetes mel-
litus. Octreotide LAR was more effective than lanreotide SR 
at reducing GH and IGF-P0.The most recent data available 
on o-ctreotide LAR concerned its effect as primary therapy 
on hormonal and tumour size parameters in 27 patients 
with acromegaly treated in nine centres in the United 
Kingdom 91 • Patients received octreotide 100-200 j.tg s.c. tid 
for 24 weeks after which time 16 patients switched to 
octreotide LAR monthly for 24 weeks.All patients experi-
enced tumour shrinkage after s.c. octreotide for 24 weeks 
(mean tumour volume reduction 43-49%), while patients 
treated with octreotide LAR for another 24 weeks subse-
quently experienced a mean tumour volume decrease of 
24%. GH levels were below 2.5 j.tg/L in 79% of patients, 
while IGF-1levels normalised in 53% after 48 weeks of ther-
apy. A high dose preparation oflanreotide SR (60mg every 
3 to 4 weeks) has been made available to overcome the dos-
ing problems associated with lanreotide SR 30mg, which 
required an intramuscular injection every 10 days 92• Despite 
the dosage increase no improvement in the rate of GH and 
IGF-1 normalisation was noted. In a parallel effort to improve 
patient acceptability of lanreotide SR, a water-based, low 
volume 30mg "autogel" preparation has recently been devel-
oped. Lanreotide autogel30mg administered every 4 weeks 
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by deep subcutaneous injection has been reported to be 
as effective as lanreotide SR 30mg given once every 
7-14 days in lanreotide-responsive patients93 • 
Thyroid disease is considered to occur with increased 
frequency in acromegaly. The physical and morphological 
effects of excess GH/IGF-I on the thyroid gland have been 
studied in depth by Bogazzi et al 94• Active acromegaly was 
associated with increased thyroid vascularity (as reflected by 
increased colour Doppler ultrasound blood flow), which was 
found to resolve in the overwhelming majority of patients 
after treatment with octreotide or lanreotide. Disease activ-
ity in acromegaly has also been assessed indirecdy by a der-
matological method. It is known that acromegalic patients 
have increased skin thickness and elasticity; and Braham et 
al measured skin tensile properties in 13 patients with 
acromegaly compared with controls. They reported that 
skin distensibility I elasticity (as measured at the forearm and 
neck by a computerized device) was consistendy higher in 
the acromegalic population. Furthermore, skin distensibil-
ity correlated positively with the patients' highest historical 
IGF-1 levels and negatively with post-treatment (surgery, 
octreotide or both) IGF-P5• 
The effects of somatostatin analogues on pituitary tumour 
characteristics continues to be an issue of interest to neu-
rosurgeons and endocrine pathologists. Losa and colleagues 
noted that octreotide treatment was associated with a 
lower level of proliferation in resected GH-secreting 
tumours compared with specimens taken from acromegalic 
patients who had not received octreotide before surgery 96 • 
Contrary to our findings with Ezzat and colleagues 72, no 
difference in the index of apoptosis was seen, which indi-
cates that the mechanism of action of octreotide in sup-
pressing pituitary tumour cell activity (tumouristatic versus 
tumouricidal) remains the subject of debate. In a compar-
ative study, Amato et al found that both octreotide LAR and 
lanreotide SR induced significant tumour shrinkage 
(approximately 30% volume reduction) in previously 
untreated acromegalic patients 97 • At 12 and 24 months' 
follow up, no differences between the two treatments had 
emerged and the mean magnitude of tumour shrinkage 
remained approximately 30%. Effects in the study were con-
sidered to be more pronounced in patients with macroade-
nomas than microadenomas. The recently-introduced 
high-dose lanreotide SR 60mg has also been shown to 
induce tumour shrinkage in a small series of acromegalic 
patients 98 • 
The impact of somatostatin analogues on the heart has 
been studied extensively in recent years, because as noted 
above cardiovascular pathology is the major cause of death 
in the acromegalic population. The importance of the dele-
terious effects of GH and IGF-1 on the heart has been 
underpinned recendy by Colao et al 99.This group described 
the effects on the cardiovascular system of short-term and 
long-term GH-excess due to acromegaly. They found that 
patients with acromegaly for less than or equal to five years 
had increased carotid artery intimal thickness, which 
decreased signi:ficandy after six months' treatment with 
octreotide LAR. Similarly, raised heart rate and increased 
ejection fraction fell with octreotide LAR therapy, as did left 
ventricular mass. Biochemical abnormalities, including 
insulin, total cholesterol and fibrinogen levels all decreased 
with octreotide LAR, while high-density cholesterol rose 
concomitantly. This study demonstrates that important 
deleterious cardiovascular effects can occur even after 
acromegaly of relatively short duration. The significant 
effect of octreotide LAR on these physical and biochemi-
cal parameters reinforces the benefit of both early diagno-
sis and treatment. The same group reported a similar decrease 
in carotid arterial intimal thickness and a favourable alteration 
in cholesterol abnormalities with lanreotide SR treatment 
for six months in 24 acromegalic patients with active disease 
(but not stratified according to duration of disease) 100 • 
However, in a small study involving acromegalic patients, 
patients with GH-deficiency and healthy controls Irving et 
al concluded that GH excess and deficiency had only a 
modest effect on peripheral vascular pathology 101 • This 
group noted lower numerical baseline and higher post-
ischaemic forearm blood flow in acromegalic patients, 
although no difference between acromegalies and controls 
was seen in terms ofblood pressure. It should be noted that 
cardiac output was not measured in the acromegalic group, 
which, along with the failure to include patients with and 
without associated diabetes mellitus represents a weakness 
that should be addressed in other studies. These differences 
in patient characteristics may explain the divergence 
between the results obtained by this group and our results 
with Chanson et al. 88 • Cardiac abnormalities have also been 
shown to resolve partially following transsphenoidal resec-
tion of pituitary adenomas, while combination octreotide 
and surgical therapy may also achieve help patients to 
achieve cardiac benefits 102•103 • 
In the time since the Clinical Development Program, a 
greater understanding of the importance of inflarnrnatory 
mechanisms in the pathophysiology of cardiovascular disease 
and cancer has been achieved. The role played by 
macrophages and other leukocytes in atherosclerosis is now 
acknowledged as being core to the development and prom-
ulgation of the disease. Light is currendy being shed on 
how GH excess can influence immune mechanisms in 
acromegaly and its associated co-morbid conditions. Mice 
with GH excess have greater thymic and splenic weight, 
which appears to impact on immune responses to 
lipopolysaccharide and other mitogens 104• In patients with 
active acromegaly,increasedT cell (CD3, CD4) and decreased 
B cell function (CD19) has been reported 105.This lympho-
cyte subtype alteration may play a permissive role in certain 
pre-cancerous conditions, such as, colorectal polyps 106 and 
prostatic hyperplasia 107 , respectively. 
The field of medical therapy in acromegaly has broadened 
with the introduction of the specific GH-antagonist, pegvi-
somant. This drug, which prevents GH-mediated GH 
receptor activation, has been shown to normalise IGF-1 
levels in a majority of patients studied 108 • Like any new drug, 
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safety issues remain important until large numbers of 
patients have been treated in the daily clinical setting. In 
terms of pegvisomant, concerns have been raised regard-
ing tumour expansion during pegvisomant treatment of 
acromegaly in one patient 109 • Moreover, the beneficial 
effects of octreotide on vascular pathology and choles-
terol abnormalities have not been shown with pegvisomant; 
indeed pegvisomant may actually alter cholesterol pro-
files adversely 110 • The development of pegvisomant has 
also permitted basic investigation of control of the GH axis, 
and has revealed interesting new information regarding the 
roles of ghrelin, GHRP-6 and GHRH at central and 
peripheral sites 111 · 112· 113 and in pathological states 114 • 
Regarding ghrelin, this important GH regulator, the impor-
tance of which was not recognized at the time of the 
Clinical Development Program in acromegaly has very 
recently been shown to be modulated by somatostatin 115 
and octreotide 116 in humans. The impact of somatostatin-
dependent ghrelin modulation on disease status in 
acromegaly remains to be determined. 
Finally, despite consensus on the pathological role of GH 
in acromegaly, there continues to be uncertainty as to 
precisely what level of GH represents a biochemical diag-
nosis and what do we mean by the term "cure" 117• 118 • 
Refinements in laboratory techniques continue apace, 
particularly in terms of more precise immunoassays. Costa 
- and colleagues reported results of an extensive profiling 
study using a highly precise immunoassay that studied GH 
levels following a standard oral glucose tolerance test 119 • 
It appears that of 32 treated acromegalic patients, only five 
(15.6%) achieved a "normal" GH nadir level of0.25 flg/L. 
However, the authors noted that a post glucose tolerance test 
GH level of1J.lg/L was associated with normal age-corrected 
IGF-1levels.This indicates that a nadir GH of1 flg/L may 
be more desirable as a goal for biochemical cure than 
previous higher levels of2.5 f.LgiL or even 5 f.Lg/L. Consensus 
guidelines for the treatment of acromegaly have been 
updated in 2002, and provide confirmation of the central 
role of somatostatin analogues, including octreotide, as the 
"mainstay of medical therapy" for acromegaly 120 (Figure 37). 
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Figure 3 7. Diagrammatic representation of treatment approach for newly diagnosed GH secreting pitu-
itary adenomas. DxRT = Direct beam radiotherapy; SRL=somatostatin receptor Ligand (e.g. octreotide). 
Adapted from Melmed et al 120 
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Chapter V. 
The Clinical Development of Octreotide 
in Gastroenterological Diseases 
V.I - GASTROENTEROPANCREATIC (GEP) TUMOURS 
V.I.I - Characteristics of GEP Tumours 
The term "gastroenteropancreatic (GEP) tumours" refers to 
a diverse group of tumours that arise due to hyperplasia or 
malignancy of hormone producing cells in the gut. Some 
cells are concentrated in organs, such as, the pancreas and oth-
ers are scattered throughout the gastrointestinal tract. 
Hormones produced by this family of cells are potent reg-
ulators of gut motility and secretion and include 5-hydroxy-
tryptamine (5-HT), glucagon, insulin, gastrin, vasoactive 
intestinal polypeptide (VIP), pancreatic polypeptide (PP) and 
motilin. Over-production of one or more hormones due to 
adenoma/ carcinoma can cause serious and debilitating 
effects, such as, secretory diarrhoea (diarrhoea which persists 
with fasting), flushing, hypotension, cardiac valvular disease 
and rashes. All GEP tumours are rare, and many are slow 
growing, only becoming evident clinically after they metas-
tasize to the liver and secrete hormones into the systemic cir-
culation by escaping hepatic first-pass metabolism. The 
incidence of carcinoid tumours alone is about 5 per million 
population per year 1, while other GEP tumours, such as 
VIPomas (0.05 - 0.2/million) and glucagonomas (0.01 -
0.1/million) occur with even less frequency 2• 
Somatostatin is also a gut endocrine peptide, formed by cells 
of the GEP system in the pancreas and diffusely along the 
gut and is a natural inhibitor of most other GEP hormones. 
As noted in previous chapters, somatostatin decreases the 
secretion of enzymes and fluid from the gut by inhibiting the 
release of the hormonal stimulators of these actions. In 
addition, somatostatin can suppress the activity of muscles in 
the wall of the gut, thereby slowing the transit of food 
between different regions of the digestive tract. In 1978, 
Thulin et al published a report in The Lancet regarding 
the use of natural somatostatin in the rescue of a patient with 
intra-operative hypotension due to GEP tumour hormonal 
hypersecretion (so-called 'carcinoid crisis') 3• As before, the 
rationale for using octreotide in GEP tumours was based its 
longer half-life and more potent inhibition of hormone 
release, gut secretion and motility compared with short-
acting native somatostatin. 
V.I.II - GEP Tumours: The Compassionate Need Program 
Before the advent of octreotide, treatment of GEP tumours 
such as carcinoids was limited to surgery and supportive care. 
The demand for octreotide for compassionate use in GEP 
tumours came from within the medical community; and was 
based upon the known inhibition by somatostatin of mul-
tiple gut peptide hormones. Clinicians viewed the increased 
inhibitory potency of octreotide relative to somatostatin as 
a clear indication that it could be of value in the treatment 
of their patients. Of central importance was the lack of 
effective therapies for certain patients suffering from GEP 
tumours. During this time octreotide was given out on a 
compassionate need, named patient basis at several centres 
worldwide through interaction between doctors and the local 
Sandoz affiliated companies. However, between 1984 and 
1985, clinicians' demand for octreotide in compassionate 
need cases grew and initial feedback from its clinical use in 
GEP tumours was favourable. 
Taking into consideration the logistical difficulties, the 
reported benefits to patients and the enthusiasm of the 
medical community; my colleague Dr. Michael Dunne with 
T. Fletcher at Sandoz in the United Kingdom, and 
Dr. Richard Elton, P. Hofker and]. Shui at Sandoz in the 
U.S., analysed data from individual cases for the purpose of 
gaining regulatory approval in the U.S. and worldwide. This 
data gathering process, which involved several hundred 
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patients with GEP tumours, could not have been performed 
without the existence of a cohesive multinational pharma-
ceutical company such as Sandoz. Similar to the case with 
acromegaly (see Chapter IV), detailed standardised case report 
forms were distributed and collected by the local Sandoz 
organization in each country, liaising directly with partici-
pating clinicians, following which the forms were returned 
to the octreotide clinical development group for analysis. The 
geographic spread of the participating centres was very 
wide, with 40 investigators in the U.S. and 38 investigators 
in 12 countries worldwide. The data collected demon-
strated some heterogeneity in terms of rating of disease 
severity, hence, an internal standardised rating system was 
developed to provide a meaningful interpretation of the 
response to octreotide therapy compared with pre-treatment. 
This five-point scale is outlined below: 
1 = symptom resolution or normalisation of measure 
(biochemical marker or clinical measure) 
2 = symptom improvement or reduction in marker of 10% 
or greater 
3 =no change 
4 = symptom worsened or increase in marker of 10% or 
greater 
5 = new symptom occurred 
As noted by Dunne et al in their publication, overall improve-
ment was judged as a mean rating of1.5- 2.4 on the above 
scale, while between 2.5 and 3.4 was judged as no overall 
change in disease severity. A full description of the method-
ology used to collect and analyse data in this case collection, 
such as, patient inclusion criteria, data recording and analy-
sis, recommendations for octreotide administration and 
evaluation parameters are outlined in detail in published form 
by Dunne et al 4.As indicated by Dunne et al in this series 
of patients with GEP tumours treated with octreotide, 
when the data collection process was completed in late 
1986,379 patients had received octreotide worldwide and 
full safety and efficacy information was available from 209 
individuals. Many of these patients were extremely debili-
tated and had failed a number of alternate therapeutic alter-
natives. Therefore, much of the GEP tumour patient 
population treated with octreotide was in fact refractory to 
standard treatment. In 1987, a New Drug Application (NDA) 
was submitted to the FDA for octreotide based largely on the 
retrospective collection of uncontrolled assessments of safety 
and efficacy of octreotide in the management of patients with 
GEP endocrine tumours, including carcinoid tumours, 
VIPomas, glucagonomas, gastrinomas, GRFomas and 
PPomas. Iri September 1987, an FDA advisory board delib-
erated over the approval of octreotide as a treatment for 
symptomatic carcinoids and VIPomas. The FDA limited 
their approval of octreotide to the treatment of carcinoid 
tumours and VIPomas owing to the limited numbers of 
patients with other GEP tumours in the NDA submission. 
Important to the process of registration were the data from 
the largest single-centre subset that were treated at the 
Mayo Clinic in Rochester, Minnesota, USA by L Kvols 
and C Moertel 5·6• Submissions by these senior investigators 
regarding the devastating and intractable nature of carcinoid 
syndrome and the benefits to patients afforded by octreotide 
therapy were extremely strong. Data were presented that indi-
cated that octreotide treatment was associated with an 
improvement in diarrhoea and flushing in 74% and 87%, 
respectively, of patients with symptomatic carcinoids. 
Impressive results were also gained with VIPorna patients, 75% 
, of whom experienced an improvement in their diarrhoea. 
Of utmost importance in this process of registering octreotide 
was the close working relationship between senior investi-
gators in the academic community and the extensive data-
gathering structures available to Sandoz. The success of this 
process can be assessed from the extremely short period of 
time it took from the first compassionate use of octreotide 
in 1984 to full FDA registration in 1988. Preceding FDA 
approval, octreotide was approved for the treatment of GEP 
tumours in Europe and New Zealand in 1988. 
Since its approval in the late 1980's, octreotide has become 
the treatment of choice for patients with carcinoids and other 
GEP tumours associated with secretory diarrhoea. On the 
whole, octreotide provides symptomatic benefits and large 
reductions in hormone secretion in over 50% of patients.We 
convened a group of experts in endocrinology, oncology; gas-
troenterology and surgery to participate in a consensus 
development conference in May 1993 to review pertinent 
dose-titration issues in the setting of approved indications, 
such as, carcinoid andVIPorna 7 • The recommendations of this 
consensus development panel are outlined in Figures 3 8 
and 3 9. In many cases, the starting dose of 150 !lg three times 
per day needs to be increased to combat expanding tumour 
bulk and rising hormone levels. Pathological studies have 
shown heterogeneous effects of octreotide on GEP tumour 
morphology, and many patients experience no decrease in 
tumour bulk. Despite dose escalation up to the milligram 
level, octreotide is well tolerated by patients with GEP 
tumours. In a review of the cost-effectiveness of octreotide 
in carcinoid and VIPoma, Schonfeld et al showed that 
octreotide was associated with a doubling of survival time 
in both conditions 8• Furthermore, this doubling of survival 
was achieved with an almost negligible monetary cost (US 
$ 752.00 per year oflife saved).As with acromegaly, a major 
inconvenience for patients was the multiple subcutaneous 
injections required for administration of octreotide. The 
LAR intramuscular form of octreotide (20 mg once 
monthly) demonstrated equivalent efficacy to three times 
daily subcutaneous injections in terms ofhormone control 
and flushing symptoms 9 • The authors noted that the con-
venience of once monthly injections did not fully obviate 
the need for subcutaneous octreotide, which was useful at 
the beginning ofLAR therapy until steady-state octreotide 
levels were reached. In conclusion, octreotide remains a 
standard option for the symptomatic treatment of GEP 
tumours 10, particularly in light of new evidence showing 
the majority of·such tumours are somatostatin receptor 
subtype 1, 2, 3 and 5 positive 11 • Combination therapy with 
alpha interferon and octreotide continues to show promise 
for improving the suppressiqn of both tumour growth and 
disease activity 12• 
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Figure 38. Relationship between octreotide dose and resolution of 
secretory diarrhoea or flushing in carcinoid syndrome patients. The 
figure demonstrates that maximum efficacy is obtained once patients' 
doses are escalated to between 300 and 450 ~g per day. (Adapted 
from Harris AG, O'Dorisio TM, Weltering EA, Anthony LB, Burton FR, 
Geller RB, Grendell JH, Levin B, Redfern JS.7). 
V.II - SECRETORY DIARRHOEA 
V.II.I - Rationale for Octreotide Use 
Somatostatin has multiple physiological effects in the gut, and 
it is heavily expressed in cells of the pancreas, visceral auto-
nomic nervous system, endocrine cells, and gut lumen. 
Somatostatin is localised to the D cells of the pancreas and 
gut mucosa, particularly in the gastric fundus, antrum, and 
duodenum. D cells are situated in the lower third of the 
crypts, from where they extend cytoplasmic processes along 
the basal membranes to the basal pole of neighbouring 
glands. Thus somatostatin is well placed to exercise paracrine 
control of other endocrine cells in the gut. D cells also have 
microvilli in direct contact with the lumen, thus allowing 
changes in gut content to influence somatostatin release 
into either the gut lumen or the portal circulation. The gut 
is innervated by extrinsic and intrinsic somatostatin con-
taining neurons, with the intrinsic neuronal activity being 
present in both the submucosal and myenteric plexuses. 
This widespread distribution explains how somatostatin 
can have multiple endocrine, paracrine, and exocrine func-
tions within the gut. Somatostatin inhibits pancreatic 
endocrine and exocrine secretion, while suppressing secre-
tion of stimulatory gastrointestinal hormones, and decreas-
ing motility and splanchnic blood flow. 
Careinoid/VIPo:ma 
syxnptoms 
Re-evo.luate dolly 
Consider d.o:se red.uctioa 
ta m.inimel etfective doce § 
e decreD.Se d.oac by 
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••• 
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qBb. until :s)'lllptoms 
nsolve or 1500 JJ4./d 
is reached •• 
Figure 39. Algorithm for octreotide dose titration in patients with carcinoid syndrome or VIPoma-watery diarrhoea syndrome. * If symptoms 
warrant rapid control, re-evaluate daily. ** Dose escalation should occur in 50 !!g increments up to 200 ~g tid, then in 100 ~g increments 
from 200 to a maximum of 500 !!g tid. *** Maintenance dose should not be lower than 50 ~g bid. **** Daily requirements delivered in three 
to four equal subcutaneous doses. (Adapted from from Harris AG, O'Dorisio TM, Weltering EA, Anthony LB, Burton FR, Geller RB, Grendell JH, 
Levin B, Redfern JS 7). 
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As outlined in preceding chapters, octreotide exerts 
significant pharmacological effects on the gastrointestinal 
tract over and above those of native somatostatin. Octreotide 
decreases GEP hormone secretion, particularly glucagon, 
VIP, pancreatic polypeptide and gastrin. Octreotide inhibits 
pentagastrin-stimulated gastric acid secretion and is also 
a strong inhibitor of secretin/ cholecystokinin-induced 
secretion of pancreatic enzymes and gallbladder contrac-
tion (reviewed in 13· 14· 15). It has also been shown to accel-
erate or delay gastric emptying, prolong transit time at 
moderate to high doses, stimulate motility at low doses, and 
inhibit gallbladder emptying. Octreotide considerably 
increases intestinal transit time, and as a result, absorption 
of water and electrolytes is increased. Because of these 
effects on gut hormone and fluid secretion and motility, it 
was suggested that octreotide could be a valuable drug for 
the treatment of a wide range of gut hypermotility and 
hypersecretory disorders. 
V.II.II - AIDS-Related Diarrhoea 
V.II.II.I - Disease Characteristics 
During the clinical development of the analogue in the 
treatment of GEP tumours, it was noted that octreotide 
had a potent effect on the severe secretory diarrhoea often 
experienced by these patients. Once this effect became 
apparent, _it was decided to broaden the perspective and 
seek out other forms of secretory diarrhoea, which were not 
being adequately managed with existing treatments. 
Secretory diarrhoea was recognised as being common in 
patients infected with HIV I AIDS 16 • Given the major pub-
lic health problem that AIDS represented in the 1980's - and 
continues to represent today - there was a great deal of 
interest in therapies that could alleviate conditions associated 
with the disease. In the era before the advent of antiretro-
viral combination therapy, patients with active AIDS infec-
tion often suffered from diarrhoea that was refractory to 
standard forms of therapy. Refractory AIDS-related diarrhoea 
can be extremely severe and is then associated with rapid 
weight loss and debilitation. 
V.II.II.II - Clinical Experience with Octreotide in AIDS 
Diarrhoea 
Based on its physiological action as a potent inhibitor of gas-
trointestinal secretion, physicians working with AIDS patients 
began to use octreotide on an individual case basis at cen-
tres in Europe and North America 17•18·19• Once again, utilizing 
the cohesive data-gathering ability of Sandoz, the clinical 
development team began analysing the effect of octreotide 
in these scattered cases. In conjunction with Fanning and 
colleagues in Canada, we conducted a pilot study of the effect 
of octreotide on refractory HIV-associated diarrhoea 20.We 
found that individual patients had experienced significant 
improvement in their diarrhoea after starting treatment 
with octreotide, which was well tolerated. Discontinuation 
of octreotide therapy was associated with a return of the 
patients' diarrhoea. The patient numbers in this study were 
small (11 evaluable patients) and the results were heteroge-
neous. Some patients experienced moderate stool volume 
reduction at octreotide doses of 150-750 f.lg/day sc. One 
patient remained on octreotide for as long as one year with 
good tolerability. Several other uncontrolled investigations 
suggested that octreotide was beneficial in the treatment of 
diarrhoea associated with AIDS. We designed and com-
pleted an open-label, prospective, multicentre trial in Canada 
and Europe to assess the effects of octreotide administered 
at doses ranging from 100 f.lg t.i.d. to 500 ~-Lg t.i.d. in 
32 patients with AIDS-related refractory diarrhoea 21 • All 
recruited patients were refractory to common anti-
diarrhoeal therapies and octreotide was administered at 
increasing doses up to 500 f.lg t.i.d. or until the patient 
responded to treatment. Of the 17 evaluable patients enrolled 
in this study, five were considered to be complete responders 
( <3 bowel movements per day) and 12 were partial respon-
ders (>50% reduction in stool weight).Another large open-
label randomised trial in North America showed that of 
51 patients, 21 (41.2 %) were considered to be partial or 
complete responders (>50% reduction in stool weight) 22 • 
Simon et al performed a double blind, placebo controlled 
U.S. multicentre outpatient study of octreotide therapy in 
HIV-infected patients with diarrhoea 23 • Following an 
initial baseline period, a three-week dose-escalation was 
performed with octreotide administered at 100 f.lg t.i.d. 
to a maximum of 300 f.lg t.i.d. based on the response to a 
72 hour stool collection. The authors were unable to show 
statistically significant benefits of therapy using their 
regimen and study population, despite having more than 
100 evaluable patients. Of the many possible reasons for a 
study with negative results, including actual lack of efficacy, 
the most obvious are heterogeneity in the study popula-
tion and its treatment, inadequate sample size, and lack of 
strictness in the criteria for efficacy. Although most 
observers agree that chronic diarrhoea in patients with 
AIDS rarely remits spontaneously, especially in patients 
with CD4 lymphocyte counts of <50/mL, the authors 
found a 36% response rate to placebo in all placebo-treated 
patients and a response rate of 4 7% in patients whose 
condition was considered idiopathic. Inability to assure 
treatment compliance, including the dose of octreotide, the 
doses of other anti-diarrhoeal therapies, and complete 
stool collections also could have affected the results. The 
treatment design, which placed the control periods first in 
all patients, also could have affected the results. This point 
is important, because the open-label phase suggested both 
a better response with higher doses (500 f.lg three times 
daily) and further improvement over time. Thus, the nature 
of the protocol may have minimised the potential effec-
tiveness of therapy. An Editorial Comment on the design 
of the study in Gastroenterology noted that the outpatient 
nature of the trial made compliance a difficult variable to 
control, but despite the inconclusive results they observed 
that octreotide represented a useful alternative. These 
results were combined with the findings of a similar study 
performed entirely in the U.S. and a number of other 
smaller studies that had appeared in the literature. 
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Octreotide is most likely to find its use in a subgroup of 
patients with AIDS who have secretory processes causing 
diarrhoea. Additional studies designed to control better for 
placebo, the effects of food intake, pancreatic function, 
and assurance of compliance in treatment and stool 
collections are needed to determine the ultimate benefit 
of octreotide in patients with AIDS who have diarrhoeal 
illnesses. 
V.III- GASTROINTESTINAL FISTULAE 
V.III.I - Disease Characteristics 
Gastrointestinal fistulae are abnormal connections between 
any portion of the gastrointestinal tract and an internal or 
external epithelial surface. Internal fistulae interconnect 
hollow viscera or potential spaces, whereas external ( ente-
rocutaneous) fistulae connect the gut directly or indi-
rectly to the body surface. Pancreatic fistulae are abnormal 
communications between the pancreas and the skin (exter-
nal) or other organs (internal). Pseudocysts may occur 
following trauma to the pancreas (e.g. during surgery) 
and they represent a walled off area of necrotic pancreatic 
tissue and secretions. A pseudocyst may rupture causing 
ascites or may become infected, leading to the develop-
ment of an abscess. Biliary fistulae may occur following sur:. 
gery or trauma to the hepatobiliary tree (e.g. liver 
transplantation), leading to the leakage ofbile either inter-
nally or to the skin surface (external). Fistulae in general, 
and small bowel and pancreatic fistulae in particular, may 
drain high volumes of fluid, thereby upsetting water/ elec-
trolyte balance, in addition to providing a source for 
recurrent infection. Fistulae are usually managed with a 
combination of strict skin hygiene and bowel rest (total 
parenteral nutrition), although high output fistulae may 
remain patent for weeks or even months. Early fistula 
closure helps to prevent skin excoriation by pancreatic 
secretions and reduces the duration of hospital stay, thus 
decreasing costs. 
V.III.II - Rationale for Octreotide Use 
Octreotide can decrease fistula output by the inhibition of 
gastrointestinal hormones, such as. gastrin, cholecystokinin, 
secretin, motilin. This, in turn, results in decreased secretion 
of bicarbonate, water, and pancreatic enzymes into the 
intestine, which was demonstrated in human studies in the 
late 1980's 24• 25• 26 • Subsequent detailed animal work has 
shown that octreotide inhibits secretin- and cholecys-
tokinin-stimulated pancreatic amylase secretion in dogs 27 
and rats 28•29•30 , probably by inhibiting cyclicAMP 31 • In vitro, 
octreotide also inhibited secretin-stimulated pancreatic 
protein and fluid secretion in a dose-dependent manner 32, 
while Nishino and colleagues reported that octreotide 
inhibited ethanol-induced increases in amylase and CCK 
secretion 33 • Reduced fistula secretion may also result from 
decreased intestinal motility and secretion 34 or possibly by 
a direct effect on mucosal cells 35 • 
The standard treatment of a fistula includes: identifica-
tion and localization of the fistula tract, treatment of under-
lying disease (especially infection), restoration of fluid and 
electrolyte balance. Most post-operative fistulae close spon-
taneously with such conservative measures, however for 
some gut fistulae, bowel rest and total parenteral nutrition 
(TPN) is necessary. This is a high-cost in hospital approach, 
that itself is associated with considerable independent 
morbidity (thrombosis, sepsis).The pharmacological effects 
of octreotide on gut secretion and motility were therefore 
attractive to the medical community as a method for 
speeding fistula healing and reducing hospital stay. Before 
a clinical development program for octreotide in fistula was 
designed, the results of retrospective case collections with 
native somatostatin had become available 36•37•38· 39 • As with 
other indications like GEP tumours, the positive trends 
toward clinical efficacy with native somatostatin provided 
further hope to doctors that the enhanced pharmacolog-
ical profile of octreotide could provide a reliable degree of 
fistula closure. Small preliminary studies of octreotide 
involving small numbers of patients were carried out to 'test' 
the hypothesis that octreotide could reduce fistula output. 
These demonstrated reduced ileostomy and pancreatic 
fluid losses. 
V.III.III - Clinical Experience with Octreotide 
Together with M. Irving, we designed and implemented a 
prospective, placebo-controlled, double blind randomised 
trial of octreotide in persistent (despite TPN) pancreatic and 
enterocutaneous fistula 37 • This study was supposed to 
recruit 200 patients at 10 centres and last for a 21-day 
treatment period. The main aim of the study was to discover 
whether octreotide treatment could decrease fistula closure 
times more rapidly than TPN alone, while secondary effi-
cacy parameters included reduction in fistula output, 
reduction in hospital stay, easier fistula management and 
reduced TPN requirements. In essence this was a surgical 
outcome study; involving patients who were refractory to 
available therapy. Also, the patient population was hetero-
geneous, with both enterocutaneous and pancreatic fistu-
lae included, while patients were recruited from 10 centres 
each with their own institutional management regime for 
fistula closure. These design obstacles were to prove crucial 
to the outcome of the study, as it soon became clear that 
200 patients was too high a number to recruit from a 
practical perspective. Scott et al eventually published the 
results of the study in 199340 • Only 29 patients with ente-
rocutaneous fistula were recruited, 10 of whom were 
excluded, which left 8 patients in the placebo arm and 
11 patients in the octreotide arm. There was no advantage 
for octreotide over placebo in the final analysis of data. 
These results are in contrast to trials conducted in paral-
lel or subsequently. Nubiola et al found that octreotide and 
TPN led to the closure of enterocutaneous fistulae in 77% 
of their 27 patients in a mean time of 5.8 days 41 • Octreotide 
(100 flg s.c. 8-hourly) and TPN resulted in a mean reduc-
tion of 55% in fistula output and the most encouraging 
results were seen in patients with high output fistulas. 
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In a prospective trial, Tulassay et al reported that octreotide 
(200 ).!g/day sc) reduced mean fistula output by 70% after 
72 hours of therapy, and spontaneous closure was reported 
in 14 of 16 patients with high-output postoperative 
pancreatic fistulae after eight days 42 • Spiliotis and colleagues 
reported that sc octreotide (300 !lgl day) caused a mean 
reduction of 94% in gastrointestinal fistula output in 32 
of 40 patients43 • Overall, 43% of fistulae closed within 
10 days of octreotide therapy, while 70% resolved after one 
month. Octreotide has also been used successfully in the 
treatment of pancreatic pseudo cysts 44 and biliary fistulae 45 • 
However, many of these positive studies were affected by 
the same problems encountered during the clinical devel-
opment study sponsored by Sandoz. Recruitment and 
stratification was difficult due to the heterogeneity of aeti-
ology, clinical condition of the patient and management 
protocols in different hospitals. While well-designed, 
prospective trials are necessary and desirable if one is to 
ascertain definitively whether octreotide is of use in fistula 
treatment, it is unlikely that such studies will ever be per-
formed. The primary reason for this remains the difficulty 
of performing trials in the surgical/post-operative setting 
where multiple variables combine to confound recruitment, 
data collection and standardization procedures. 
V.IV - BLEEDING OESOPHAGEAL VARICES 
V.IV.I - Disease Characteristics 
Portal hypertension secondary to hepatic cirrhosis (due to 
alcohol or other causes),portal obstruction (e.g. portal vein 
thrombosis), or infection (schistasomiasis) leads to a diver-
sion ofblood away from the liver and towards collateral cir-
culation. From a clinical perspective, the most important 
collateral vessels in portal hypertension are the thin-walled 
oesophagogastric junction veins. These vessels engorge to 
form varices above a portal pressure of 12 mmHg, and 
larger varices are at significant risk of spontaneous rupture 
beyond a pressure of15 mmHg due to increased wall ten-
sion. Bleeding from oesophageal varices carries a very poor 
prognosis, with an estimated mortality of30-50% following 
an index bleed 46 • Furthermore, an index bleed from 
oesophageal varices is a poor prognostic indicator in liver dis-
ease, as 60-90% of patients re-bleed within four weeks 47 • 
V.IV.II - Rationale for Octreotide Use 
The scientific basis for developing octreotide as a treatment 
for variceal bleeding came from preclinical and clinical 
data garnered from studies of somatostatin in this indication. 
Somatostatin reduces splanchnic blood flow, thereby decreas-
ing portal venous pressure 48• Studies of somatostatin showed 
that it decreased portal pressure to a similar extent to vaso-
pressin, and did not affect systemic haemodynarnics when 
administered as an infusion 49 • Clinical trials with somato-
statin in variceal bleeding showed some positive results 
when compared with established medical therapy such as 
balloon tamponade and vasopressin. Burroughs et al per-
formed a randomised, double blind, placebo controlled 
trial of somatostatin and placebo for the treatment of active 
bleeding and subsequent re-bleeds 50 • Somatostatin was 
successful in treating variceal bleeds in 64% of cases, com-
pared with 41% placebo patients, while the somatostatin 
group required significantly fewer blood transfusions. When 
considering the medical treatment of acute variceal bleed-
ing, both at the time of the inception of the development 
plan for octreotide and currently in the early 21st century, 
the main pharmacological alternative remains vasopressin 
and it's analogues. The posterior pituitary hormone was first 
used in treating bleeding varices in the late 1950's and 
early 1960's. It came into common usage despite a lack of 
hard evidence of it's clinical efficacy, and in a review of 
13 controlled trials, Jenkins & Baxter reported that the 
response to treatment with vasopressin (52%) was similar to 
the rate of spontaneous resolution of bleeds 51 • The side 
effects of vasopressin (and analogues such as terlipressin/ gly-
pressin) are significant and common. One quarter of patients 
report adverse events, often cardiovascular in origin, and to 
this end nitro-glycerine is often added to treatment to pre-
vent serious events. Clinical trials have compared the effi-
cacy and tolerability of somatostatin and vasopressin, with 
favourable results for somatostatin overall. Saari et al reported 
that somatostatin controlled bleeding significantly more 
often than vasopressin (84.4% vs. 57.1%, p=0.0281), with 
less adverse events, but more common rebleeding in the 
somatostatin group 52 • Mortality was similar in the two 
groups. Controlled studies have also shown that somatostatin 
compares relatively favourably with endoscopic sclerotherapy 
as a primary treatment for bleeding varices. While the effi-
cacy rates between somatostatin and sclerotherapy groups 
are similar, somatostatin may be associated with a lower inci-
dence of adverse events than sclerotherapy 53· 54 • 
The decision to develop octreotide as a potential therapy in 
the setting of acute variceal bleeding was based upon a 
number of points: 
1. Mortality in variceal bleeding is huge (30-50% per bleed), 
and treatment is very costly. 
2. Despite the existence of various standard medical treat-
ments, all available therapies were associated with significant 
weaknesses with respect to efficacy and/ or adverse events. 
3. The primary treatment for bleeding oesophageal varices 
was endoscopic injection sclerotherapy, an invasive pro-
cedure that requires months/years of training to perfect. 
Not all hospitals are equipped with an endoscopy unit, and 
medical therapy had to date failed to provide adequate 
haemostasis during the "holding period" while a patient 
was being transferred to a endoscopic unit. 
4. Interventional therapies themselves (sclerotherapy, bal-
loon tamponade) were themselves associated with signif-
icant side effects. 
V.IV.III - CLinicaL Experience with Octreotide 
Following on from the results of clinical and preclinical 
trials with somatostatin, it was felt that octreotide might 
have similar or better effects in variceal haemorrhage, 
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given its more favourable pharmacological profile. 
Octreotide was shown to reduce splanchnic blood flow 
in cirrhotic rats 55 and in patients with cirrhosis and por-
tal hypertension 56 • Baxter et al studied the effect of 
octreotide in nine patients with liver cirrhosis and 
portal hypertension and found directly recorded 
intravariceal pressure to be reduced by 38% 57 • At the 
time that the cli.nical development program for octreotide 
in variceal bleeding was being proposed, only ohe com-
parative clinical trial had been reported. McKee et al 
compared octreotide (25f..lg/h for 48h) with balloon tam-
ponade in the setting of endoscopically proven actively 
bleeding varices 58 • In both groups of patients, injection 
sclerotherapy was performed after 48 h. They found that 
bleeding was well controlled at 4 hours (19 /20 with 
tamponade, and 18/20 with octreotide) and 48 hours 
(14/20 with tamponade, and 10/20 with octreotide) in 
both treatment groups. However, patients tolerated 
octreotide better, as balloon tamponade was associated 
with discomfort due to pressure effects of the tube. 
Importantly, survival was significantly higher in the 
octreotide group compared with patient who under-
went balloon tamponade (100% (20/20) vs. 75% (15/20), 
respectively). On the basis of the result of this trial and the 
positive preclinical data regarding octreotide (in addition 
to the positive clinical trials with somatostatin), a clini-
cal trial program was devised in 1987. 
Variceal bleeding represents a major consumer of medical 
resources. Definitive treatment of variceal bleeds is more 
successful is specialist centres with access to endoscopy than 
in district hospitals. However, patients often present with 
variceal bleeds to outlying centres, and an easily admin-
istered, well tolerated and effective "holding therapy" is 
required in the interim period between diagnosis and 
transportation to a special centre for endoscopic treatment. 
The existing "holding therapies" consisted of resuscitation, 
insertion of a Sengstaken-Blakemore tube to control 
bleeding via tamponade, and/ or administration of vaso-
pressin to reduce portal pressure. Both balloon tampon-
ade and vasopressin treatment have been associated with 
significant adverse events and failure rate. On the basis of 
the work of McKee et al, in a centre experienced in using 
tamponade, octreotide demonstrated bleeding control 
comparable with balloon tamponade, particularly in the 
first few hours. This indicated that octreotide could be 
highly beneficial as a short-term measure. The argument 
that the gold standard of efficacy against placebo had not 
been tested could be defended as placebo would be uneth-
ical in the acutely bleeding patient, and octreotide could 
be compared with existing treatments and placebo for a 
few hours while sclerotherapy was being arranged. 
Octreotide is easily administered intravenously, and requires 
little or no expertise, is not associated with significant 
adverse events and does not interfere with later surgi-
cal/ endoscopic intervention. The ease of administration of 
octreotide means that it could be given in the hospital or 
ambulance setting by any staff with basic emergency care 
training. 
On the basis of these points, in addition to the small amount 
ofbasic and clinical data, a study of octreotide as a holding 
therapy in acute variceal bleeding was proposed. No formal 
comparisons with placebo as a "holding therapy" before scle-
rotherapy had been made, and similarly the efficacy of 
octreotide vis-a-vis the main medical treatment, vasopressin, 
had not been tested. Since the late 1980's/ early 1990's, a 
group of well-controlled, large-scale trials have been pub-
lished in the literature. The findings of these trials have been 
clear-cut and have borne out the beliefs of the working 
group almost in their entirety. The results of these trials are 
outlined below. 
One trial looked at the use of octreotide in the control of 
post-sclerotherapy bleeding from oesophageal varices (n=42), 
but also from oesophageal ulcers (n=31) and oesophagitis 
(n=4) 59 • Patients recruited between 1989 and 1992 received 
octreotide at a dose of 50 ~-tg/h, but if bleeding was not con-
trolled, hourly boluses of 50 !-lg were administered for 24 h. 
The treatment was well tolerated and highly effective (bleed-
ing controlled in 38'/ 42 varices; 30/31 ulcers, 4/4 oesophagi-
tis). In the remaining patient with ulceration, and in 2/4 with 
varices not controlled with infused octreotide, bleeding was 
stopped with the addition ofbolus doses. The authors con-
cluded that octreotide was a safe and effective treatment for 
the control of re-bleeding after successful sclerotherapy. 
In a study by Sung et al, one hundred patients with bleed-
ing esophageal varices were randornised to receive either 
octreotide (50 !-lg i.v. bolus, then 50 1-tg/hr i.v. infusion for 
48 hours) or sclerotherapy 60 • All patients receiving 
octreotide underwent sclerotherapy after their infusion. 
There were no significant differences between the groups 
on the basis of immediate control of bleeding, rebleeding 
rate, duration of hospital stay, transfusion requirements, 
while mortality rates at 48 hours, during hospital stay and 
at 30 days did not differ significantly between the two 
groups. The authors recommended the use of octreotide in 
cases where endoscopy was obstructed by heavy bleeding 
and also in cases where emergency sclerotherapy was 
unavailable. Besson et al studied the use of sclerotherapy plus 
octreotide (25 1-tg/hr, i.v. infusion) versus sclerotherapy 
plus placebo in a large French randornised, double blind, 
prospective trial of 199 patients with cirrhosis and variceal 
bleeding 61 • The primary outcome measure was survival 
without rebleeding five days after sclerotherapy. The pro-
portion of surviving patients was 85/98 patients (87%) in 
the octreotide group, which was significantly higher than 
the placebo group (72/101 patients, 71%;p=0.009). Patients 
receiving octreotide required transfusions of fewer units of 
blood than the placebo group (mean 1.2 units, range 
0-7 compared with 2.0 units, range 0-10; p=0.006). The 
odds ratio for treatment failure in the placebo group com-
pared to the octreotide group was 3.3 (95% C.l.1.5 to 7.3). 
The mean (±SD) 15-day cumulative survival rate was 
88 ± 12% in both groups, and both groups experienced 
similar and minor side effects. From these data, the authors 
concluded that the combination of sclerotherapy and 
octreotide is more effective at controlling acute variceal 
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bleeding than sclerotherapy alone, but they found no 
difference in the overall mortality rates in the two approaches. 
A more recent study by Freitas et al has confirmed these 
benefits 62• The effect of iv octreotide on rebleeding rates 
following endoscopic ligation therapy ("banding") has also 
been studied. In 100 consecutive patients with endoscopically 
proven variceal bleeding, Sung et al found that patients who 
received octreotide (50 flg bolus, 50 flg/h iv infusion for 
5 days) during before ligation at endoscopy had a significantly 
lower rate of rebleeding than patients who underwent liga-
tion alone (9% vs. 38%, respectively; p=0.0007) 63 • 
Since the early 1990's, groups have also compared 
octreotide with vasopressin and its analogues. In a ran-
domised trial, Hwang et al reported that iv octreotide 
(100 flg bolus than 25 flg/hour for 24 hours) controlled 
bleeding more effectively than vasopressin (0.4U/h) 
6 hours after beginning treatment (p=0.03) 64.At 24 hours, 
there was a trend in favour of octreotide on the basis of 
bleeding control (63% vs. 46%), but this was not signifi-
cant. Mortality rates were similar in both groups, but 
octreotide was associated with a lower rate of adverse 
events than vasopressin. In a French multicentre, 
randomised trial, Silvain et al reported that octreotide 
(25 flg/hour for 12 hours continuous sc infusion, then 
100 flg s.c. at hour 12 and hour 18) and combined terli-
pressin/nitroglycerin therapy were equally effective in 
the treatment of acute variceal bleeding in cirrhotic 
patients 65 • Octreotide was found to be associated with sig-
nificantly smaller transfusion requirements and side effects 
than terlipressin/ nitroglycerin. The octreotide group had 
significantly smaller (p=0.012) transfusion requirements. 
How do the predictions of the late 1980's measure up to 
what is known now? From the preclinical standpoint, evi-
dence has accrued that octreotide reduces portal blood flow 
via alterations in hepatic venous pressure, azygous blood 
flow and total splanchnic blood flow, although this data is 
not clear cut. It should be noted that the data regarding the 
modes of action of native somatostatin and vasopressin 
remain similarly unclear to this day, despite being available 
for 2-3 times as long as octreotide. When compared with 
the mainstream medical therapies of the time, octreotide 
has proven itself equal in efficacy to balloon tamponade, 
vasopressin plus nitroglycerin, and terlipressin. The adverse 
event profile of octreotide in all of these comparative 
trials has been lower than it's comparator, and in some tri-
als transfusion requirements or even mortality rates have 
been decreased. No consensus has yet been formed regard-
ing the best first-line medical therapy in variceal bleeding, 
but in the light of these data, taken in combination with 
other somatostatin studies 66' 67 , a very strong case can be 
made in favour of octreotide. Our clinical trial program 
envisaged that octreotide would be best placed to play 
the role of "holding therapy" while sclerotherapy was 
being arranged. This role can now be seen as limited in the 
light of the data published above. Not only could octreotide 
represent a relevant choice pre-endoscopy, but it also has 
been shown to decrease the rate of rebleeding from varices 
post-sclerotherapy /ligation. 
A series of meta-analyses of therapies for bleeding 
oesophageal varices have been published in 2001 and 
2002. The most extensive reviews has come from the 
Cochrane Collaboration, which compared endoscopic 
sclerotherapy with pharmacotherapy ( octreotide, somato-
statin, terlipressin, vasopressin) in the management of acute 
variceal bleeding68 ' 69 • The Cochrane Collaboration 
performs rigorous, highly standardised, regularly updated 
systematic reviews that judge the efficacy and safety of var-
ious therapies, and is the gold standard of what is commonly 
termed evidence-based medicine. The reviewer group 
analysed a group of12 randomised controlled trials, includ-
ing six with octreotide, and found no difference between 
endoscopic sclerotherapy and pharmacotherapy in terms 
of failure to control bleeding, five-day treatment failure, 
rebleeding before other elective treatments, 42-day rebleed-
ing, mortality before other elective treatments, 42-day 
mortality, number of blood transfusions, or adverse events. 
When all pharmacotherapy studies were combined adverse 
events (including serious adverse events) were more com-
mon in the sclerotherapy-treated patient group. It is impor-
tant to note that when sclerotherapy is compared with 
pharmacotherapy for the treatment of acute variceal bleed-
ing, the trials are almost invariably performed at busy 
well-staffed university centres. In contrast, many patients 
present to regional or district medical units that lack 
24-hour expert endoscopist cover. Therefore published 
direct comparisons between sclerotherapy and pharma-
cotherapy may not describe accurately the real world 
scenario where an effective holding therapy is a vital step 
in maximizing patient survival while transfer to a central 
endoscopy unit is underway. 
Another meta-analysis of the efficacy of the various phar-
macotherapies for acute variceal bleeding noted no 
differences between terlipressin and octreotide 70.A further 
meta-analysis examined octreotide in particular, and found 
that octreotide improved significantly the control of bleed-
ing, and was comparable to sclerotherapy 71 • Overall 
octreotide had a better adverse event profile than vaso-
pressin/terlipressin and complication rates that were com-
parable to placebo. The authors highlighted that much of 
the previous confusion over the clear benefits of octreotide 
in variceal bleeding resulted from poor study design and dif-
ficulties over definitions of rebleeding/ control ofbleeding. 
The role of octreotide in this indication appears to both as 
a "holding therapy" before definitive treatment can be 
performed, and also as an adjunct to endoscopy, in the pre-
vention of rebleeding.Mter many years of debate, current 
authoritative gastroenterology textbooks have now adopted 
octreotide as a viable alternative to other pharmacother-
apies and as an adjunct to sclerotherapy. One possibility that 
was raised at the inception of the clinical trials program was 
that a putative depot preparation of octreotide could be 
used in the long-term prophylaxis of variceal bleeding in 
portal hypertensive patients. As octreotide LAR form is now 
available, what is the future of this possible indication? 
Initial safety work has been reported, which noted that 
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octreotide LAR 20mg single dose had no negative impact 
on renal profiles in cirrhotic hypertensive patients 72 • One 
trial has been published to date that has looked at the use 
of octreotide in the prevention of recurrent rebleeds over 
6 months 73 • Cirrhotic patients with proven variceal bleed-
ing were programmed to have sclerotherapy alone, or scle-
rotherapy plus 50 Jlg octreotide sc twice daily for 6 months. 
Significantly fewer patients experienced rebleeding while 
receiving octreotide (1/16) than with sclerotherapy alone 
(7 /16) (p=0.037). Survival was improved, with all five 
deaths occurring in the sclerotherapy alone group, four from 
rebleeding. Overall, this improved survival was maintained 
for 12 months after the end of treatment, but decreased 
thereafter. The authors concluded that octreotide may 
represent a viable long-term adjunct to sclerotherapy, and 
comparison with the efficacy of beta-blockers in this 
regard would be particularly desirable in light of the devel-
opment of sustained release somatostatin analogues. Such 
trials with LAR octreotide may expand the use of 
octreotide in gastroenterology further. 
In summary, gastroenterological societies have now 
embraced octreotide as a therapeutic option for the treat-
ment of acute variceal bleeding, but only after the results 
of extensive trials and systematic meta-analytic reviews 
demonstrated the efficacy and safety of octreotide compared 
with all available therapies. 
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Chapter VI. 
Other Clinical Applications of Octreotide 
VI.I - INTRODUCTION 
As has been noted in previous chapters, somatostatin has a 
wide range of physiological actions in endocrine and non-
endocrine tissues. By necessity the Clinical Development 
Program for octreotide concentrated on diabetes mellitus, 
acromegaly and GEP tumours as the main goals of research, 
and in the latter two indications this ended in registration. 
Individual clinical groups showed an early interest in col-
laborating with Sandoz to study the effects of octreotide on 
gut blood flow, motility and secretion, e.g., variceal bleed-
ing, AIDS-diarrhoea and fistulae. These indications were 
studied as part of the Clinical Development Program 
(Chapter V). Through our interactions with academic opin-
ion leaders, other potential clinical uses for octreotide were 
suggested to us, some of which were based on a solid phys-
iological rationale, while others were more theoretical. In 
general, these clinical entities can be sub-divided into pan-
creatology; oncology/palliative care medicine and endocrine 
diseases. Studies were designed, performed and published in 
multiple conditions during my stewardship of the Clinical 
Development Program for octreotide. The success of stud-
ies into these various potential indications was heterogeneous, 
with some failing to show efficacy, and others becoming 
minor - yet important- off-label indications of octreotide 
today. This chapter traces the scientific rationale and study 
results of miscellaneous applications of octreotide under 
the general headings of pancreatic/ gastrointestinal disease, 
oncology/palliative care and pituitary disease. 
VI.II - PANCREATIC AND GASTROINTESTINAL DISEASE 
VI.II.I - Acute and Chronic Pancreatitis 
VI.II.I.I - Disease Characteristics 
Pancreatitis is a heterogeneous disease. Many subtypes of 
pancreatitis exist, each with its own specific aetiological and 
histopathological pattern, for which there are numerous 
classification systems. In general, pancreatitis is divided into 
acute and chronic forms.Acute pancreatitis is a predorninandy 
self-limiting disease that runs a benign course in > 75% 
of individuals. The commonest causes are acute alcohol 
ingestion, gallstones and infections. A minority of cases 
evolves into severe necrotizing pancreatitis, which is associ-
ated with systemic shock, organ morbidity and a mortality 
rate of up to 50%. Damage occurs due to initial destruction 
of pancreatic and peri-pancreatic tissues, with release of 
enzymes. Inflammatory cytokines are then liberated and 
systemic collapse can occur in some individuals. No specific 
treatment for acute pancreatitis exists, and at the time of the 
clinical development of octreotide, it was felt that inhibition 
by octreotide of pancreatic exocrine secretion could reduce 
the severity of pancreatic damage and reduce morbidity and 
mortality. Chronic pancreatitis on the other hand is a pro-
gressive destructive disease usually due to recurrent acute pan-
creatitis, chronic alcohol intake, cholelithiasis and anatomical 
duct distortions. Chronic pancreatitis reduces exocrine and 
endocrine pancreas function gradually due to inflamma-
tion, and :fibrosis and calcification become prominent. The pre-
cise pathophysiology remains essentially unknown, although 
duct obstruction and inflammatory cytokines probably play 
an important role. Chronic pancreatitis is complicated by acute 
attacks that may require supportive treatment in hospital, or 
intervention to drain fluid collections, i.e., pancreatic pseudo-
cysts and fistulas. Patients with chronic pancreatitis often 
suffer from pain, which can require opiate analgesics. 
The rationale for using octreotide in the treatment of acute 
and chronic pancreatitis related to the inhibition of pancreatic 
exocrine secretion, as 'autodigestion' of the pancreas was held 
to be a major cause oflocal and systemic pathology. Also, 
Limberg and Kommerell reported clinical efficacy of sornato-
statin-14 in acute pancreatitis in 1980 1, and this was followed 
by a small number of clinical reports2.3· 4•5•6• 
VI.II.I.II - Clinical Experience with Octreotide 
VI.II.I.II.I - Acute Pancreatitis 
In the latter part of the 1980's independent investigators 
undertook small clinical trials across Europe, some with 
financial and logistical support from Sandoz. For instance, in 
a study of 19 patients with acute pancreatitis, Beechey-
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Newman found that patients treated with octreotide 
(n = 9) experienced significandy less severe disease markers 
than a placebo group 7• Patients with mild disease were 
included, and no difference in mortality rates was noted 
between the groups. These somewhat positive findings were 
followed up by other investigators in larger patient groups, 
and most of these were published in the literature in the mid-
1990's. Fiedler et al and Paran et al performed open-label tri-
als in 93 and 38 patients, respectively, that included cases of 
severe pancreatitis 8· 9• Both trials exhibited significant ben-
efits of octreotide in terms of morbidity. In 2000, Paran et 
al reported the results of an extension of their original trial 
and noted again that octreotide was associated with lower 
morbidity (infection and acute respiratory distress) than a 
control group 10.Andriulli et al performed a meta-analysis of 
trials of octreotide in acute pancreatitis in 1998 11 • The effect 
of octreotide on mortality was found to be significant when 
all trials were assessed together, however, once one open-label 
trial published in abstract form was removed from the analy-
sis, mortality effects were non-significant. In general, open-
label trials demonstrated better effects on complications 
and mortality than randomised trials. Uhl et al performed a 
large acute pancreatitis trial that involved 302 patients with 
an adequate degree of disease severity 12• No advantage of 
octreotide (at doses of100 ~g or 200 ~g tid) over placebo 
was noted in terms of complications and mortality. In the era 
of evidence-based medicine, the negative results oflarge, well-
designed trials outweigh the putative benefits suggested by 
open-label trials that are published in incomplete form. 
VI.II.I.II.II - Chronic Pancreatitis 
Chronic pancreatitis is a more complex disease than acute 
pancreatitis and may be complicated by intractable pain, fluid 
collections (pseudocysts), bile duct or duodenal obstruction 
and effusions. Fluid collections can become infected or may 
impinge on surrounding structures, and surgical drainage is 
often necessary 13 • As before, octreotide was suggested as a 
potential treatment for chronic pancreatitis because of its 
inhibitory effects on exocrine pancreatic secretion. Few 
clinical trials of octreotide in chronic pancreatitis per se 
have been performed, although more investigators have 
examined the utility of octreotide in treating pancreatic 
pseudocysts. Clinical trials have shown heterogeneous results, 
and as is the case with acute pancreatitis, one must place 
greater emphasis on the negative findings of well-designed 
randomised trials 14, than on positive open label reports 15 • 
VI.II.I.II.III - Post-ERCP Pancreatitis 
Endoscopic retrograde cholangiopancreatography (ERCP) 
is a widely used diagnostic and therapeutic intervention. 
ERCP is used to diagnose pancreato-biliary diseases, such 
as gallstones, pancreatic ampullary tumours and sphincteric 
strictures. Cutting or biopsy tools can be deployed via the 
endoscope, which allows treatment at diagnosis in certain 
conditions. During ERCP, the pancreatic and biliary ducts 
are cannulated and radi<;>-opaque dye is injected to visual-
ize the ducts under X-ray screening. ERCP can be com-
plicated by post-ERCP pancreatitis, which may develop 
due to pressure or irritant effects of dye in the pancreatic 
ducts or because of physical damage during cannulation. The 
rate of post-ERCP pancreatitis is about 1-5% after diagnostic 
endoscopy, and rises to more than double that in cases 
where pressure measurements or sphincterotomies are made. 
- The spectrum of severity of post-ERCP pancreatitis is 
wide, with most or all patients exhibiting early asymptomatic 
hyperamylasemia and in most cases overt pancreatitis is of 
mild severity. Severe pancreatitis can occur, with its attendant 
high morbidity and significant mortality. 
The inhibitory effect of octreotide on pancreatic enzymes 
(amylase and lipase), bicarbonate and hormone secretion 
raised the potential of using octreotide as a pharmacologi-
cal treatment for ERCP pancreatitis. Animal studies of 
octreotide had demonstrated its efficacy in reducing histo-
logical and biochemical severity of pancreatitis 16•17 and a series 
of small trials using octreotide as a preventative intervention 
were completed. The results of these small preliminary tri-
als were mixed, with some showing prevention of post-
ERCP pancreatitis, while others showed no effect 18•19•20 • In 
order to verifY whether the preclinical rationale and the early 
clinical results did indeed indicate any value of octreotide in 
the prophylaxis ofERCP pancreatitis, formal well-designed 
trials were planned and implemented. In collaboration with 
Binmoeller et al in]. Delmont's group at Nice University 
Hospital, France, we conducted a double blind, placebo 
controlled comparison of octreotide (1 00 ~g iv before 
ERCP, then 100 ~g s.c. after ERCP) and placebo in the pre-
vention of complications 21 • No significant differences were 
noted in serum biochemical measures (amylase, lipase) at 
baseline and 8 and 24 hours after ERCP (Figure 40). Similarly, 
no significant differences were seen between the octreotide 
and the placebo groups in the rates of pancreatitis and 
abdominal pain. 
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Figure 40. Median serum amylase and lipase activities at baseline 
and at eight and 24 hours after endoscopic retrograde cholan-
giopancreatography (ERCP) in octreotide treated (100 J.l.9 iv before 
ERCP, 100 J.l.g sc thereafter) and placebo groups. No significant 
differences were noted between the octreotide and placebo groups 
in this study in terms of biochemical or clinical scores (P > 0.05) 
(Adapted from Binmoeller KF, Harris AG, Dumas R, Grimaldi C, 
Delmont JP 21 ). 
Subsequendy Sternlieb and colleagues ternrinated a ran-
demised controlled trial after only 84 of the proposed 440 
patients had been enrolled 22 .At first glance, the finding that 
the rate of pancreatitis in octreotide-treated patients was over 
three times that of placebo-treated patients seemed very sur-
prising. An accompanying editorial, however, noted that 
the trial used a very liberal definition of pancreatitis, which 
probably led to a high diagnosis rate in the octreotide group 
due to post-procedure pain. It is possible that abdominal dis-
comfort, common after beginning octreotide, may have 
been misinterpreted by the investigators as a clinical symp-
tom of post-ERCP pancreatitis. Furthermore, patients 
treated with octreotide that underwent sphincterotomy had 
a lower rate of post-ERCP pancreatitis than those that had 
no sphincterotomy. This was a very unusual finding, because, 
as noted above, interventional ERCP is associated with a 
higher rate of pancreatitis than cannulation procedures. 
One recent randomised controlled trial was performed by 
an Italian group in patients at high risk of post-ERCP pan-
creatitis 23 • Again octreotide was ineffective in preventing 
pancreatitis and also had no significant effect on post-pro-
cedure hyperamylasemia. 
In the pre-octreotide era, the pathophysiology of pancreatitis 
was uncertain and no specific pharmacotherapy existed. 
On the basis of the above trial results in acute, chronic and 
post-ERCP pancreatitis, octreotide has not yet been demon-
strated to have clinical efficacy. Subsequent prospective tri-
als and meta-analyses, such as those of Andriulli et al, that 
were performed in recent years have confirmed these neg-
ative findings further 11•24•25•26.The main reason for the fail-
ure of the clinical development of octreotide in this condition 
was the false assumption that the pathophysiology of pan-
creatitis was caused predominandy by enzymatic secretory 
processes within the pancreas. Recent advances in inflam-
mation research have uncovered the immunological events 
that underpin the local and systemic effects of pancreatitis 
27
•
28
•
29
•
30
• These mechanisms are complex and involve many 
levels of cell-cytokine interactions 31 • In this context, the 
failure of octreotide as monotherapy for reducing acute, 
chronic and post-ERCP pancreatitis is unsurprising. If any-
thing, the failure of octreotide to influence pancreatitis 
helped to underline the view that the disease is due to a com-
plex inflarnrnatory immune mechanism, rather than simple 
'auto-digestion'.Even today no single pharmacotherapy has 
shown clear-cut benefit in the prevention and treatment of 
pancreatitis, and improvements in outcome have been 
achieved with better disease recognition, and higher qual-
ity intensive care management. 
VI.II.II - Postoperative Complications of 
Gastrointestinal Surgery 
Following resection or transplantation surgery of the bowel, 
pancreas or liver, functional disturbances can occur that 
increase patient morbidity and impact negatively on qual-
ity of life. Complications or sequalae of such surgery may 
occur early, such as fluid collections, fistulae and pancreatic 
pseudocysts.Alternatively, absorptive or nutritional problems 
may result later from bowel resection, such as dumping 
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syndrome and short bowel syndrome. The recognised 
inhibitory effects of octreotide on digestive tract motility, 
blood flow and secretion meant that individual research 
groups began usmg octreotide very soon after its develop-
ment in an off-label manner to reduce the severity of such 
post-operative complications of digestive surgery. One of the 
major problems associated with the study of pharma-
cotherapies in surgical patients is the wide heterogeneity of 
the patient population. Two different individuals may be 
offered similar operations, such as bowel resection, for very 
different reasons, such as, cancer and inflammatory bowel dis-
ease. Similarly; the complexity and physical challenge to 
the patient of operations on one organ may make it difficult 
to study the overall effects of a drug, for instance, in pancreatic 
surgery where outcomes after Whipple's procedure may be 
analysed together with surgery of lesser severity. With 
octreotide, initial animal studies and open-label trials in 
most surgical indications proved positive. However, larger and 
better-controlled multi-centre trials proved difficult to per-
form and in some cases were unsuccessful. 
VI.II.II.I - Dumping syndrome 
Vl.II.II.I.I - Disease Characteristics 
Dumping syndrome occurs after meals in patients after gas-
tric surgery that have had their pyloric sphincter either 
resected or functionally deactivated. Patients experience either 
early or late dumping. Early dumping occurs within 30 nrin-
utes of eating a starchy I sugary meal and consists of symptoms 
of fainting, palpitations and abdominal pain, accompanied by 
signs such as sweating. Late dumping syndrome occurs 2-3 
hours after eating and consists of more severe problems like 
confusion and loss of consciousness .The aetiology of dump-
ing syndrome remains unclear but early dumping probably 
results from the body's response to unregulated entry of · 
highly osmotic food into the duodenum. Late dumping has 
been attributed to vascular and hormonal responses, e.g., 
insulin secretion, that lead to hypoglycaemia and hypotension. 
VI.II.II.I.II - Clinical Experience with Octreotide 
Six placebo-controlled trials of octreotide in dumping syn-
drome were published during my time overseeing the 
Clinical Development Program for octreotide 32·33•34·35•36·37• The 
majority of the studies were short-term carbohydrate meal 
provocation tests, and almost uniformly octreotide reduced 
symptoms and cardiovascular/haematological signs of 
haemodynamic instability. Some patients experienced 
improvement of pre-existing diarrhoea, while octreotide 
treatment was associated with the development/worsening 
of diarrhoea in others. Li-Ling and Irving reviewed the 
published literature in 2001 and identified seven well-con-
trolled-trials 38 • They concluded that administration of 
octreotide 30 minutes before or immediately after a meal was 
a pragmatic treatment for dumping syndrome, and octreotide 
was recommended for treating patients with severe or refrac-
tory complaints. Octreotide remains a therapeutic option for 
dumping syndrome 39 • · 
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VI.II.II.II - Short Bowel Syndrome 
VI.II.II.II.I - Disease Characteristics 
Resection of varying lengths of small intestine may be 
reqillred for the alleviation of cancer, Crohn's disease, infec-
tion or other diseases. Following extensive resection, patients 
may experience symptoms of malabsorption (including vita-
mins and minerals) and fluid and electrolyte loss, which is 
termed short bowel syndrome. The severity of this syndrome 
is dependent upon the length of remaining intestine. Certain 
patients, such as those with patients with an intact duodenum 
and more than two meters ofjejunum and an intact colon may 
be maintained quite successfully on supplemental oral feeds 
alone. Patients with one to two meters ofjejunum and/ or par-
tial colonic resection may also reqillre occasional parenteral 
nutritional 'top-ups'. However, there exists a subset of sufferers 
with high jejunostomies who are always in a net fluid loss sit-
uation. For these patients a normal daily existence is difficult 
as they are entirely reliant on parenteral nutrition and rehy-
dration and high stoma output can be socially challenging. 
During the clinical development in other mainstream indi-
cations like diabetes and acromegaly, there was great interest 
from specialists in short bowel syndrome in harnessing the 
anti-secretory actions of octreotide to reduce the supplemental 
needs of these patients and therefore improve their quality of 
life. As before, previous experience with somatostatin in the 
early 1980's together with findings in other gut indications 
provided the initial suggestion to us and clinical research 
groups that octreotide might be efficacious in short bowel syn-
drome 40 • Trials of octreotide in short bowel syndrome began 
as early as 1984 and continued throughout the period of my 
involvement with the clinical development program. 
VI.II.II.II.II - Clinical Experience with Octreotide 
Studies of octreotide in short bowel syndrome are in gen-
eral open label, as patient numbers are small. The results of 
these studies are also difficult to interpret due to the het-
erogeneity of the patient population. However, most trials 
demonstrated significant benefits of octreotide in terms of 
reduced intestinal output. In a review of the subject in 
1993, Farthing noted that in short term studies, daily intes-
tinal output was reduced by 16-72 %, while in long-term 
studies 7 5-100 % of patients maintained their reduced intes-
tinal output for 4-28 months 41 • In a double-blind trial, 
Lemann et al found that octreotide (100 !lg t.i.d. s.c.) was bet-
ter than placebo in the reduction of fluid and electrolyte losses 
(p<0.001) in seven patients with high-output jejunostomy 
after extensive bowel resection (mean residual small bowel 
length=30 em) 42• When compared with a control period, 
stomal electrolyte output was significantly reduced (p<0.001) 
during octreotide therapy, while bowel transit time was 
increased significantly (p<0.01). In another randornised 
trial, Kusuhara et al studied the effect of octreotide (100 !lg 
tid sc) on ileostomy output in 12 patients 43 • After a five-day 
run-in period, patients were randomly assigned to receive 
either octreotide or placebo for five days, after which they 
crossed over to the other treatment for five days. Mean 
daily ileostomy output fell significantly on octreotide 
(p<0.05), while placebo had no effect. Daily sodium and 
chloride concentrations from dried ileostomy fluid were sig-
nificantly decreased during the octreotide treatment period. 
Despite the almost uniformly positive reports regarding 
octreotide, its role in the treatment of short bowel syn-
drome remains unclear. Reductions in fluid effiux may 
decrease parenteral fluid requirements in patients with severe 
disease, but the magnitudes of these reductions are variable. 
Furthermore, octreotide is rarely so effective that patients can 
dramatically curtail or cease parenteral nutrition. In this 
regard, octreotide will remain an adjunctive, although use-
ful, therapy for short bowel syndrome. 
VI.II.III - Complications of Pancreatic Surgery 
VI.II.III.I - Disease Characteristics 
Major pancreatic surgery, such as Whipple's procedure and 
resections are associated with significant post-operative com-
plications like pseudocyst, fistula, pancreatic ascites, abscesses 
and sepsis. A pseudocyst is a walled-off area containing pan-
creatic secretions, which may form an abscess if infected. 
Rupture of a pseudocyst may allow the buildup of pancre-
atic secretions in the peritoneal cavity (pancreatic ascites) or 
a fistula may form.The mortality rate in major pancreatic sur-
gery is approximately 5 %, while the complication rate can 
be as high as 20 - 40 %.These complications are caused mainly 
by leak and build-up of pancreatic exocrine secretions, par-
ticularly enzymes. Octreotide is a potent inhibitor of exocrine 
pancreatic secretion and therefore perioperative adminis-
tration could reduce the rate of post-operative complications 
by minimising secretion volumes. Similar to studies in dump-
ing syndrome, short bowel syndrome and other minor poten-
tial indications, we interacted with individual research groups 
to supply octreotide and provide logistical support for data 
collection and analysis. In the case of pancreatic complications, 
small studies and individual case reports provided the basis of 
extensive trials to test the hypothesis that octreotide could 
reduce postoperative morbidity. 
VI.II.III.II - Clinical Experience with Octreotide 
Four large multicentre, randornised, placebo-controlled 
studies have indicated a beneficial role for octreotide in the 
prevention of post-operative complications of pancreatic 
surgery. Together with Buchler et al we undertook the first 
German study, in which 246 patients underwent pancreatic 
resection for the treatment of chronic pancreatitis ~ow risk 
of complications) or pancreatic/periampullary tumours 
(high risk of complications) 44• Patients treated perioperatively 
with octreotide (100 !lg t.i.d. s.c.) had a significantly 
(p<0.005) lower rate (32 %) of post-operative complications 
(pancreatitis, haemorrhage, anastamotic leakage, pancreatic 
fistula, abscess or pseudocyst formation, renal or pulmonary 
insufficiency) than patients receiving placebo (55 .4%). 
Octreotide was most effective in reducing post-operative 
complications in the high-risk tumour group (p<0.01). 
Bassi et al reported a similar multicentre, double blind, 
placebo-controlled study performed in Italy, with a patient 
population of252 evaluable patients, who were randomised 
to receive either octreotide (100 !lg t.i.d. s.c.) or placebo 45 • 
Patients were classified as either 'low-risk' (chronic pancre-
atitis) or 'high-risk' (pancreatic tumours) in a manner sim-
ilar to the Buchler et al study above, while the post-operative 
complications assessed were identical in both studies.Again, 
it was found that the group of patients receiving octreotide 
perioperatively had a lower rate of post-operative compli-
cations than the placebo group (15.6% and 29.2 %,respec-
tively (p<0.01)). However, when each complication was 
assessed individually, only the rate of pancreatic fistula for-
mation was significantly lowered (p<0.03) in patients receiv-
ing octreotide, compared with placebo. In contrast to the 
German study, Bassi et al found that octreotide was more 
effective in reducing the post-operative complication rate in 
the 'low-risk' group than in the 'high-risk' group. 
Subsequently a second German and a second Italian trial have 
been performed. The German trial studied only patients 
requiring surgery due to chronic pancreatitis 46 , while the 
Italian study combined patients with chronic pancreatitis 
and tumour diagnoses 47 • The second German study found that 
the complication rate in the octreotide group (16.4 %) was 
significantly less than the placebo rate (29.6 %; p = 0.007). 
In the second Italian trial, the complication rates were 21.6% 
and 36.4% in the octreotide and placebo groups, respectively 
(p <0.05). Significantly more patients in the placebo group 
suffered from fistulae than in the octreotide group. Berberat 
et al have reviewed the field in 1999 48 and analysed the 
results of these four studies and three other large trials, one 
US (open label, prospective), one French (randomised, dou-
ble-blind, placebo-controlled), and one Spanish (randomised, 
double-blind, placebo-controlled). No differences in overall 
complication rates were seen in the US and Spanish studies, 
although the latter reported significantly fewer fistulas with 
octreotide. The French study was similar in size to the 
German and Italian studies (230 patients) and significantly 
fewer patients receiving octreotide experienced complications 
compared with placebo-treated patients. Berberat et al con-
cluded that based on the weight of data from large, well-
designed placebo-controlled trials, octreotide can significantly 
reduce post-operative complications of surgery in those 
with pancreatic cancer of chronic pancreatitis. 
The combined number of patients in the studies outlined 
above is over 1000, and these patients were assessed, cate-
gorised and treated with octreotide in a reproducible man-
ner. Results of the studies taken individually or together 
demonstrate a clear benefit of octreotide treatment in 
patients undergoing major pancreatic surgery. The research 
groups made a conscious effort to define patient risk groups 
clearly, and endpoints were pragmatic. In this way the flaws 
encountered in some of the post-ERCP pancreatitis trials 
(described in an earlier section) were avoided. 
VI.II.IV - Chemotherapy-induced Diarrhoea 
Studies of patients treated with cytotoxic cancer chemother-
apeutics report diarrhoea in about 20% of cases. The 
aetiology of chemotherapy-induced diarrhoea is complex 
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and may be due to direct toxic effects on DNA in gut 
cells, in addition to disruption of normal gut absorption and 
motility. Often, chemotherapy-induced diarrhoea is resist-
ant to treatment with common anti-diarrhoeals, such as, 
loperamide and other opiates. Initial early experience with 
octreotide in secretory diarrhoea due to VIPoma and AIDS 
led oncologists to use octreotide on an investigational basis 
in refractory chemotherapy diarrhoea. Many case reports and 
small collections have been published, in addition to mod-
est open-label trials 49• 50• 51 • In general, open label studies 
demonstrated a response rate of 75 - 95%. However, as 
with other indications, the positive benefits of uncontrolled 
studies have not been borne out in controlled trials. Until 
large-scale comparisons with existing therapy (opiates) are 
carried out, octreotide will remain an unproven adjunctive 
therapy for chemotherapy-induced diarrhoea. 
VI.III - PITUITARY DISEASE 
VI.III.I - TSH-secreting Adenomas 
The clinical development of octreotide as a treatment for 
acromegaly brought the development team at Sandoz into 
close contact with most major pituitary endocrinology 
groups in Europe and North America. This collaboration 
facilitated the use of octreotide in many miscellaneous 
endocrine conditions, particularly other pituitary tumours, 
where somatostatin was thought to play a regulatory role. 
We were able to collect data on the response of patients with 
TSH-secreting and non-functioning pituitary adenomas. 
TSH adenomas are rare and aggressive and responded 
poorly to available surgical and medical treatment, before 
the advent of octreotide.We collected and analysed data in 
52 patients from the largest single series of patients with TSH 
secreting pituitary adenomas and found that octreotide 
was safe and effective 52 • The hormonal response (TSH 
and a-subunit levels) to single doses of octreotide (50 -
100 !lg sc) were measured initially and demonstrated falls 
in the majority of patients (Figure 41, 42). In 33 patients 
studied for short-term (1 - 2 weeks) responses to octreotide 
(median dose 300 !lg daily s.c.), mean(± SD) TSH fell from 
14.7 ± 25.9 to 3.8 ± 7.4 mU/1 (p<0.01). Interestingly,TSH 
responses improved as treatment progressed over the short 
term. In approximately three-quarters of patients, thyroid 
hormone levels were normalised. Following long-term 
therapy (mean= 20 months), 84% (21/25) of individuals 
had normal thyroid hormone levels. During short and long 
term therapy a minority of individuals experienced escape 
of thyroid hormone levels, which resolved with dose esca-
lation in some cases. Seven patients experienced tumour 
shrinkage (30- 70 %).Three patients developed asympto-
matic gallstones during long-term therapy. More recently, 
a large series from the NIH has been published 53 • This 
study describes the clinical progress of 25 patients treated 
at a single centre (in contrast to our multicenter study), how-
ever, the therapeutic interventions used were heteroge-
neous with approximately one third of patients receiving 
surgery and the rest a combination of various therapies. 
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Figure 41. Individual levels of thyroid-stimulating hormone {TSH) 
and free (-subunit during single-dose octreotide studies {50 -
100 J.Lg sc) in patients with TSH-secreting adenomas. Closed circles 
denote basal levels and open circles denote nadir levels after 50 -
100 11g octreotide subcutaneously. (Adapted from Chanson P, 
Weintraub BD, Harris AG 52). 
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Figure 42. Individual levels of free thyroxine {FT4) during short-term 
{1 to 2 weeks) octreotide therapy (mean dose 300 J.Lg daily sc) in 
patients with TSH-secreting adenomas. Closed circles denote basal 
levels, and open circles denote levels at the end of the short-term 
study. In patients who also received levothyroxine (indicated by sin-
gle asterisk) or antithyroid drug (indicated by double asterisk) 
treatment, interpretation of free T4 {FT4) course was impossible. The 
horizontal hatched area indicates the normal range for FT4. (Adapted 
from Chanson P, Weintraub BD, Harris AG 52). 
VI.II.II - Non-functioning Pituitary Adenomas 
Similar to the case with acromegaly and TSH pituitary ade-
nomas, we were able to collaborate with academic researchers 
in neurosurgery and neuroendocrinology to study putative 
effects of octreotide on non-functioning pituitary adenomas. 
In 1989, we collaborated with Warnet and Chanson and col-
leagues to study a series of eight patients with pituitary 
macroadenornas that had visual disturbance due to chiasmal 
impingement 54• In a letter to the New England Journal of 
Medicine in 1987 this group had reported improvement in 
visual defects in a patient with a TSH-secreting pituitary ade-
noma treated with octreotide 55 • Our eight patients included 
two with non-functioning adenomas, two with TSH-secret-
ing adenomas, two with gonadotropin-secreting adeno-
mas, one with a silentACTH-secreting adenoma and one 
with acromegaly. The patients with gonadotropin-secreting 
adenomas were unresponsive to octreotide, which was insti-
tuted at a dose of 100 !-Lg/ day via sc infusion. The six other 
patients experienced rapid (within hours to days) and pro-
longed visual field/ acuity improvements (Figure 4 3). These 
changes were not accompanied by demonstrable changes in 
tumour size in five of six patients. The rapidity of improve-
ments in some of the patients suggested to us that somato-
statin agonism could have direct visual effects via the optic 
nerve or the retina. De Bruin at al used 111 In-octreotide 
scintigraphy to demonstrate the presence of somatostatin 
receptors on six of seven postoperatively-confirmed non-
functioning pituitary adenomas. Three of four somatostatin 
receptor positive patients that received 1200 !lg octreotide 
s.c. daily experiencedvisual field improvement, despite a 
lack of objective improvements on CT scanning 56 • 
Working subsequently with Warnet et al, we reported the 
results of the French Multicenter study looking at the effects 
of octreotide on opthalmological and surgical outcomes 
BEFORE TREATMENT MAXIMAL IMPROVEMENT 
Figure 43. Visual acuity and visual fields before (left) and during 
(right) octreotide treatment in six patients with pituitary macroade-
noma. Visual fields were plotted using a Goldmann perimeter with 
a 64-sq mm object at 1-candela/sq m light intensity (outer plot) and 
with 4- and 1-sq mm objects at 0.315 candela per square metre of 
light intensity (inner plots). (Adapted from A Warnet, E Lajeunie, 
F Gelbert, M Duet, SN Diop, P Chanson, J Cophignon, AG Harris 54) 
only in patients with non-functioning adenomas 57 • The 
patient population was heterogeneous, unlike the TSH ade-
noma group described above. Of 24 patients, 22 had non-
functioning adenomas that were immunohistochernically 
positive for ACTH (n=2), gonadotropin (n=7), (-subunit 
(n=1), GH (n=1) or negative (n=4). Nine others had no 
tumour staining performed. Doses of octreotide varied from 
100-600 !lg/ day and total octreotide treatment time varied 
greatly from as short as one day to as long as 700 days. The 
data collected in this study did not demonstrate clear-cut 
benefits of octreotide treatment peri operatively. Some ben-
efits in terms of visual fields were noted, but response to treat-
ment was difficult to predict, and a small number of patients 
experienced worsening of visual function. As in the smaller 
study above, tumour shrinkage did not accompany or pre-
dict improvements in visual fields or acuity. We suggested that 
improvements in visual function associated with octreotide 
might be mediated via vascular effects at the level of the 
tumour and/ or chiasma or via direct somatostatinergic neu-
ronal actions. In conclusion, some patients with large non-
functioning pituitary macroadenomas accompanied by 
visual disturbance may experience rapid and prolonged 
improvement in visual function during octreotide therapy. 
These improvements are not explained by tumour shrink-
age alone, as this occurred in a minority of patients. Those 
who respond rapidly to octreotide may benefit from longer-
term treatment and the judgement regarding the 
urgency/timing of neurosurgery in such patients should 
take these effects into account. 
Before SMS 201-995 6 months 
.6SDS/BA Number of SmC .6SDS/BA 
Patients GR GHpulses U/ml GR 
1 -0.6 6 1.6 -2.2 
2 +0.2 3 1.4 -1.5 
3 +0.3 13 1.7 0.6 
4 +0.4 8 1.6 -2.5 
5 +0.9 8 2.8 -2.9 
6 +0.5 9 1.3 -3.4 
7 +0.7 6 1.7 -1.7 
8 +0.2 8 -3.3 
9 +0.1 6 0 
10 -0.6 8 -2.2 
Mean +0.4 7.5· 1.7 -2.0 
SD 0.2 2.6 0.5 1.1 
*p<O.Ol. 
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VI.III.III - Tall Stature 
Treatment of tall and short stature in endocrinologically 
normal children has always been an area of great contro-
versy. Previous interventions like oestrogen (for girls) and 
testosterone (for boys) were associated with unwanted 
hormonal side effects. The use of a somatostatin analogue 
to modulate growth spurts via precisely targeted GH axis 
inhibition was therefore attractive. We conducted a small 
study of octreotide with Tauber et al in French adolescents 
with constitutionally tall stature (>2 SD above chrono-
logical age and a predicted height of> 180 em for girls and 
> 190 em for boys) 58 • The response to octreotide was gen-
erally rapid, although great inter-individual variability 
existed. Although final height had not been reached by the 
end of the study, a mean reduction of 4. 9 em was achieved, 
which was considered modest (Table 11). One patient had 
asymptomatic microlithiasis, which disappeared after 
ursodeoxycholic acid therapy and remained normal after 
octreotide was discontinued. Our results were followed in 
1995 in a British study of nine tall children who received 
continuous octreotide infusions at night for two years 59 • 
Median reductions in height were again modest (3.5 em), 
and the authors suggested that prepubertal height could be 
blunted with octreotide, thereby reducing the baseline 
height from which the growth spurt would begin. No 
effect on thyroid secretion was noted. 
12months 
Number of SmC .6SDS/BA Number of SmC 
GH pulses U/ml GR GHpulses U/ml 
1 1.1 -0.4 2 1.0 
2 0.6 
3 2 -1.7 3 0.7 
5 0.6 -0.4 4 1.4 
2 1 -1.4 6 0.4 
5 1.1 -2.2 3 1.4 
4 1.3 0 4 1.0 
3 
8 
3 
3.6· 1.1* -1.0 3.7 l.O• 
2 0.5 0.9 3.4 0.4 
Table 11. Evolution of growth rate (GR), number of growth hormone (GH) pulses during 24 hours and IGF-1 (SmC) before and after 6 and 
12 months of octreotide therapy. Octreotide therapy reduced significantly both the number of GH pulses and mean IGF-1level, while the growth 
rate (estimated as rate of change of stature relative to basal height) was slowed modestly (Adapted from Tauber JP, Vigoni F, Harris AG, 
Rochicchioli P 58). 
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VI.IV - ANALGESIC EFFECTS OF OCTREOTIDE 
Somatostatin receptors are found throughout the central and 
peripheral nervous systems and the immune system. A neu-
roimmune regulatory circuit of somatostatin and substance 
P has been suggested to be involved in the modulation of 
joint inflammation (and pain) in patients with rheumatoid 
arthritis 60 • Somatostatin may inhibit the transmission of 
nociceptive stimuli through its inhibitory effect on sub-
stance P release. In the rat brain, octreotide binds to opiate 
receptors with an affinity about 200 times higher than 
somatostatin and octreotide may mediate analgesic effects via 
interactions with opiate receptors in the brain and spinal cord 
61
• Clinical studies in pain syndromes like fibromyalgia have 
shown no effect of octreotide 6\ although the complex psy-
chopathology and deconditioning associated with this dis-
ease has confounded analgesic pharmacotherapy. However, 
octreotide has recently been shown to be a substrate of the 
transporter protein p-glycoprotein 63' 64• P-glycoprotein acts 
as a protectant against exogenous toxins/xenobiotics and is 
expressed in high concentrations in the small intestine, kid-
ney, liver and blood-brain barrier. At the blood-brain barrier, 
p-glycoprotein limits the access of many drugs to privileged 
sites within the brain. As such, p-glycoprotein may prevent 
adequate access of octreotide to receptors within the cen-
tral nervous system in the clinical setting, thus limiting 
potential somatostatinergic analgesic effects. Combination 
therapy with octteotide and a p-glycoprotein antagonist 
might represent a future mechanism for delivering thera-
peutic octreotide doses into the brain. 
In cancer-related pain, intrathecal octreotide has been very 
effective in a small number of patients with terminal cancer. 
Penn et al reported that pain relief and a reduction in opi-
ate requirements were achieved with an intrathecal octreotide 
infusion in six patients with terminal intractable neuro-
pathic pain 65• 66 • The efficacy and safety of high doses of 
octreotide (3 mg/ day) as analgesia in cancer pain has been 
reported in small studies both during the Clinical 
Development Program 67 and subsequently 68.Together with 
Schmidt and colleagues we studied the effect of octreotide 
as an analgesic in two acromegalies patients with intractable 
headache 69 • This study was performed double blind, with the 
patients receiving octreotide 100 f..Lg or placebo in a series 
of15 hospital visits. Pain was rated on a visual analogue scale. 
We found that the patients experienced nearly complete pain 
relief 4- 15 minutes after octreotide injection. The pain con-
trol was long lasting with a duration of action of2 - 8.5 hours 
(Figure 44). Both patients had been receiving multiple anal-
gesic drugs pre-octreotide, and once regular octreotide ther-
apy was instituted, these requirements fell dramatically. 
Analgesia was rtot mediated by opiate receptors, as naloxone 
injection failed to block the activity of octreotide in both 
patients. Withdrawal of octreotide or dose-reduction resulted 
in return ofheadaches, and both patients remained stable on 
therapy 71-82 months after beginning octreotide treat-
ment.We also screened 11 patients with chronic pain of var-
ious aetiologies and found that a minority (3/11) reported 
improvements, however, these were not studied in a double-
. blind manner. It is difficult to extrapolate the effects of 
octreotide on headache in acromegalic patients to general 
analgesic activity in heterogeneous groups of patients with 
serious intractable pain. Given the difficulty and ethical 
issues surrounding pain trials in cancer patients, octreotide 
is likely to remain an acljunctive therapy for palliative care spe-
cialists treating severe opiate resistant pain. 
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Figure 44. Growth hormone (GH) levels and average pain intensity 
(VAS) after sc injection of octreotide. Patients were given 100 ~g 
of octreotide at 0 min and 100 g of glucose orally at 30 min. 6. = 
GH level, e = pain intensity (mean and S.D.). (Adapted from K 
Schmidt, PH Althoff, AG Harris, H Prestele, PM Schumm-Draeger, KH 
Usadel 69). 
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Chapter VII. 
Safety Issues with Octreotide during 
the Clinical Development Program 
Most side effects associated with octreotide adminis-
tration are either local or gastrointestinal. 
VII.I - LOCAL REACTIONS 
Local reactions include pain, a sensation of stinging, tingling 
or burning at the site of injection, with redness and swelling. 
These reactions rarely last more than 15 minutes. We found 
that local discomfort may be reduced by allowing the solu-
tion to reach room temperature before injection or by inject-
ing a smaller volume using a more concentrated solution. 
VII.II - GENERAL GASTROINTESTINAL ADVERSE EVENTS 
Gastrointestinal side effects include anorexia, nausea, vom-
iting, cramp-like abdominal pain, abdominal bloating, flat-
ulence, loose stools, diarrhoea and steatorrhea. Avoiding 
meals around the time of injection may reduce these side 
effects. In rare instances, gastrointestinal side effects may 
resemble acute intestinal obstruction with progressive abdom-
inal distension, severe epigastric pain, abdominal tender-
ness and guarding. 
VII.III - PANCREATIC FUNCTION 
Impairment of pancreatic function was not a significant 
problem during acute and long-term octreotide adminis- · 
tration in normal volunteers and acromegalic patients 1· 2• 3• 
Exocrine and endocrine pancreatic functions were evaluated 
by non-invasive means (faecal fat excretion, mouth-to-
caecum transit time, Lundh meal, hormonal profiling). 
Octreotide (200-400 J.Lg/day for up to 30 months) signifi-
cantly increased average faecal fat excretion compared with 
the off treatment level (12.9 versus 1.9 g/day,p<O.OS).Three 
of five patients reported an increased bowel frequency indi-
eating possible steatorrhoea and in two others this was tran-
sient.Although measured faecal fat excretion increases, there 
is no evidence that long-term treatment with octreotide 
leads to significant diminution of pancreatic function and 
nutritional deficiency due to malabsorption 4•5•6•7• 
A case of acute pancreatitis was reported in an acromegalic 
man taking octreotide. However, the causal relationship of 
acute pancreatitis to octreotide therapy has been ques-
tioned, as cholelithiasis cannot be excluded on the basis of 
a single ultrasound scan 8• Moreover, computed tomography 
(CT) and ERCP had not been performed in this patient. 
VII.IV - HEPATOBILIARY ADVERSE EVENTS 
VII.IV.I - Hepatic Adverse Events 
Isolated cases of hepatic and biliary dysfunction in patients 
on octreotide have been reported9.Acute noncholestatic hep-
atitis followed by normalization of transaminase values on 
withdrawal of octreotide has been reported in some cases. 
Administration of octreotide can produce hyperbilirubi-
naemia associated with elevations of alkaline phosphatase, 
gamma-glutamyl transpsptidase and, to a lesser extent, 
transarninases. Cases ofbiliary colic on abrupt withdrawal of 
octreotide have been reported 10 • While the attacks can be 
severe, they were short-lived with no apparent sequelae. It 
is possible that rebound gallbladder hypercontractility is the 
cause of biliary colic on abrupt cessation of octreotide. 
Rhodes et al have suggested that patients on long-term 
octreotide therapy may benefit from a drug-free period 
each week to enable evacuation of the contents of the gall-
bladder and reduce the risk of gallstone formation 11 • 
When the first reports of gallstones occurring in patients 
treated with octreotide appeared, we implemented a cogent 
program with leading academic centres in France, the United 
Kingdom, The Netherlands and Germany to unravel the 
pathogenesis of octreotide-induced gallstones. This pro-
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Figure 45. Peak liver radioactivity as assessed by technetium scan-
ning is higher at 35 min in the octreotide treated subjects compared 
to the placebo groups (29 min) (P = 0.07) (Adapted from C Grimaldi, 
J Darcourt, AG Harris, E Lebot, F Lapalus, J Delmont 13). 
Normals Acromegalic patients: 
acute effect of octreotide 
Units (N = 14) Before 2 hr after 
bx(L) min 5-15 9.4 ± 0.6 14.0 ± 1.7'" 
tvz (L) min 30-50 39.3 ± 5.0 53.3 ± 5.0' 
l12omin % <10 9.8 ± 1.0 20.9 ± 3.1b 
t& (L) min <60 58.6 ± 1.5 85.7 ± 7.2b 
tc min 10-30 20.3 ± 3.0 23.4 ± 2.4 
tm..,(G) min 30-60 43.1±6.3 110.0 ± 6.5' 
kd(D) min <60 31.5 ± 5.0 >120 
Table 12. Dynamics of bile excretion in 14 normal adults and acute 
effect of octreotide in 7 untreated acromegalic patients compared 
with values before injection of 5 _g octreotide: 
a= p < 0.05; b = p < 0.005; '= p < 0.001. 
tm..,. maximum liver (L) radioactivity 
t11z(LI: 50% of maximum liver radioactivity 
L1zo: remaining radioactivity in the liver at 120 minutes 
t& (L): disappearance of liver radioactivity 
tc: time at which gallbladder was visualized 
l:max(c): Peak gallbladder radioactivity 
1:r..d (D): radioactivity in duodenum 
(Adapted from Zhu XF et al. 16). 
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Figure 46. Peak gallbladder radioactivity was significantly delayed 
(P = 0.03) in the octreotide group (tm" = 90 min) compared to the 
placebo group (tm., = 68 min). (Adapted from C Grimaldi, J Darcourt, 
AG Harris, E Lebot, F Lapalus, J Delmont 13). 
Acromegalic Acromegalic patients: 
patients: Long-term and 
acute effect J:ost withdrawal 
of octreotide e ects of octreotide 
Units Before OCT During OCT After 
withdrawal 
kx(L) min 9.4± 0.6 9.2 ± 0.8. 9.5 ± 0.9 
t112(L) min 39.0 ± 3.0 40.0 ± 5.8 30.0 ± 1.3 
L1zo min % 9.8 ± 1.0 15.2 ± 4.0 11.2 ± 2.5 
tru,(L) min 58.5 ± 1.5 75.0 ± 11.2 61.7 ± 3.9 
tc min 20.3 ± 3.0 40.0 ± 15.8 16.7 ± 3.3 
tn~,(G) min 43.1±6.1 103.3 ± 7.9 t 51.7 ± 6.9 + 
tad (D) min 31.7 ± 5.0 63.3 ± 17.1 36.7 ± 7.9 
Table 13. Dynamics of bile excretion during long-term octreotide 
(oct) treatment (500 ± 100 (/day) and after discontinuation of ther-
apy in 6 acromegalic patients. EHIDA imaging was repeated approx-
imately two weeks after cessation of therapy, when gallbladder 
contractility had normalized as assessed by fat meal test in all six 
patients. t Compared with values of untreated patients, P < 0.001. 
tCompared with values during long-term treatment, P < 0.001. 
(Adapted from Zhu XF et al. 16). 
PRGC (%) 
Patients Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Mean± SEM 
Before treatment 70.3 81.3 83.3 90.5 77.5 72.4 79.2 ± 2.4 
End of treatment 6.6 34.2 2.5 2.8 14.1 5.4 10.9 ± 5.0t 
After 1 week 89.8 84.4 64.3 95.7 40.6 43.8 69.7 ± 10.1 
After 2 weeks 94.6 84.3 95.1 90.5 65.4 69.3 83.2 ± 4.6* 
Table 14. The restoration of percentage relative gallbladder contractility (PRGC) in six acromegalic patients after cessation of octreotide 
treatment. Pt =patient. Comparison with value at end of treatment: *p<0.001; tp<O.OOl. (Adapted from Shi YF et al 18). 
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gram focussed on studying the composition of bile and 
gallstones associated with octreotide therapy and establish-
ing the prevalence and incidence of octreotide-associated 
gallstones. 
VII.IV.II - Gallstones 
VII.IV.II.I - Background Research 
The aetiology of gallstones is complex and multifactorial, 
involving concentration of ions, pigments, cholesterol, water 
and gallbladder motility amongst others. The effect of 
octreotide (1 !,.lg sc tid) on gallbladder bile composition was 
investigated in 10 prairie dogs in comparison to 14 control 
animals receiving normal saline 12• Octreotide increased 
hepatic bile concentrations ofbilirubin monoglucuronide, 
total bilirubin and total protein. Gallbladder stasis, bile calcium, 
bilirubin monoglucuronide, total bilirubin, total protein, and 
total lipids were increased in the octreotide group. Animals 
receiving octreotide decreased hepatic and gallbladder bile pH. 
No differences in cholesterol saturation index were observed. 
These alterations in gallbladder bile composition may increase 
the likelihood of cholesterol and calcium bilirubinate 
precipitation, which may explain the increased incidence 
of gallstone formation during chronic octreotide therapy. 
Healthy Volunteer Studies 
In a double blind randomized placebo controlled study 
with Grimaldi and Delmont et al at Nice University, we 
investigated, using cholescintigraphy, the effect of octreotide 
(100 !,.lg iv) on hepatic bile secretion and gallbladder emp-
tying in 12 healthy volunteers. While there was no signifi-
cant difference between the time to peak 99 Tc-PBIDA 
activity in the octreotide and the placebo group, the ratio of 
gallbladder activity at 90 minutes to the activity at 60 min-
utes was significandy higher in the octreotide group (1.53) 
than in the placebo group (0.95) (p<0.01).Thus, the delayed 
release of99 Tc-PBIDA from the livers of the octreotide 
treated subjects after a fatty meal probably reflected a decrease 
in bile secretion, which occurred in conjunction with the 
inhibition of gallbladder contraction (Figures 45, 46) 13 • 
VII.IV.II.II - Studies in Acromegalic Patients 
We have shown with Erlinger et al in Paris that octreotide 
treatment may induce the formation of cholesterol crystals 
but does not increase the cholesterol saturation index 14• 
Thirteen patients with active acromegaly took part in the 
study. Each patient received octreotide (1 00 !,.lg t.i.d. s.c) for 
a three-month study period, after which 12 patients con-
tinued with octreotide therapy. Fasting gallbladder bile was 
sampled during upper gastrointestinal endoscopy after stim-
ulation with ceruletide. Bile was studied before and the 
end of treatment (n=7), only before treatment (n=4), or only 
at the end of treatment (n=2). Prior to octreotide treatment 
the bile of 10 of 11 patients was supersaturated with cho-
lesterol, although cholesterol crystals could not be detected 
on microscopic examination. At the end of the treatment 
period 7 of 9 bile samples were supersaturated with 
cholesterol and cholesterol crystals were detected in three 
samples. There was no significant difference in relative 
proportions of bile acids, cholesterol and phospholipids 
before and after treatment. Gallstones were detected on 
follow-up ultrasonography of four patients, including three 
who had already developed cholesterol crystals. We concluded 
that octreotide impairs gallbladder motility and/ or decreases 
cholesterol nucleation time. 
With Buscail et al in Toulouse we studied the risk of gall-
stone formation during long-term treatment with contin-
uous subcutaneous infusion of octreotide (mean duration 
26.5 months, mean dose 541 !,!g/ day) in 12 patients with 
acromegaly 15 • Bile was collected by duodenal intubation and 
abdominal ultrasound/ cholecystograms were performed 
before, during, and 45 days after octreotide treatment. 
Cholesterol crystals were present in 58.3% of patients dur-
ing treatment, compared with only 3% before octreotide 
treatment. Twenty-five percent of patients had cholesterol 
microcrystals 45 days after discontinuing octreotide. In three 
patients treated with octreotide for more than su-: months, 
cholesterol crystals preceded the appearance of radiolucent 
gallstones. One of these patients underwent cholecystectomy 
because of biliary colic, while gallstones dissolved com-
pletely after 10 months of ursodeoxycholic acid treatment 
in combination with maintenance octreotide therapy. 
In a study we conducted with Zhu and Shi's group in 
Beijing, China, percentage relative gallbladder contraction 
(PRGC) was measured 6 hours after small doses (5 and 
12.5 !,!g) of octreotide, and was found to be significantly 
lower than pre-treatment levels (28.8 ± 7.4 %,p<0.001) 16.Ten 
hours after administration of 5 !,.lg and 12.5 !,.lg doses of 
octreotide, PRGC levels returned to pre-treatment levels. We 
concluded that owing to the significant inhibition of gall-
bladder contractility at doses as low as 5 !,.lg, the lowering of 
octreotide doses in long-term therapy might not be effective 
in preventing gallbladder dysfunction. In another [99mTc] 
EHIDA study we conducted with Zhu et al 17, PGRC was also 
inhibited by single doses of octreotide in acromegalic patients 
compared with a matched group of healthy controls. When 
this study assessed the long-term effects of octreotide on 
gallbladder function, we found that after cessation of octreotide 
therapy for two weeks, gallbladder function had returned to 
baseline, indicating that the effects ofoctreotide on biliary 
function were relatively short-lived (Tables 12, 13). 
With Shi et al we also reported that withdrawal of octreotide 
therapy in 6 Chinese acromegalic patients who did not 
develop gallstones during long-term octreotide therapy 
(500 ± 245 !,!g/day for 16.3 ± 7.6 months) was associated 
with a return of gallbladder contractility within one week 
(Table 14) 18• Of the eight acromegalic patients who developed 
gallstones during chronic octreotide therapy (1 020 ± 
554 !,!g/ day for 32.6 ± 11.5 months), four normalized their 
gallbladder contractility within two weeks after cessation 
of octreotide. Gallbladder contractility improved without 
returning to normal six months after withdrawal of octreotide 
in the other three patients and was found to be normal five 
months after discontinuation in the fourth patient. 
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In 1992, Hopman et al reported that in a group of 5 acrome-
galies, compared with eight normal control subjects, 
octreotide (100 )lg twice/thrice daily sc for 6-32 months) 
reduced ( -125 ± 194 cm3 at 120 min,) significantly the inte-
grated post-prandial gallbladder contraction 45 minutes 
after administration of the final 100 )lg dose 19 • Octreotide had 
no effect on basal levels of cholecystokinin (CCK) 45 min-
utes and eight hours after injection. Postprandial CCK 
elevations, 45 minutes and eight hours after octreotide 
administration, were significantly lower than CCK levels 
measured two weeks after withdrawal of octreotide (p<O.OS). 
Hopman et al also assayed plasma pancreatic polypeptide 
levels after the ingestion of a standard meal and found that 
integrated post-prandial rises were inhibited during a period 
of 45 minutes after octreotide injection (0.1 ± 0.2 nmol/1 
at 120 min), but inhibition diminished eight hours and two 
weeks after administration (3.0 ± 1.0 nmol/1 at 120 min and 
106 ± 1.6 nmol/1 at 120 min, respectively, p<O.OS). The 
authors concluded that the inhibition of CCK and pancre-
atic polypeptide-mediated systems was not involved in the 
reduction in postprandial gallbladder contraction in acrome-
galic patients receiving octreotide. 
Bigg-Wither found no significant difference found between 
the rates of gallstone development in 15 acromegalic and 
10 obstructive sleep apnoea syndrome (OSAS) patients 
during octreotide treatment (100-500 )lg three times per 
day sc, 4-32 months duration in acromegalies and 100 )lg 
twice daily sc, 2-3 months duration in OSAS patients), 
although an increased risk of cholelithiasis was associated 
with octreotide therapy in both groups 20 • In the six of the 
15 acromegalies and in two of the 10 OSAS patients who 
developed gallstones, a wide variation in the concentration 
of gallstones in the gallbladder was reported (from "a few" 
to "packed'). Gallbladder volume was significantly increased 
in all individuals, more markedly in acromegalic patients 
(from 27 ± 3 rnl to 71 ± 8 mL, p=0.0002 and from 
30 ± 4 rnL to 50± 6 rnL, p=0.0006, in acromegalic and 
OSAS groups, respectively). Eight months after withdrawal 
of octreotide, it was found that gallstones had resolved 
spontaneously in seven of eight patients after octreotide 
therapy. It was concluded that octreotide was associated with 
increased risk of gallstone formation, possibly due to 
increases in gallbladder volume, presumably caused by the 
inhibition of contraction and emptying, which resolved 
after the termination of octreotide treatment. 
Catnach el al stated that fasting gallbladder volume had 
little effect on the development of gallstones in acromegalic 
patients receiving octreotide 21 • They disagreed with the 
conclusion of Bigg-Wither et al above that increased 
gallbladder volume was possibly linked to cholelithiasis. The 
authors highlighted studies in which increased gallbladder 
volume was not associated with a parallel rise in the risk 
of gallstone formation. Catnach and colleagues also pointed 
out that the gallbladders of acromegalies not undergoing 
octreotide therapy have been found to be three times 
larger than normal, with no associated increase in reported 
incidence of cholelithiasis. Catnach et al noted the increase 
in biliary cholesterol concentrations seen in acromegalic and 
normal patients with octreotide and identified octreotide 
as being a likely culprit for the increased risk of gallstone 
formation during therapy. 
The studies performed during the Clinical Development 
Program indicated that incidence of gallstones in 
octreotide-treated patients is greater than that of age-, 
sex- and weight-matched controls. We performed these 
studies in acromegalic patients because of the consistent 
availability of pre-treatment gallbladder ultrasonography. It 
should be noted, however, that acromegalic patients could 
have a greater risk of gallstones because of their inherent 
gallbladder hypomotility as reported by Catnach et al 
above 21 • Thus the incidence of gallstones in patients treated 
with octreotide for other disorders may be lower. Dowling 
and colleagues investigated the mechanisms of gallstone 
formation during long-term octreotide therapy (see Figures 
4 7, 48) and expanded the understanding of cholelithiasis 
by using octreotide-induced gallstones as a human in vivo 
disease model. These studies 22•23· 24 demonstrated that most 
octreotide-associated gallstones are cholesterol-rich, prob-
ably stemming from cholesterol-supersaturated bile, and a 
high molar ratio of cholesterol to phospholipids in the 
vesicular biliary fraction. These features are also associated 
with rapid nucleation of cholesterol microcrystals and a 
doubling of deoxycholic acid concentration independent 
of gallstone formation. In addition to abnormalities in 
biliary composition, octreotide also had been shown to 
impair emptying of the gallbladder 1, with the principal 
mechanism for this being inhibition of cholecystokinin 
secretion 25• 26 • Therefore, the pathogenesis of octreotide-
induced gallstones consists of multiple defects, the first of 
these being the production of supersaturated bile with a 
cholesterol saturation index > 1. Secondly, there is a nucle-
ation defect, which consists of an imbalance between the 
promoters and inhibitors of cholesterol microcrystal 
formation that facilitates the development of microcrystals 
in supersaturated bile. Thirdly, the development of gallstones 
is enhanced by gallbladder stasis secondary to the inhibi-
tion of meal-stimulated cholecystokinin release from the 
intestinal wall. Gallbladder hypomotility promotes stagna-
tion of bile and enhances the ability of excess surface 
mucus to capture cholesterol microcrystals. To these direct 
biliary effects must be added the impact of octreotide-
induced impairment of small and large intestinal motility, 
which disrupts normal patterns of reabsorption of water and 
biliary components 27 • There are few studies of gallstone 
composition in patients developing stones during octreotide 
treatment. Initial reports suggest that octreotide-associ-
ated gallstones are radiolucent, cholesterol-rich and dissolve 
with oral ursochenodeoxycholic acid treatment 28 • It has 
been suggested that gallstones in these patients might be 
prevented during octreotide therapy by administration of 
either cholecystokinin, non-steroidal anti-inflammatory 
agents or other anticholic agents. Cisapride does not 
reverse the effects of octreotide on the gallbladder but it can 
increase small and large bowel transit times 29 , which may 
impact biliary composition 30 • Intra-hepatic cholelithiasis is 
also a potential problem -albeit a rare one- in patients 
with acromegaly undergoing octreotide therapy that are 
pre-disposed to slow intra-hepatic biliary flow 31 • 
SAFETY ISSUES WITH 0CTREOTIDE DURING THE CLINICAL DEVELOPMENT PROGRAM 95 
J, Gallbladder 
contraction 
1 
T' Gallbladder 
absorption 
J, Nucleation time 
T Gut microorganisms 
Altered aerobic: anaerobic 
bacterial ratio 
Induction of bacterial 7a.-
dehydroxylase 
T Biliary Ca++ 
T Biliary Lipids 
T Arachidonic acid 
rich phospholipids 
T gallbladder mucus 
glycoprotein synthesis 
and secretion , 
Figure 47. Model for somatostatinjoctreotide-induced gallstone formation. CCK =cholecystokinin, DCA= deoxycholic acid, Ca++ =Calcium. 
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Figure 48. Factors involved in gallstone formation and points at 
which octreotide may influence gallstone formation; GB = gall-
bladder, CCK =cholecystokinin, DCA= deoxycholic acid. 
VII. V - GASTRITIS 
Plockinger et al reported that acromegalic patients treated with 
octreotide for over two years showed signs of atrophic gastritis 
on gastric biopsy specimens without any clinical manifesta-
tion32.We subsequently asked the Besser group in the UK to 
conduct a prospective study in 48 acromegalic patients treated 
and untreated with octreotide 33. Thirty percent of the patients 
were found to have gastritis before octreotide therapy versus 
47% of the octreotide treated patients. Fourteen percent of 
patients treated with octreotide for 6-23 months developed 
gastritis. The authors concluded that gastritis is not an invari-
able consequence of octreotide therapy even after prolonged 
periods of treatment. 
VII. VI - ANTIBODY FORMATION 
With Orskov and colleagues we first reported the development 
of specific IgG antibodies to octreotide during 2-3 years of 
treatment for acromegaly in two patients 34. The presence of 
these antibodies reduced the plasma disappearance rate of 
total extractable octreotide by 60 and 80% respectively. The 
plasma half-life of octreotide in the two patients with octreotide 
antibodies was 300 and 450 vs. 110 min in those with no 
. detectable octreotide antibodies.A consequence of this immu-
nization was a marked prolongation of the interval of maxi-
mum GH inhibition from a mean of 5 to 8 and 10 hours, 
respectively, in the two patients described. 
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Subsequently, Kwekkeboom et al reported a case of anti-
body formation to octreotide, visualised by radiolabelled 
octreotide scintigraphy35 • Before therapy (for carcinoid syn-
drome), no octreotide antibodies were detectable and the 
patient was treated with octreotide (1000-1500 J..Lg/day sc) 
for 20 months. Serum samples taken after 20 months of 
treatment showed a ten-fold increase in radiolabeled 
octreotide binding (from 2.3% to 22.5%) over pre-treat-
ment levels. Radiolabeled octreotide was displaced from 
serum by the addition of excess octreotide, thus indicat-
ing the presence of specific binding sites. Radiolabeled iod-
inated octreotide was still increased after a 1:15 dilution 
of serum was performed. The authors stated that this was 
the fourth reported case of octreotide-specific antibody 
formation. In all four cases high-dose octreotide 
(1500 J..Lg/ day or more) was employed. The clinical 
response of the patient in this study was equivocal, so the 
authors made no definite conclusion about the ramifica-
tions of octreotide-specific antibody formation on the 
clinical efficacy of the drug. However, increased back-
ground radioactivity after injection of radiolabeled 
octreotide indicated prolonged circulation due antibody-
coupled octreotide. Scintigraphy demonstrated radiolabeled 
octreotide accumulation at the injection site. The authors 
subsequently recovered octreotide-specific IgA and IgG 
antibodies from a subcutaneous induration at the drug's 
injection site. 
VII.VII- ENDOCRINOLOGICAL ADVERSE EVENTS 
VII. VII .I - Glucose Tolerance 
Adverse endocrinological effects are rare during octreotide 
therapy. Because of its inhibitory action on insulin release, 
octreotide may impair post-prandial glucose tolerance. 
Rarely, a state of persistent hyperglycaemia may be induced 
with chronic octreotide administration. On the other hand, 
studies with acromegalic patients have shown that octreotide 
can improve whole body insulin sensitivity by increasing the 
ability of insulin to suppress hepatic glucose production 
without affecting its impairment of peripheral insulin 
action 36· 37 • Together with Koop and Ezzat, we studied the 
effect of octreotide on glucose tolerance in 90 patients with 
acromegaly 38 • In particular we examined daily blood glucose 
profiles, oral glucose tolerance and insulinogenic index. We 
found that while 61% of patients had normal glucose tol-
erance before octreotide, 20% developed impaired glucose 
tolerance and 29% developed diabetes after beginning 
octreotide. In contrast, three of 11 patients who were dia-
betic at baseline became normoglycaemic or had only 
impaired glucose tolerance on octreotide. Patients with ele-
vated insulin levels at baseline and females were more likely 
to develop diabetes mellitus on octreotide. Our conclusion 
was that glucose monitoring be mandatory during octreotide 
therapy for acromegaly (Table 15, Figures 49, 50). 
Number of Patients Baseline Octreotide Treatment Glycaemic Status Number of Patients % 
OGTT (N=90) 
55 Normal Normal 28 51 
IGT 11 20 
DM 16 29 
24 IGT Normal 10 42 
IGT 10 42 
DM 4 17 
11 DM Normal 2 18 
IGT 1 9 
DM 8 73 
Mixed meals (N = 39) 
31 Normal Normal 25 81 
IGT 2 6 
DM 4 13 
3 IGT Normal 1 33 
IGT 1 33 
DM 1 33 
5 DM Normal 1 20 
IGT 0 0 
DM 4 80 
Table 15. Change in glucose tolerance status during octreotide therapy. Overall, patients that were normal pre-octreotide therapy had a greater 
likelihood of developing impaired glucose tolerance or diabetes than patients who were diabetic pre-treatment becoming normoglycaemic 
during octreotide therapy. 
Percentages represent the proportion of acromegalic patients whose WHO classification for diabetes mellitus (DM) was altered during 
octreotide treatment as assessed by the oral glucose tolerance test (OGIT) or mixed meals. 
IGT: impaired glucose tolerance. (Adapted from Koop BL, Harris AG, Ezzat S. 38). 
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Figure 49. Effect of different doses of octreotide on mean circadian blood glucose concentrations in acromegaly. Values represent the mean 
of 12-hourly glucose determinations during treatment with the indicated doses of octreotide. (Adapted from Koop BL, Hanjs AG, Ezzat S. 38). 
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Figure 50. Effect of different doses of octreotide on the insulin/glucose ratio. Values represent median changes of insulin area under the 
curve (AUC)/glucose AUC compared to baseline in response to oral glucose ingestion during treatment with different doses of octreotide. (Adapted 
from Koop BL, Harris AG, Ezzat S. 38). 
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VII.VII.II -Thyroid Function 
With Christensen et al under the direction of H. Orskov we 
found the effects of octreotide on thyroid function to be 
minimal. Following three days of continuous subcutaneous 
infusion of octreotide (100 ~g/24 hours), a slight but 
significant decrease in serum total tri-iodothyronine and a 
concomitant increase in serum TSH was demonstrated 39 • 
After an additional three days of treatment, serum, tT3 and 
TSH had returned to pre-treatment values. The only long-
term effect of octreotide was a clinically insignificant 
increase in serum TSH, possibly caused by a slight inhibi-
tion of peripheral deiodination of thyroxine. In a study of 
seven type I diabetic patients receiving a continuous sc. infu-
sion of octreotide we conducted with Kirkegaard et al. 40 
mild transient hypothyroidism occurred but was not 
considered clinically relevant by the investigators. RolfSema 
et al. 41 found that pulsatile secretion ofTSH in eight 
acromegalic patients treated with 300 ~g/ day octreotide for 
1 month remained unaffected. 
Vli.VIII - CONCLUSION 
As outlined above, we made extensive efforts to identify and 
describe the mechanisms behind adverse events associated 
with octreotide. Gallstone formation is a recognized com-
plication of octreotide therapy, but our work along with oth-
. ers has helped to define it and we have noted that withdrawal 
of octreotide leads to rapid return of gallbladder function. 
Defining the incidence of gallstones associated with 
octreotide therapy was also a goal during the Clinical 
Development Program. In 1995, Redfern and Fortuner 
reviewed the data on octreotide-associated biliary dysfunc-
tion and concluded that gallstones occurred in approxi-
mately 25% of patients; in most cases gallstones were 
asymptomatic 42 • Interestingly these data are in line with 
the more recent findings concerning octreotide LAR, with 
approximately 25% of patients developing largely asympto-
matic cholelithiasis 43 • Verification of our extensive safety 
program in terms ofbiliary and other adverse events can be 
seen from the safety labelling for octreotide, while the 
descriptions of octreotide in pharmacological reference 
textbooks note that few precautions are required for patients 
starting on octreotide therapy. 
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Chapter VIII. 
Discussion 
VIII.! - INTRODUCTION 
This chapter draws together the results and lessons of the 
Clinical Development Program for octreotide during my 
involvement with the program. Chapter II described the 
background to the discovery of somatostatin and the incep-
tion of pharmacological analogue programs in the phar-
maceutical industry. Chapter II also outlined the differences 
between octreotide and somatostatin that make octreotide 
a useful therapeutic agent. In Chapter III the rationale 
behind pursuing diabetes mellitus as a primary clinical indi-
cation for octreotide was outlined. Diabetes mellitus proved 
to be an important learning ground, as the results of our tri-
als demonstrated a good safety profile, which provided us 
with the background against which we could study 
octreotide extensively in other disorders. The initial view that 
the Clinical Development Program in diabetes mellitus was 
unsuccessful has been reassessed, as octreotide may still have 
an important role to play in diabetic retinopathy, while the 
challenge of widespread metabolic syndrome and type II dia-
betes mellitus means that a polypharmaceutical approach to 
the treatment of these conditions will need to be considered 
in the future. Chapters IV andV described the successful pro-
gram in acromegaly and GEP tumours, where academiar: 
industry collaborations provided cohesive pharmacological 
and epidemiological data. These data were used in a unique 
fashion to register octreotide in these indications, and fol-
low-up studies have verified our multi-centre case collec-
tions. Chapter IV also outlined other important uses of 
octreotide, namely, variceal bleeding, fistulae and secretory 
diarrhoea.Although clinical development studies were pur-
sued for the latter two indications, these were partially 
unsuccessful due to heterogeneous populations. Variceal 
bleeding has become a common clinical application for 
octreotide, and it is employed currently as an effective emer-
gency treatment. In Chapter VI, some of the multiple smaller 
indications for octreotide were discussed, and their relative 
successes were highlighted. The manner in which safety 
research was pursued was described extensively in Chapter 
VII. This issue was always investigated proactively during my 
involvement in the Clinical Development Program, .and 
we interacted extensively with academic groups to satisfy the 
medical and regulatory communities regarding the reliable 
safety profile of octreotide, particularly in terrns of gall-
stone formation. In the current Chapter some of the key 
issues arising from my experiences with the Clinical 
Development Program for octreotide will be discussed as 
they relate to pharmaceutical research and development 
today. 
VIII.II - MULTIFACETED CLINICAL RESEARCH: 
THE IMPORTANCE OF AN INFORMED 
SCIENTIFIC RATIONALE 
Retrospective assessment of a large and multifaceted clini-
cal development program, such as that of octreotide, allows 
one to draw conclusions that are instructive for other 
researchers in this and other fields. Modern scientific meth-
ods and concepts have moved on significantly since the 
clinical development of octreotide, but it is my belief that the 
nature of octreotide and the manner in which we studied it 
are highly relevant for new pharmaceutical therapies today. 
Modulation of small peptide function has yielded significant 
successes in the case of cytokines in inflammatory diseases, 
and many other cytokine and chemokine targeted therapies 
are in clinical development. These cellular messengers differ 
from classical hormones due to their pleiotropic nature, as 
they are involved in the regulation of multiple functions at 
sites such as the brain, the immune system, peripheral nerves 
and epithelial surfaces. In this sense, the multiple biological 
effects of somatostatin are somewhat cytokine-like. Our 
experience with octreotide in terms of efficacy and safety 
evaluations can teach important lessons to modern 
researchers. Primary amongst these issues is the importance 
of a strong scientific rationale that informs and underpins crit-
ical and costly development steps. With octreotide we were 
able to utilise the body of classical endocrinological research 
relating to native somatostatin. This revealed to us the wide 
range of potential indications for octreotide and our plan-
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ning was always multi-faceted in nature. Therefore, when the 
main investigative indication, diabetes mellitus, proved not 
immediately viable, we had already begun detailed research 
into acromegaly, GEP tumours and gut hypersecretion/motil-
ity disorders. By being based within a large pharmaceutical 
corporation, it was possible to avail of the organizational and 
strategic support necessary to develop a strong scientific 
rationale for octreotide in multiple potential indications. 
By keeping our focus wide and interacting with key inves-
tigators in many specialties, we were able to develop several 
echelons of active clinical/basic research. Lessons learned in 
the diabetes mellitus research program regarding carbohydrate 
metabolism and counter-regulatory hormones were impor-
tant to demonstrate safety in this regard in non-diabetic 
subjects. If we had restricted our focus to acromegaly or 
diabetes mellitus alone, we would potentially have missed the 
opportunity to identify and study gastrointesti.gal applications 
of octreotide like variceal bleeding where the mechanism of 
action of the drug is largely vascular/non-endocrine. 
Research today on pleiotropic cytokines in clinical practice 
could benefit from a multifaceted development program 
like that employed for octreotide. This necessitates detailed 
interactions with academic research groups to develop 
informed scientific rationales, a process which represents a 
significant organisational and financial challenge for individual 
biotechnology firms to manage. The large pharmaceutical 
corporation has the ability to organize and fund such a 
process of information gathering, which was crucial to the 
success of our multifaceted program. If a new pharmaceu-
tical agent is developed across multiple indications, it increases 
organisational complexity but insulates against unsuccessful 
indications. However, the corporation must ensure that the 
process of high quality academic data gathering and advice 
is maintained throughout the clinical development phase in 
order to predict pitfalls early and benefit from the identifi-
cation of new indications.At Sandoz, a particular effort was 
made to maintain a culture of highly scientifically informed 
decision making. This allowed us to direct research proactively 
and se.ek out potential safety issues such as gallstone forma-
tion, raW-er 'than merely responding to independent obser-
vations." 
Of particular relevance for smaller pharmaceutical develop-
ers is the necessity to maximise the potential applications of 
the agent being developed. Clinically directed teams may wish 
to concentrate wholly on potential drug therapies as they yield 
the greatest benefit for the corporate entity and the patient 
population. By being over-focussed on therapeutics, the 
opportunity to develop valuable diagnostic agents may be 
missed. In the case of octreotide, E. Krenning's and S. Lamberts' 
groups at Erasmus Medical Centre, Rotterdam harnessed 
the somatostatin receptor binding characteristics of octreotide 
to produce an indium-111-radiolabelled analogue. This prod-
uct, called OctreoScan was commercialised with Mallinckrodt, 
and has proven extremely useful for the imaging of somato-
statin receptor positive tumours 1•2• The experience gained by 
this group and others with somatostatin receptor imaging has 
led to the development of a potential somatostatin receptor 
directed radiotherapeutic (OctreoTher) 3• 
VIII.III - When Concepts Fail: PitfaLLs and Opportunities 
When assessing the overall impact of the clinical development 
of octreotide, the relative disappointments are arguably as 
important as the many successes. Unsuccessful indications and 
methodologies can help to highlight potential pitfalls for other 
research groups in industry and academia. As outlined in the 
section above, we pursued the clinical development of 
octreotide in various indications on the basis of a strong pre-
clinical and clinical rationale. In retrospect, unsuccessful 
indications were due in some instances to the logistical chal-
lenges raised by restrictive inclusion criteria and patient 
characteristics than incorrect scientific concepts.At Sandoz, 
study planning benefited from the availability of high qual-
ity advice from scientific and medical experts in the academic 
community. Thus, our decisions on the viability of indications 
were based on academic consensus in concert with market 
research and in-house concepts. Our most important unsuc-
cessful indication was the development of octreotide as a 
treatment for diabetes mellitus. Indeed, this potentially prom-
ising indication was the reason that octreotide received such 
active initial development. The diabetes mellitus Clinical 
Development Program was characterised by some successes 
in terms of metabolic control in type I and type II disease. 
More importandy for subsequent studies in acromegaly and 
other conditions, the diabetes mellitus program showed that 
octreotide treatment was not associated with hazardous or 
precipitous hypoglycaemia. The importance of tight gly-
caemic control in preventing complications of type I diabetes 
mellitus was only becoming apparent during octreotide's clin-
ical development. The Diabetes Control and Complications 
Trial showed subsequendy that lower HbAlc levels achieved 
with intensive insulin therapy lowered the risk of retinopa-
thy and nephropathy4.The most obvious method for improv-
ing glycaemic control was escalated insulin dosing, rather than 
the addition of another injectable drug such as octreotide.The 
decision not to pursue octreotide as a metabolic therapy for 
type I diabetes mellitus was probably justified, as subsequent 
diabetes intervention studies led to the optimization of 
existing insulin dosing and delivery rather than new thera-
pies. In terms of diabetic complications, final conclusions 
regarding the value of octreotide cannot be drawn yet. 
Diabetic nephropathy was and remains today an important 
cause of renal failure, dialysis and transplantation. As was 
described in detail in Chapter III, octreotide has been shown 
in numerous studies to improve renal haemodynarnics and 
filtration indices and is an effective treatment in some ani-
mal models of renal failure. The advent of ACE inhibitor ther-
apy as a convenient, safe and efficacious method for retarding 
the progression of renal disease in diabetes mellitus made 
further development of octreotide in this indication difficult 
to justify. In type II diabetes, the control ofblood pressure by 
ACE inhibitors or other anti-hypertensives has been shown 
by the results of the United Kingdom Prospective Diabetes 
Study (UKPDS) to be almost as important as glycaemic 
control in the prevention of diabetic complications s, 6 • An 
argument for using a somatostatin analogue in diabetic 
nephropathy could be made if effective receptor-selective 
compounds were developed. If such targeted therapies were 
more effective than octreotide in altering renal haemody-
namics and filtration then they might find a role as an 
adjunctive therapy to preserve renal tissue and prolong time 
before organ failure and dialysis/transplantation, particu-
larly in patients with an insufficient response to ACE inhibitor 
therapy. In contrast to metabolic control and nephropathy, 
diabetic retinopathy represents a major unmet need in dia-
betes therapy. Patients may undergo rapid loss of sight due to 
proliferative retinopathy despite adequate glycaemic control. 
As outlined in the chapter on diabetes mellitus, octreotide 
continues to show significant potential as a therapy for slow-
ing retinopathy and studies are ongoing with octreotide 
LAR. The only effective treatment for proliferative diabetic 
retinopathy is destructive panretinallaser photocoagulation, 
which is not completely effective in all patients. If octreotide 
were to demonstrate efficacy in terms of slowing disease pro-
gression, it could represent the first specific "retinopreserv-
ative" therapy for diabetic retinopathy. Also, preclinical 
research into somatostatin receptor subtypes in retinal 
endothelium could point the way to newer subtype-specific 
somatostatin analogues, although putative analogues would 
have to have the same good glycaemic safety profile that we 
showed with octreotide. 
The clinical development of octreotide in some gastroin-
testinal indications was problematic. For instance, the pre-
clinical rationale for treating gut fistulae with octreotide 
was particularly strong. Furthermore, small studies and indi-
vidual cases had shown octreotide to be remarkably effec-
tive. However, larger studies were difficult to perform and 
monitor due to the heterogeneity of fistula aetiology, patient 
health status and individual clinical practice. Similar prob-
lems were encountered in studies of post-ER CP pancreatitis, 
where it was difficult to find consensus on disease definitions. 
In AIDS-related diarrhoea, individual reports of octreotide 
use were hopeful, but larger clinical trials were inconclusive. 
These partially unsuccessful potential indications emphasise 
the importance of patient stratification and the definition of 
endpoints, in addition to highlighting the eternal difficulty 
of performing clinical trials in surgical populations. Since my 
involvement with the clinical development of octreotide 
ended, groups from Germany and Italy, with whom we 
collaborated, have learned from our early negative experi-
ences with octreotide in gut surgery indications. These 
groups have designed and performed four large, well-
designed clinical studies of octreotide in complications of 
pancreas surgery. These trials stratified patients according to 
risk, recruited large numbers of patients (over 1 000 in total), 
and applied pragmatic standardised endpoints to assess 
octreotide's efficacy7· 8·9•10• In doing so, these researchers have 
demonstrated a uniformly beneficial effect of octreotide in 
reducing post-operative complications of pancreatic sur-
gery.This exemplifies the importance of matching scientific 
rationale with robust, pragmatic trial design. 
Finally, the case of octreotide in variceal bleeding deserves 
consideration. As noted in Chapter V, animal and human 
studies ofhepatic haemodynarnics have shown that somato-
statin-14 and octreotide reduce hepatic venous pressure. 
Clinical studies in patients with bleeding oesophageal varices 
have compared octreotide with all major therapies: 
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Sengstaken-Blakemore tube, vasopressin, endoscopic band-
ing and injection sclerotherapy. Octreotide has demonstrated 
excellent efficacy and tolerability in the treatment of variceal 
bleeding. Meta-analyses have favoured octreotide over other 
pharmacotherapies and found it equivalent to endoscopic pro-
cedures, which are treatments of choice 11•12.Despite these ben-
efits, the gastroenterological community has been reluctant 
until recendy to adopt octreotide wholeheartedly as a treat-
ment for bleeding oesophageal varices. Some of this resist-
ance may come from the idea that octreotide was being 
suggested as a replacement for endoscopy. Endoscopic pro-
cedures combine the ability to diagnose and treat varices 
definitively in one treatment. As such, octreotide represents 
a good holding therapy in situations where endoscopy is 
unavailable or delays occur. Also, octreotide infusions can be 
used in the acute period to prevent rebleeding by reducing 
hepatic venous pressure. The weight of clinical experience and 
positive studies that have accumulated over time have made 
variceal bleeding a major gastroenterological application for 
octreotide. Prophylaxis of variceal bleeding in high-risk cir-
rhotic patients using octreotide LAR could represent a major 
advance in this high-mortality medical emergency. 
VIII.IV - THE INDUSTRY-ACADEMIA DYNAMIC: OPENNESS, 
COOPERATION AND HIGH STANDARDS 
For the industry-based physician to interact efficiendy with 
academic researchers, the relationship must be informed 
by a sense of mutual trust and common goals. During my 
stewardship of the Clinical Development Program for 
octreotide, we made a conscious effort to maximise the 
links between Sandoz and our academic collaborators in 
terms of publication of study results. The publication of 
peer-reviewed results in the literature represented a major 
goal for our industry-based team, as we viewed this as an 
independent validation of our academic collaborations. 
With octreotide, we fostered discussion and debate regard-
ing actual and potential adverse events. From the advice and 
suggestions of academia sprang an extensive range of stud-
ies into the effect of octreotide on carbohydrate metabolism 
and gallbladder dynamics. The safety debate was under-
taken in the public domain in an atmosphere of cooperation 
between Sandoz and university collaborators. At Sandoz, a 
conscious effort was made to tease out the potential impact 
of octreotide on gallbladder function during clinical devel-
opment and it was seen as an integral part of the program 
that had to be dealt with in its own right, rather than as an 
adjunctive issue. It is my belief that such a cooperative 
atmosphere allows industry and academic researchers to 
collaborate in the most efficient way and deliver the max-
imum amount of useful data regarding the efficacy and par-
ticularly safety of a novel pharmacotherapy. 
The requirement for peer-reviewed data to support 
sales/marketing efficacy claims was not as evident during the 
development of octreotide as it is now. If clinical research is 
designed and implemented with an intention to publish it 
in peer-reviewed literature, it requires a useful degree of 
proactive thinking by the industry-based physician. The 
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peer review process subjects internally developed study 
concepts and results to independent objective analysis. Peer-
review can identifY methodological weaknesses and suggest 
improvements, while demanding of the writer a cohesive 
explanation of concepts from first principles. Publication of 
results facilitates debate and challenges external proponents 
and opponents to encapsulate their positions clearly. Peer 
review publication is an efficient way of verifying the qual-
ity of informed corporate decision making and transmitting 
the efficacy and safety benefits of a drug to the medical/sci-
entific audience. With octreotide, I was afforded the oppor-
tunity of steering many studies through peer-review into 
print and had to work closely with academic groups to 
defend study concepts, contextualise results and suggest 
new avenues of research. This experience is unique to the 
pharmaceutical physician and provides parallel benefits to the 
industrial and academic/medical communities when carried 
out in a forthright atmosphere of cooperation. 
VIII.V- THE PHARMACEUTICAL PHYSICIAN 
Physicians who hold a position directing the clinical devel-
opment of a drug have a number of responsibilities. 
Interactions with academic and clinical colleagues allow 
the so-called pharmaceutical physician to seek out and 
identifY new indications based on his/her medical training. 
The pharmaceutical physician is a physician-scientist who 
interfaces with basic and clinical scientists, patient groups and 
the corporate environment to guide new drugs from labo-
ratory findings to patient availability. The business environ-
ment of the pharmaceutical company allows the physician 
to call on marketing analysis to assess the potential of new 
indications identified. In the case of octreotide, this thesis has 
outlined the myriad of indications that were pursued simul-
taneously. This was unusual, but was backed by a good 
understanding of the mechanism of action of octreotide and 
its safety considerations; many of these indications were at 
least partially successful. Similarly, medical training and a 
healthy relationship with academia allow the well-informed 
pharmaceutical physician to anticipate potential adverse 
events. We investigated safety aspects of octreotide in an 
efficient and open manner by acknowledging the increased 
risk of asymptomatic gallstones. By fostering biliary research 
we helped to define the nature of octreotide-related 
cholelithiasis, but also advanced the understanding of the roles 
played by intestinal motility and nucleation dynamics in 
gallstone formation. We encouraged the reporting of efficacy 
and safety data in the post-marketing phase, and acted on rel-
evant data where appropriate. In this way my role iri the 
Clinical Development Program for octreotide incorpo-
rated functions of a modern Phase IV post marketing sur-
veillance department. 
We sought at all times to promote a culture of peer-reviewed 
publication of results in the myriad of indications in which 
octreotide was undergoing parallel development. This allowed 
us to assess the relative value of pursuing registration based 
on good quality preclinical and clinical evidence. Also the 
publication strategy facilitated a regular flow of clinical data 
into the public arena where the medical community could 
assess it critically. Critique of study results by non-interested 
parties provided us with an extra layer of strategic planning 
in the development of potential new indications. The data 
gathering abilities of a large pharmaceutical company allowed 
me to co-ordinate the collection of epidemiological and 
· descriptive evidence on large patient populations in rare dis-
orders. This was particularly true in the cases of acromegaly 
and TSH -secreting pituitary adenomas. Despite the forma-
tion of case registries in the past few years 13· 1\ our case col-
lection of patients with acromegaly remains one of the 
largest pharmacological trials in pituitary disease 15 • 
Furthermore, our data collection led to the publication of 
a series of 500 patients with acromegaly, which remains 
the largest patient collection to date 16.The description of 52 
patients with TSH adenomas is similarly a landmark paper 
in terms of pharmacotherapy of the condition and also in 
terms of the large number of patients for such an extremely 
rare condition 17• It is really orily international organizations 
that can collect such series and physicians in positions of 
responsibility in pharmaceutical multinationals should be 
encouraged actively to use the cohesion of the corporate 
entity to collect and publish valuable information on less 
common diseases. The success of our combined efforts with 
octreotide was recognised by the awarding of the Prix 
Galien to Sandoz in 1991. This international prize is given 
annually to an outstanding innovative therapeutic agent, 
and in the case of octreotide recognised the efforts of Pless, 
Bauer, Huguenin and Fetcher (drug discovery and synthe-
sis), Doepfuer, Marbach and Briner, Bruns and Weckbecker 
(preclinical pharmacology), and our clinical research team 
including Boerlin,James-Dedier, Elton and Dunne. 
Recent years have seen an enormous growth in the impact 
of evidence-based medicine on clinical decision-making 
and allocation ofhealthcare expenditure. In many ways this 
move away from a reliance on the individual opinions of 
experts (so-called "eminence-based medicine") towards a 
data-centric view of disease and treatment is laudable. 
Evidence-based medicine attempts to standardise treat-
ments, thus providing patients with a uniform standard of 
care. It has been argued, however, that over-reliance on evi-
dence-based decision-making is as fallible as operating on 
clinical experience alone 18 • Randornised controlled trials 
apply restrictive inclusion and exclusion criteria to patient 
populations, which often means that a study's results can be 
applied to orily a limited group of patients in the clinical set-
ting. Our experience with the Clinical Development 
Program for octreotide in GEP tumours and acromegaly 
indicates that -for rare diseases at least- the use of a carefully 
managed inclusive, open label and retrospective approach to 
data gathering can be useful in study.ing the disease and the 
effectiveness of treatment. The validity of our approach is 
underpinned by the similarity between our retrospective 
results and the results of prospective controlled trials man-
dated by regulatory authorities. In contrast to evidence-
based approaches, our retrospective case collection did not 
have to sacrifice the individuality of patients' disease char-
acteristics and their experience of octreotide's effectiveness 
in the drive for statistically cohesive efficacy data. 
VIII. VI- REGULATORY ISSUES: THE ADVENT OF GOOD 
CLINICAL PRACTICE (GCP) GUIDELINES 
It was not uniform among European academic investigators 
in the 1980's to operate according to GCP guidelines. Fully 
informed consent with explanations of all potential side 
effects, maintenance of copious records and standardisation 
of investigations and disease models were among the prac-
tices that had to be introduced with the advent ofGCP.The 
pharmaceutical company sponsoring a GCP trial has vari-
ous responsibilities including the writing of standard oper-
ating procedures, verifYing the investigators credentials, 
co-signing all protocol documents, providing a compre-
hensive briefing regarding the investigational drug to inves-
tigators and monitoring, collecting and analyzing data on 
efficacy and safety. Analogous responsibilities exist for the 
monitor and investigator in maintaining the reliability of 
applied study methods and patient wellbeing. For Sandoz and 
other multinational pharmaceutical companies, the advent 
of GCP in Europe represented an opportunity to stan-
dardise trial conduct, data collection, data analysis and record 
keeping across regulatory boundaries. This had the effect of 
facilitating the use of trials conducted in one jurisdiction, e.g., 
Europe, in support of regulatory submissions in another 
jurisdiction, e.g., the United States of America. 
In Europe the introduction of GCP guidelines by the 
Committee for Proprietary Medicinal Products (CPMP) was 
gradual. The CPMP initially introduced a conduct paper in 
1987, which outlined procedures involved in drug testing, 
trial conduct, ethics and finance. The company had earlier 
made the decision to adopt US-style GCP guidelines, as it 
was felt that international adoption of such protocols was 
inevitable. Also, for trials to be considered by the FDA, 
GCP guidelines had to be followed, therefore, trials per-
formed in Europe had to be GCP-compliant if they were 
ever to be used in support of a US filing. Legal adoption of 
the 1990 final GCP guidelines came in 1991. 
With octreotide, the advent of GCP in Europe did not 
represent an obstacle to the Clinical Development Program. 
As mentioned above, Sandoz had already adopted GCP 
standards of ethics, record keeping and consent. Indeed, a 
full-time GCP compliance officer was in place at the time 
we began to develop octreotide in clinical trials. The initial 
indication we pursued was diabetes mellitus, and it should 
be noted that of the multiple trials in retinopathy, nephropa-
thy and metabolic control, most were placebo-controlled. 
The good quality of the structure of the metabolic control 
trials allowed us to make a critical decision rapidly when it 
became evident that the benefit afforded by octreotide was 
not clear-cut. In the US, although initial small studies in 
diabetic retinopathy were positive, clinical and regulatory 
experts recommended large-scale, placebo-controlled trials 
if the indication was to be considered further. At that time, 
a long-acting formulation of octreotide that permitted more 
sustained suppression ofGH and IGF-I was not available to 
pursue this indication. It is interesting to note that the use 
of octreotide as a treatment for diabetic retinopathy has 
undergone a renaissance in the last few years, and long-term 
studies are underway. 
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As was described in the relevant chapters, the approval of 
acromegaly and GEP tumours was pursued using an inter-
national retrospective case collection. Typically the FDA 
required two identical placebo-controlled studies to be 
performed before considering approval. In the case of 
GEP tumours this was bypassed due to the compassionate 
use data. In Europe and other countries worldwide, the 
acromegaly case collection results were considered suffi-
ciently robust to license octreotide for treatment of 
acromegaly. In the US, however, despite the fact that the 
case collection contained two small placebo-controlled 
trials, a request was made for a further large randomised 
placebo-controlled study. This delayed the approval of 
octreotide in the US by about 3 years, and it is a testament 
to the good practice followed in the case collections and 
small controlled studies, that the results of the US multi 
centre trial were virtually identical to the retrospective 
data. As noted above, a carefully maintained retrospective 
data set can provide important information regarding 
real-world patient characteristics, and deliver valid data 
on safety and effectiveness without resorting to the type of 
highly restrictive inclusion criteria required for a prospec-
tive controlled trial. 
VIII.VII- THE FUTURE: OUTSTANDING ISSUES AND 
UNANSWERED QUESTIONS 
In the previous sections I have discussed various aspects of 
the success and failure of potential indications for octreotide 
and identified some useful approaches for researchers today. 
Some issues regarding octreotide are still topics of debate 
despite the wealth of research conducted to date. The role 
of octreotide in diabetes mellitus is still being investigated. 
In particular, the suppressive effects of octreotide on reti-
nal vascular endothelial growth are now thought to be 
potentially clinically useful. Trials of octreotide in diabetic 
retinopathy are ongoing and if positive would represent 
a verification of our clinical development concepts of 
mid-1980's. In oncology, octreotide has been useful in 
certain types of somatostatin-receptor positive tumours, but 
the dosages used have been relatively small. By delivering 
high-dose octreotide pamoate (rather than acetate) via a 
LAR preparation, it may be possible to suppress growth in 
susceptible tumours. Similarly, high dose octreotide LAR 
or octreotide pamoate at milligram doses or may be used 
in the future for other clinical conditions such as cirrho-
sis-associated variceal bleeding. While octreotide has been 
used in acromegaly for more than 15 years, there has been 
no assessment of its effects on major mortality/morbidity 
outcomes such as cardio-respiratory disease and cancer. The 
average historical age at diagnosis is about 40 years and 
patients have over double the overall normal mortality 
rate, with a mean age at death of 57-64 years. Over the next 
decade we should be able to compare historical data with 
long-term octreotide-treated acromegalic patients and 
discover if any decrease in the rate death due to cardiac 
disease and cancer occurs with octreotide. Eventually, 
it will be possible to identify the effect of tight or 
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lax GH/IGF-1 control on morbidity/mortality in 
acromegaly. Iflower GH/IGF-1 concentration has a sta-
tistically important effect on major outcomes, then we may 
see more widespread use of intensive octreotide regimes. 
Octreotide treatment in acromegaly and GEP tumours has 
proven effective in the majority of patients. Despite 
this, a significant proportion of patients have a clinically 
insufficient response to octreotide, which may be explained 
by inter-individual pharmacological variations and differing 
somatostatin receptor subtype expression. Octreotide can 
be eliminated from the body by routes, such as p-glyco-
protein, the expression of which is genetically polymor-
phic in terms of responses to various exogenous regulators. 
Combination of octreotide with modulators of p-glyco-
protein could increase plasma exposure to the analogue. 
In patients on multiple drugs for other conditions, physi-
cians should try to choose drugs that have a lower chance 
of increasing the elimination of octreotide. Patients with 
a poor response to octreotide may express somatostatin 
receptor subtypes for which octreotide has a lower affin-
ity.This raises the possibility of designing new somatostatin 
analogues that have enhanced binding to all somatostatin 
receptors or to specific subtypes. In the future it may be 
possible to test for patterns of receptor expression using a 
family of subtype-specific radiolabeled somatostatin ana-
logues. Thereafter, patients could be treated with indi-
vidual tailored analogues or cocktails of somatostatin 
analogues with high affinity for expressed receptor sub-
types. Alternatively, advances in gene therapy could be 
harnessed to increase somatostatin receptor expression by 
target cells.A new and highly novel study by Mearadji with 
Krenning and others demonstrated that it was possible to 
transfect somatostatin-receptor negative colon cancer cells 
with the sst2 gene and cause liver metastases in rats 
following portal vein injection of these cells. Treatment of 
animals who had received sst2-transfected tumour cells 
with octreotide coupled to a radioactive molecule resulted 
in less liver metastases than control animals with 
sst2-negative tumours 19 • 
Octreotide remains the subject of extensive pre-clinical and 
clinical research interest, despite the length of time that has 
passed since it was first synthesised. Its efficacy and safety 
profiles are well known for both approved and investiga-
tional indications. Table 16 outlines these approved and 
potential uses for octreotide, most of which have been out-
lined in detail in this thesis. It is heartening to note that 
many of the prospects for octreotide that were discussed 
in my review of 1990 20 have come to be considered as 
realistic current treatment and diagnostic options. For 
new analogues, such as, SOM 230 21•22,BIM compounds 23 , 
and others 24 a full series of safety and efficacy studies 
similar to those carried out with octreotide will be needed 
to verify a similar safe balance between effective 
hormone/ cellular growth suppression and avoidance of 
enhanced carbohydrate and gallbladder adverse events as 
was demonstrated for octreotide. It must be hoped that 
highly effective subtype specific somatostatin analogues 
could represent the advent of primary pharmacotherapy 
for diseases like acromegaly and GEP tumours. 
APPROVED INDICATIONS FOR OCTREOTIDE 
Acromegaly 
GEP Tumor Syndromes 
Carcinoid tumors 
Pancreatic endocrine tumor syndromes 
Somatostatin receptor scintigraphy ([111-ln-DTPA-D-phe] octreotide) 
POSSIBLE EFFICACY * OF OCTREOTIDE 
Endocrinology (Proven efficacy) 
GH pituitary adenomas 
TSH secreting pituitary adenomas 
Non functioning pituitary adenomas 
Gastroenterology/Digestive surgery 
Diarrhoeal States 
AIDS Related Diarrhoea 
Chronic Secretory Diarrhoea 
Irritable Bowel Syndrome 
Short Bowel Syndrome 
Ileostomy 
Chemotherapy 
Radiotherapy 
Grafts vs. Host Disease 
Scleroderma 
Variceal Bleeding (proven efficacy) 
Enterocutaneous and Pancreatic Fistulae 
Peri operative Use in Digestive Surgery 
Pancreatic Surgery (proven efficacy in reducing complications) 
Dumping Syndrome (proven efficacy) 
Pancreatic Pseudocysts 
Short Bowel Syndrome 
Small Bowel Obstruction 
Postoperative Ileus 
Neurology 
Autonomic Neuropathy 
Orthostatic Hypotension 
Post Prandial Hypotension 
Pain Control 
* Except where otherwise indicated 
Table 16. Approved and potential indications for octreotide. 
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Chapter IX. 
Directions for Octreotide and Future 
Somatostatin Analogues in Clinical Practice 
IX.I - INTRODUCTION 
Approximately fifteen years have passed since the Clinical 
Development Program for octreotide was begun and in 
that time biological research has undergone a fundamental 
revolution. Genetic and molecular techniques such as the 
polymerase chain reaction (PCR), which are workhorses of 
the modern biomedical laboratory, were not present even in 
conceptual form in the early to rnid-1980's.A major deter-
minant of the future of octreotide and other somatostatin 
analogues in clinical practice is the impact that new molec-
ular techniques have made on the way pharmaceutical/med-
ical research is now performed. Data yielded from the 
application of new technologies to pathological models has 
provided a new understanding of the mechanisms of disease. 
In parallel, however, we are now gaining a true appreciation 
of the immense complexity and inter-connectedness of 
physiological pathways. Biological research has been cross-
fertilised by information technology, as the vast scope of 
potential patterns of DNA, RNA and protein regulation 
requires enormous computational power. The current chal-
lenge facing the pharmaceutical physician is to avail of the 
power of g<::netic and protein expression analysis, while not 
becoming enmeshed in the huge volume of data produced. 
Similar advances have taken place in the field of drug design, 
with the advent of more precise methods of computerised 
combinatorial chemistry and three dimensional imaging 
using electron microscopy providing researchers with pow-
erful tools to build and visualise new molecules. These 
methodologies permit the modelling of receptors, the design 
of potential ligands, and the analysis of interactions between 
the two. In the future, this should allow pharmaceutical 
and biotechnology companies to design better receptor 
agonists and antagonists (both peptide and non-peptide). 
IX.II -ADVANCES IN TECHNIQUES 
IX.II.I - Genomics anl:l Proteomics 
The robotic automation of the study of genetic and protein 
expression has led to the advent of the sciences of genornics 
and proteornics. Thousands of unique genetic sequences 
can be constructed or printed onto glass slides or proprietary 
'chips'.These fluorescently labelled sequences combine with 
complimentary DNA or RNA contained in physiological 
samples such as plasma or celllysates. Comparison of fluo-
rescence intensity for each genetic marker between physi-
ological samples and references allows the identification of 
upregulated or downregulated genes. Robotic printers are 
now available for the construction of individual chips/ slides 
at a relatively low cost compared with a few years ago. 
Therefore, researchers can analyse the expression - or non-
expression- of specific families of receptors and growth fac-
tors in pathological states. In terms of somatostatin research, 
gene expression techniques have proven useful in cancer 
research, where response to octreotide has been difficult to 
predict. In patients with neuroblastoma, for instance, expres-
sion of the sst2 gene, which codes for the somatostatin sub-
type receptor 2 (SSTR2), was more useful than other patient 
and tumour characteristics, for predicting disease response 
and event-free outcomes 1. Furthermore, sst2 expression in 
other cancers such as pancreatic cancer can predict response 
or non-response to octreotide. 
Detection of messenger RNA (mRNA) using PCR ampli-
fication or rnicroarray technology is useful, but does not pre-
dict accurately the final amount of protein expressed. This 
is because mRNA can undergo degradation or post-trans-
lational inactivation, thus decreasing protein concentration. 
Also simply detecting the expression of mRNA does not take 
into account downstream inhibitory and stimulatory signals 
that may come from existing or subsequently expressed 
intracellular proteins. Proteomics, and other sub-genres, 
study transcribed proteins, and thus allow assessment of 
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post-translational modifications of mRNA, and intracellu-
lar shuttling/ translocation of protein products. Application 
of this developing field will help to model physiological 
responses to GH, IGF-1 and identify how octreotide acts at 
a molecular level. Also, these technologies could help to 
explain the poor responses of some somatostatin receptor 
positive cancer cells to octreotide, by comparing relative pro-
tein expression with cells that are octreotide-responsive. 
Furthermore, technologies are being developed which will 
permit the detection of post-translational changes in proteins, 
such as the phosphorylation state of a receptor. It is known 
that phosphorylation of somatostatin receptors occurs and 
is involved in the desensitization and downregulation of a 
receptor. Such phenomena can turn off signalling via that 
receptor. This could be used to determine whether the loss 
of clinical effectiveness oflong-term octreotide treatment is 
due to receptor desensitization or could be employed to 
determine whether somatostatin analogue treatment would 
be effective in the first place, if the receptor (e.g., SSTR2) 
is fully phosphorylated. 
IX.II.II - Antisense Technology 
This technology harnesses the physicochemical properties 
of ribonucleic acids to hybridise small nucleotide chains 
(oligonucleotides) to them and modulate mRNA/protein 
expression. By knowing the nucleotide structure of a spe-
cific rnRNA, an oligonucleotide can be designed that is both 
opposite (antisense) and complimentary. Intracellular enzymes 
exist that target abnormal double-stranded mRNA and 
destroy them. Administration of antisense oligonucleotides 
can be used pharmacologically to target specific mRNA for 
destruction, thereby reducing protein formation. This is 
both a research method and a potential therapeutic tool. In 
terms of somatostatin analogue research, antisense technol-
ogy has been used to better define the pathways that cause 
cell surface receptor expression. In pituitary tumour cells 
'(GH3), it has been reported that sstl gene expression can be 
controlled by the growth promoter Pitl 2.Administration of 
Pit1 antisense oligonucleotides blocked Pitl expression and 
reduced sst1 and SSTRl receptor expression. Application of 
this to other receptor subtypes will help to define the role 
of genetic promoters and inhibitors in the pathogenesis of 
endocrine tumours. Such technology can be useful in lieu 
of the development of selective antagonists for each somato-
statin receptor subtype. 
IX.II.III - Combinatorial Chemistry 
Combinatorial chemistry is now a standard strategy for 
the identification of selective receptor ligands, whether 
they are agonists or antagonists. One of the most recent uses 
of combinatorial chemistry for somatostatin receptor drug 
discovery was reported by Rohrer et al. 3.They used com-
binatorial chemistry together with high throughput screen-
ing technologies to identify non-peptide agonists at each of 
the somatostatin receptor subtypes. These technologies 
have now advanced to the point that ligands of selective 
design can be generated against each receptor. This can 
allow for development of agonists, partial agonists, inverse 
agonists, or antagonists, which can improve solubility and 
oral availability, or be designed. to be directed to some tis-
sues and not others such as ligands that avoid the central 
nervous system, for example. This can aid in the removal of 
drug side effects. 
IX.III - ADVANCES IN SOMATOSTATIN PHYSIOLOGY 
The five human somatostatin receptors have been well 
characterised in the years since the clinical development of 
octreotide 4•5· 6.Radiolabeled octreotide has been used exten-
sively as a research and diagnostic tool to identify somato-
statin receptor density in various normal and diseased tissues, 
primarily endocrine tumours 7•8• More recendy the con-
struction of emitting radionuclide-labelled octreotide deriv-
atives have raised the possibility of specific somatostatin 
receptor-directed cancer radiotherapy 9 • It is now clear that, 
although somatostatin receptors all appear to work prima-
rily through G-proteins, activation and recruitment of other 
downstream adapter proteins occurs. Differential patterns of 
intracellular stimulatory and inhibitory signals may be appor-
tioned to the activity of various somatostatin receptor sub-
types. In different tissues, specific somatostatin receptors 
may work in different ways.Also, binding ofligands, such as, 
octreotide to somatostatin receptors may have indirect 
effects on cell cycle function and protein secretion via mod-
ulation of other G-protein coupled receptors or down-
stream effects on calcium ions and phosphorylation events. 
A further important potential mechanism of action for 
somatostatin receptors is via heterodimerisation. It has 
become increasingly clear that G-protein coupled receptors 
may heteroclimerise with excitatory or inhibitory subunits 
of other G-protein-coupled receptor components. Through 
this mechanism ligands binding to one receptor subtype can 
influence the intracellular apparatus downstream of a second 
receptor subtype for which it is not a natural ligand. 
Furthermore, new receptor subtypes can be formed through 
heteroclimerisation, thus increasing the complexity of pos-
sible receptor-ligand interactions many-fold. Specifically 
for somatostatin, heterodimerization has been reported · 
between somatostatin receptors and dopamine receptors, 
which is of particular significance for pituitary cells which 
often co-secrete growth hormone and prolactin 10 • The exis-
tence of heterodimerisation between somatostatin and 
dopamine receptor components raises the intriguing possi-
bility of designing ligands specifically to target these het-
eroclimeric receptors and thus inhibit hormonal secretion 
more readily 11 • 
A deeper understanding of the relative functions of differ-
ent somatostatin receptors in different tissues may help to pre-
dict response to octreotide therapy: 
• Pituitary cell somatostatin receptor expression/function 
• Vascular somatostatin receptors in diabetic retinopathy and 
tumours 
• IGF-1/somatostatin receptors and shared downstream 
targets 
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• Pro-apoptotic signals mediated via somatostatin receptors; 
octreotide activates apoptosis in human peripheral blood 
lymphocytes in vitro 12• 
• Anti-inflammatory and immune system activities of 
somatostatin and its receptors 13 • Does octreotide medi-
ate some of its clinical effects in acromegaly (analgesia, 
joint cartilage disease, depression) by modulating inflam-
matory cytokines or glucocorticoid activity via molec-
ular receptor interactions as reported by Chrousos, Tolis 
and colleagues 14• 15 ? 
Studies over the years have indicated that somatostatin 
receptor subtypes may subserve distinct physiological func-
tions either because the receptors are uniquely expressed only 
in some tissues or because they only couple -with distinct cel-
lular effector systems and not others. For example, SSTRS 
is believed to be expressed in insulin secreting beta cells while 
SSTR2 is primarily expressed in glucagon secreting alpha 
cells in animal studies. Since octreotide binds to both recep-
tors, it would be expected to inhibit release of both hor-
mones. However, highly selective SSTR2 and SSTRS 
agonists would be predicted to selectively inhibit insulin and 
glucagon secretion, which has been found in animal stud-
ies. Similarly, SSTR2 is believed to mediate effects of somato-
statin ligands on gall bladder function. Thus, ligands that affect 
growth hormone secretion but which do not bind to 
SSTR2, such as SSTRS agonists, might be expected to not 
have the same side effects as octreotide. The importance of 
relative expression levels of somatostatin receptor subtypes 
for predicting clinical efficacy of somatostatin analogues, 
including octreotide, has become clearer in recent years. 
Pituitary tumour cells that are poorly responsive to somato-
statin analogues express significandy lower levels ofSSTR2 
mRNA and higher levels ofSSTRS mRNA than tumours 
that are somatostatin analogue sensitive 16 • Studies by Reubi 
et al. 17•18 have shown that SSTR1 is selectively expressed in 
prostate tumours. The other somatostatin receptors were not 
detected in this tissue. This suggests that SSTR1 ligands 
could be used as selective markers for prostate cancer pro-
gression and be used as a possible therapeutic agent. 
SSTR2 and SSTRS have been linked to effector systems 
involved in cell proliferation and tumorogenicity. Thus, lig-
ands at these receptors would be predicted to inhibit tumour 
progression, whereas litde information exists that SSTR1, 3 
and 4 ligands would do the same. Similarly, there is substantial 
evidence that while all somatostatin receptors are able to cou-
ple to G-proteins, their interactions and degrees of coupling 
differ so that some receptors may induce different cellular 
actions that other somatostatin receptors because their G 
protein coupling and effector system regulation differs. 
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Chapter X. 
Conclusions 
The previous chapters have described the conceptualisa-
tion, design, implementation and analysis of the branches 
of the large clinical development program for octreotide 
during and since my tenure. The development of a robust 
scientific rationale was a crucial requirement that facilitated 
the successful pursuit of registration studies for octreotide 
in multiple indications simultaneously. The cohesive strate-
gic and operational abilities of a multinational pharma-
ceutical corporation like Sandoz allowed standardised 
collection and analysis of data in rare diseases like 
acromegaly and GEP tumours. This approach brought 
about a major advance in the treatment of these diseases and 
the quality of our approach was verified subsequently in 
placebo-controlled trials. The pharmaceutical physician 
can have a major impact within the corporate and research 
communities by developing a network of open, mutually 
rewarding relationships with academic opinion leaders. 
This industry-academia relationship allowed me to col-
laborate on the identification of clinical indications and the 
design and implementation of high-quality clinical trials 
that were published in peer-reviewed literature. We under-
took proactive research into adverse events of octreotide 
including gallstone formation, carbohydrate and thyroid 
metabolism. Multifaceted clinical development studies 
were performed in diabetes mellitus, acromegaly, GEP 
tumours, gut hypersecretory-hypermotility disorders and 
cancer. Although the primary indication of diabetes mel-
litus was not initially successful, research with octreotide in 
diabetic retinopathy continues to this day, with increasingly 
positive results. Octreotide has been used in acromegaly, 
GEP tumours and multiple gastrointestinal indications 
with great efficacy; the extensive safety data and results of 
clinical development studies have contributed significantly 
to our understanding of disease processes (for review see 
Lamberts et al. 1). The impact of the advent of octreotide 
on the medical and scientific research communities can be 
judged by the large number of publications indexed on 
electronic databases, such as Medline.Approximately 25% 
of studies published in the field of somatostatin research are 
devoted to octreotide, indicating the high level of scientific 
and clinical interest in this analogue. Modern medical 
library sciences allow the tracking of articles published in 
terms of their impact on the literature as a whole. This "cita-
tion index" is a measure of how often a study is referenced 
or quoted in other studies as support for the themes dis-
cussed2.A citation search conducted in late September 2002 
that targeted the articles that form the basis of this thesis 
demonstrates the continuing interest in key publications, 
particularly in terms of acromegaly and diabetes mellitus. 
This search is included as Appendix 2 of this thesis, while 
the essential bibliography that forms the core of this the-
sis is listed in Appendix 3. 
The Clinical Development Plan for octreotide can be 
seen as a roadmap for the development of not only new 
targeted somatostatin analogues, but also to advance novel 
pharmaceuticals, such as, cytokine modulators of inflam-
mation. Carefully constructed international clinical 
databases can be used successfully to study the character-
istics of complex rare diseases (e.g. acromegaly, GEP 
tumours) and to measure the effectiveness and safety of a 
new treatment. Finally, this thesis has outlined how impor-
tant industry-academia relationships are to the successful 
and safe development of a novel pharmacotherapy like 
octreotide across multiple pathologically distinct indications. 
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Somatostatin 
Absolute stereochemistry. 
SMS-201-995: Octreotide 
Absolute stereochemistry. 
116 Appendix 1: Stereochemical Structures 
BIM-23104: Lanreotide 
Absolute stereochemistry. 
~CH2 
RC-160: Vapreotide 
Absolute stereochemistry. 
MK 678: Seglitide 
Absolute stereochemistry. 
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Summary 
The Clinical Development Program for octreotide illustrates 
how a dynamic and collaborative industry-academia rela-
tionship can maximise the potential of a new therapeutic 
compound such as octreotide. As a pharmaceutical physi-
cian, my involvement with the Clinical Development 
Program for octreotide from November 1984 to December 
1991 (and subsequent close involvement whilst in academia 
at the University of California, Los Angeles from 
1992-1994) allowed us to identify valuable areas of clinical 
interest and to perfOrm high-quality research in partnership 
with recognised academic leaders. The main aim of this the-
sis is to demonstrate how a pharmaceutical corporation 
can pursue multifaceted clinical drug development when the 
process is underpinned by an informed scientific rationale 
that is updated continuously by the best academic advice. 
This relationship also allowed the pharmaceutical company 
and I to explore safety issues with octreotide in a spirit of 
openness and discovery. This openness to new ideas and the 
availability of cutting-edge academic opinion enabled me to 
help switch the corporate focus for octreotide rapidly from 
development of octreotide in diabetes mellitus to acromegaly, 
GEP tumours and other indications, in which we demon-
strated its utility and achieved registration rapidly. 
Chapter IT describes the discovery of somatostatin and 
the launching of the somatostatin analogue program. 
The progress of octreotide through the stages of drug design 
and the phases of preclinical and clinical development 
(I - IV) are traced, including the essential requirements for 
octreotide in terms of its pattern of hormonal inhibition of 
GH and insulin. 
In chapter ID the clinical development of octreotide in the 
initial main indication, diabetes mellitus, is described. The 
presumed role of GH/IGF-1 in diabetes mellitus at the 
time of the Clinical Development Program is outlined and 
contrasted with current concepts, particularly with respect 
to diabetic retinopathy. The medical/scientific and regula-
tory hurdles encountered during our work in diabetes mel-
litus are detailed. 
Chapters IV and V discusses the success in developing 
octreotide for use in acromegaly and gut endocrine tumours. 
The process by which we leveraged the cohesive data-gath-
ering ability of a multinational pharmaceutical corpora-
tion to produce patient registries in acromegaly and GEP 
tumours are of central importance to this thesis, and as such 
are described in detaiL Our work with academic groups 
worldwide produced published clinical research that 
advanced the understanding of not only the effect of 
octreotide on biochemical parameters in acromegaly, but also 
helped to define disease responses across a wide variety of 
organ systems. Our experiences gaining registration for 
octreotide in acromegaly in Europe and in the United 
States differed significantly, and this thesis discusses how 
our unique data gathering approach was verified in subse-
quent formal placebo controlled randomised studies. 
The excellent working relationship between academic research 
groups and myself as a pharmaceutical physician facilitated the 
development of octreotide simultaneously in multiple different 
indications. The basic rationales and the manner in which we 
balanced the various results of clinical trials in gastroentero-
logical (variceal bleeding, fistulae, pancreatitis, gastrointestinal 
surgery, and secretory diarrhoeas) and other applications 
(non-growth hormone secreting pituitary adenomas, analgesia) 
are described in chapters V and VI. The consistent reliance 
on academic advice in these diverse settings allowed us to 
direct the development of octreotide for clinical use in a 
multifaceted manner. The outcomes from and validation of 
this approach are discussed in these chapters. 
Chapter VII consists of a detailed description of how we 
characterised and studied the potential adverse effects of 
octreotide. This was done in an open and pro-active man-
ner, combining research collaborations and publications 
with endocrine and gastroenterological groups in Europe, 
the United States and Asia. Through this approach, the 
effects of octreoti.de on carbohydrate metabolism and biliary 
dynamics are now well understood. 
In chapter VIII I discuss the results of the Clinical 
Development Program for octreotide in terms of: the impor-
tance of the informed scientific rationale; overcoming failed 
clinical concepts; openness, cooperation and high standards 
underpinning the industry-academia relationship; the role 
of the pharmaceutical physician and the impact of good clin-
ical practice regulations. 
Chapter IX points to the future and examines how tools 
and technologies available now could assist in the develop-
ment of future somatostatin analogues with enhanced effi-
cacy I safety benefits over octreotide. 
The conclusions of the above chapters of this thesis are 
presented concisely in Chapter X. 
Samenvatti ng 
Het klinisch ontwikkelingsprogramma van octreotide 
illustreert hoe een dynamische samenwerking tussen indus-
trie en universiteit de mogelijkheden van een nieuw 
geneesmiddel als octreotide heeft versterkt. Ik heb van 
november 1984 tot december 1991 leiding gegeven aan het 
klinisch ontwikkelingsprogramma van octreotide en ben 
ook in de daaropvolgende periode tijdens mijn verblijf 
in het Cedars Sinai Medical Center, Universiteit 
van Californie, Los Angeles van 1992-1994 als consultant 
hierbij nauw betrokken gebleven. Deze positie gaf me 
de gelegenheid om de meest waardevolle klinische 
onderwerpen te identificeren en om kwalitatief goed 
wetenschappelijk onderzoek te verrichten in nauwe samen-
werking met erkende universitaire onderzoekers. De belan-
grijkste doelstelling van dit proefschrift is om aan te tonen 
dat een farmaceutisch bedrijf tegelijkertijd op velerlei 
terrein een klinisch geneesmiddel kan ontwikkelen indien 
dit proces wordt ondersteund door een zich steeds 
vernieuwende wetenschappelijke basis, welke continue 
wordt geformuleerd door uitstekend advies door weten-
schappers. Door deze goede relatie tussen universiteit en 
industrie was het ons mogelijk om in een sfeer open 
samenwerking belangrijke wetenschappelijke aspecten van 
de veiligheid van octreotide te bestuderen. Deze openheid 
voor nieuwe ideeen en de beschikking over uitstekend 
advies uit de universitaire wereld stelden mij in staat om 
de aanvankelijke focusering van mijn bedrijf op een 
snelle ontwikkeling van octreotide op het gebied van 
suikerziekte te veranderen naar acromegalie, hormonale 
darmtumoren en andere indicaties, waarin een succesvolle 
plaats voor octreotide kort na het aantonen van effectiviteit 
snelleidde tot registratie. 
In Hoofdstuk I worden de doelstellingen van dit proef-
schirft besproken, alsmede de indeling van de verschillende 
hoofdstukken. 
Hoofdstuk II beschrijft de ontdekking van somatostatine 
en de start van het programma om somatostatine analogen 
te ontwikkelen. De voortgang van octreotide door de sta-
dia van geneesmiddelontwikkeling en de preklinische en 
klinische ontwikkelingsfasen (I-IV) worden geanalyseerd, 
waarbij de basisvoorwaarden voor octreotide ten aanzien 
van het werkingsprofiel ten aanzien van groeihormoon-
en insuline-remming aan de orde komen. 
In hoofdstuk Ill wordt de klinische ontwikkeling van 
octreotide in de aanvankelijk als eerste indicatie gefor-
muleerde richting: suikerziekte beschreven. De veronderstelde 
betekenis van Groeihormoon I Insulin-like-growth Factor 
I in de pathofysiologie van suikerziekte, zoals deze in de 
begintijd van het klinisch ontwikkelingsprograrnma bestond, 
wordt bediscussieerd. Daarnaast wordt gewezen op de 
veranderingen in de ideeen over de betekening hiervan, 
welke zich voordeden in de tijd met name ten aanzien van 
het ontstaan van retinopathie. De medische, wetenschap-
pelijke en regulatoire moeilijkheden welke zich voordeden 
tijdens onze studies naar suikerziekte worden besproken. 
In hoofdstuk IV en V wordt het succes van de ontwik-
keling van octreotide in de behandeling van acromegalie en 
endocriene darmtumoren besproken. Het proces waarbij we 
er in slaagden om een samenvattend dossier op te bouwen, 
gebaseerd op de beschrijving van individuele case histories, 
de betekenis van een groot internationaal geneesmidde-
lenbedrijfhierbij, en de mogelijkheid om hiermee patien-
tenregisters voor acromegalie en endocriene darmtumoren 
te starten, spelen een rol van betekenis in dit proefSchrift en 
worden in detail beschreven. Mijn wereldwijde contacten 
met universitaire onderzoekers resulteerden in breed gepub-
liceerde klinische onderzoeken welke het begrip omtrent de 
werking en effectiviteit van octreotide bij deze ziekten 
verbeterden, maar ook in hoge mate bijdroegen tot inzicht 
in de biochemisch te meten activiteit van de ziekte en de 
reactie van vele orgaansystemen tijdens behandeling. Onze 
ervaringen wat betreft het verkrijgen van registratie voor het 
gebruik van octreotide voor acromegalie verschilde aanzien-
lijk in Europa en de Verenigde Staten. In dit proefschrift 
wordt beschreven hoe onze aanvankelijke unieke benader-
ing van gegevens verzameling via individuele patienten, 
uiteindelijk in formele gerandomiseerde placebo-gecon-
troleerde studies tot vrijwel identieke resultaten leidde. 
De uitstekende werk-relaties tussen de universitaire onder-
zoeksgroepen en mij, als arts verbonden aan de farma-
ceutische industrie, vergemakkelijkte de gelijktijdige 
ontwikkeling van octreotide in meerdere, verschillende 
richtingen. De wetenschappelijke uitgangspunten en de 
manier waarop we de uitkomsten van de verschillende 
klinische onderzoeken op het gebied van de gastroen-
terologie (oesophagus varices bloedingen, fistels, pancreatitis, 
maag-darmchirurgie en secretoire diarrhee) hebben gei:n-
terpreteerd, alsmede een aantal andere gebruiksgebieden 
(niet-groeihormoon producerende hypofysetumoren, 
pijnbestrijding) worden beschreven in hoofdstukken V en 
VI. De mogelijkheid om continue een beroep te doen op 
advies uit universitaire kring in deze zo verschillende 
wetenschapsgebieden, stelde me in staat om de ontwik-
keling van octreotide gelijktijdig te sturen in zoveel sterk 
verschillende richtingen, welke leidden tot klinisch gebruik. 
De resultaten en de validering van deze benadering wor-
den in deze beide hoofdstukken besproken. 
In hoofdstuk VII wordt een gedetailleerde beschrijving 
gegeven van de wijze waarop we de mogelijke bijwerkin-
gen van octreotide karakteriseerden en bestudeerden. Dit 
werd op een zeer open en pro-actieve wijze gedaan in de 
vorm van wetenschappelijke samenwerking en publicaties 
met endocriene en gastroenterologische onderzoeksgroepen 
in Europa, de Verenigde Staten enAzie. Door deze benader-
ing, bestaat er nu een goed begrip en inzicht in de effecten 
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van octreotide op de koolhydraatstofwisseling en de 
dynamiek van de galproductie, waardoor clinici de mogelijke 
problemen goed kunnen verrnijden. 
In hoofdstuk VIII worden de resultaten van het klinisch 
ontwikkelingsprogramma van octreotide nader geanaly-
seerd. Hierbij komen aan de orde: het belang van een goede 
wetenschappelijke basis; de wijze hoe met een falend 
klinisch concept om te gaan; openheid, samenwerking, en 
hoge kwaliteit met nadruk op de relatie tussen industrie en 
universiteit; de rol van de farmaceutische arts en de rol van 
de regels ten aanzien van "good clinical practice". 
Hoofdstuk IX bespreekt de toekomst en welke methoden 
en technologische vernieuwing ter beschikking staat om 
nieuwe somatostatine analoga te ontwikkelen met grotere 
effectiviteit en grotere veiligheid dan octreotide. 
De conclusies van de negen hoofdstukken van dit proefSchrifi: 
worden in het kort gepresenteerd in hoofdstuk X. 
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